Nothing Special   »   [go: up one dir, main page]

US20030195162A1 - Genetic marker for spondyloepimetaphyseal dysplasia - Google Patents

Genetic marker for spondyloepimetaphyseal dysplasia Download PDF

Info

Publication number
US20030195162A1
US20030195162A1 US09/898,200 US89820001A US2003195162A1 US 20030195162 A1 US20030195162 A1 US 20030195162A1 US 89820001 A US89820001 A US 89820001A US 2003195162 A1 US2003195162 A1 US 2003195162A1
Authority
US
United States
Prior art keywords
seq
nucleic acid
papss2
sequence
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/898,200
Inventor
Daniel Cohn
Muhammad Faiyaz-Ul-Haque
Lily King
Deborah Krakow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/898,200 priority Critical patent/US20030195162A1/en
Publication of US20030195162A1 publication Critical patent/US20030195162A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR reassignment NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: CEDARS-SINAI MEDICAL CENTER
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: CEDARS-SINAI MEDICAL CENTER
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • This invention relates to the medical arts.
  • it relates to a genetic marker that is useful for diagnosing or treating spondyloepimetaphyseal dysplasia and for identifying genetic carriers of heritable alleles associated with spondyloepimetaphyseal dysplasia.
  • Osteochondrodysplasias are a genetically heterogeneous group of disorders related to cartilage producing cells. Abnormalities in cartilage formation can cause defects in bone deposition, skeletal development, linear growth, and the continued maintenance of cartilage and bone. (Reviewed in Mundlos, S. and Olsen, B. R., Heritable diseases of the skeleton. Part II: Molecular insights into skeletal development - matrix components and their homeostasis , FASEB J. 11 (4):227-33 [1997]).
  • sulfate is activated to a high energy form in two enzymatic steps (Geller, D. H., et al, Co - purification and characterization of ATP - sulfurylase and adenosine -5′- phosphosulfate kinase from rat chondrosarcoma , J. Biol. Chem. 262:7374-7382 [1987]).
  • Geller, D. H., et al Co - purification and characterization of ATP - sulfurylase and adenosine -5′- phosphosulfate kinase from rat chondrosarcoma , J. Biol. Chem. 262:7374-7382 [1987].
  • an ATP sulfurylase activity catalyzes the synthesis of adenosine 5′-phosphosulfate (APS).
  • PAPS 3′-phosphoadenosine 5′-phosphosulfate
  • Hastbacka, J., et al., Atelosteogenesis type II is caused by mutations in the diastrophic dyplasia sulfate transporter gene ( DTDST ): Evidence for a phenotypic series involving three chondrodysplasias , Am. J. Hum. Genet. 58:255-262 [1996]; Superti-Furga, et al., A family of chondrodysplasias caused by mutations in the diastrophic dysplasia transporter gene and associated with impaired sulfation of proteoglycans , Ann. N. Y. Acad. Sci.
  • the severity of the three known disorders i.e., the moderately severe diastrophic dysplasia phenotype and the lethal forms, atelosteogenesis type II and achondrogenesis type IB, is correlated with the consequences of the mutations on the activity of the transporter.
  • Achondrogenesis type IB is caused by mutations in the diastrophic dysplasia sulfate transporter gene , Nature Genet. 12:100-02 (1996).
  • the mutations lead to dramatically reduced proteoglycan sulfation in cartilage, particularly the chondroitin sulfate side chains of aggrecan.
  • brachymorphic (bm) mouse Biochemical evidence that a defect in another step in the sulfation pathway can produce an osteochondrodysplasia phenotype was provided by studies in the brachymorphic (bm) mouse.
  • the brachymorphic phenotype is characterized by disproportionate short-limb dwarfism, a short spine and tail, and a domed skull. (Lane & Dickie [1968]).
  • the brachymorphic mouse also exhibits an increased bleeding time, but tests of platelet function, including aggregation and secretion, have so far failed to reveal specific functional deficits in brachymorphic platelets. (Rusiniak, M. E., et al., Molecular markers near the mouse brachymorphic ( bm ) gene, which affects connective tissues and bleeding time , Mamm. Genome 7:98-102 [1996])
  • Cartilage from this recessively inherited mutant phenotype shows small, diffuse proteoglycan granules and reduced staining for sulfated glycosaminoglycans, consistent with a defect affecting sulfation of the proteoglycans of the cartilage extracellular matrix.
  • Mahe, P. & Dickie, M. M. Three recessive mutations producing diproportionate dwarfing in mice: achondroplasia, brachymorphic, and stubby , J. Hered. 59:300-08 [1968]).
  • proteoglycan granules show a 50% reduction in size in the reserve zone of the growth plate matrix, and are difficult to identify in the proliferative and hypertrophic zones.
  • Orkin, R. W., et al. Undersulfated chondroitin sulfate in the cartilage matrix of brachymorphic mice , Dev. Biol. 50:82-94 [1976]; Orkin, R. W., et al., Defects in the cartilaginous growth plates of brachymorphic mice, J. Cell Biol. 73:287-99 [1977]).
  • Heparan sulfate proteoglycans have been implicated in the sequestration and presentation of growth factors, particularly fibroblast growth factors, to receptors at the cell surface.
  • fibroblast growth factors particularly fibroblast growth factors
  • Yayon, A., et al., Cell surface, heparin - like molecules are required for binding of basic Fibroblast Growth Factor to its high - affinity receptor , Cell 64:841-48 [1991]
  • Schlessinger, J., et al. Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors ?, Cell 83:357-60 [1995]).
  • Skeletal defects in mice lacking heparan sulfate 2-sulfotransferase include dwarfism, with shortened long bones, ribs and spine, implying a specific role for heparan sulfate proteoglycans in skeletal development. (Bullock, S. I., et al., Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2- sulfotransferase , Genes Dev. 12:1894-1906 [1998]).
  • a cDNA encoding a murine bifunctional ATP-sulfurylase/APS-kinase enzyme (known as Papss1, formerly known as Atpsk1) was isolated from brachymorphic mice and studied by mutational analysis.
  • Papss1 murine bifunctional ATP-sulfurylase/APS-kinase enzyme
  • the bm mutation was placed on the mouse phenotypic map by Lane and Dickie (1968). Subsequent application of microsatellite markers to mice from a large backcross localized the bm mutation to a 2.5 cM region located at approximately 32 cM on mouse chromosome 19. (O'Brien, E. P., et al., Molecular map of chromosome 19 including three genes affecting bleeding time: ep, ru and bm , Mamm. Genome 5:356-60 [1994]; Rusiniak, M. E., et al. [1996]). In addition, a liver cancer susceptibility gene, Hcs6, has been localized near bm in mouse strain C3H/He. (Manenti, G., et al. [1994]).
  • brachymorphic mouse liver shows decreased PAPSS activity, the brachymorphic phenotype does not manifest any grossly recognizable liver defects. It has been observed that brachymorphic mouse liver has a decreased ability to esterify xenobiotic carcinogens with sulfate (Lyman, S. D. & Tru, A., Effect of the brachymorphic trait in mice on xenobiotic sulfate ester formation , Biochem. Pharmacol. 32:3345-50 [1983]), which implies that altered susceptibility to such agents could result from defects in a PAPSS gene.
  • brachymorphic mice have decreased susceptibility to carcinogen-induced hepatocarcinoma, presumably due to a decreased ability to generate sulfated carcinogens.
  • Boberg, E. W., et al. Strong evidence from studies with brachymorphic mice and pentachlorophenol that 1′- sulfooxysafrole is the major ultimate electrophilic and carcinogenic metabolite of 1′- hydroxysafrole in mouse liver , Cancer Res. 43:5163-73 [1983]; Lai, C.
  • PAPSS enzymes have been isolated and characterized in non-murine systems, for example, in association with rat chondrosarcomas.
  • Rosenthal, E. and Leustek, T. A multifunctional Urechis caupo protein, PAPS synthetase, has both ATP sulfurylase and APS kinase activities , Gene 165(2):243-48 [1995]; Schwartz, N. B., et al., Sulfate activation and transport in mammals; system components and mechanisms , Chem. Biol Interact. 109(1-3):143-51 [1998]; Lyle, S.
  • Rat chondrosarcoma ATP sulfurylase and adenosine 5′- phosphosulfate kinase reside on a single bifunctional protein , Biochemistry 33(19):5920-25 [1994]; Lyle, S. et al., Intermediate channeling between ATP sulfurylase and adenosine 5′- phosphosulfate kinase from rat chondrosarcoma , Biochemistry 33(22):6822-27 [1994]).
  • Human cDNAs for PAPSS have also been cloned, and their activities have been analyzed biochemically and mutationally. (Yanagisawa, K.
  • SEMD spondyloepimetaphyseal dysplasia
  • SEMD is a subgroup of osteochondrodysplasias affecting skeletal development, linear bone and cartilage growth, and bone and cartilage maintenance. Effects of SEMD can include dwarfism, stunted or malformed limbs, enlarged joints, kyphoscoliosis (spinal warping), and brachydactyly (short fingers and toes).
  • SEMD typically runs in families, and can be inherited in autosomal dominant or recessive manners. (Ahmad, M.
  • a nonsense mutation in a novel, cartilage-specific human PAPSS has been indicated as the cause of a recessive form of SEMD in an inbred Pakistani family.
  • PAPSS2 formerly ATPSK2
  • a distinct, autosomal recessive form of spondyloepimetaphyseal dysplasia segregating in an inbred Pakistani kindred Am. J. Med. Genet. 78:468-73 [1998]; ul Haque, M.
  • SEMD Pakistani type This disorder, designated SEMD Pakistani type, is characterized by short, bowed lower limbs, enlarged knee joints, kyphoscoliosis, a mild generalized brachydactyly, and early-onset degenerative joint disease in the hands and knees. Radiographs of patients with SEMD Pakistani type show delayed epiphyseal ossification, especially at the hips and knees, and platyspondyly.
  • DNA-based diagnostic approaches have been suggested for some type 2 collagen disorders, such as Stickler syndrome, spondyloepiphyseal dysplasia, and achondrogenesis; achondroplasia (a defect in the fibroblast growth factor receptor 3 (FGFR3) gene); the collagen oligomeric matrix protein (COMP) disorders pseudoachondroplasia and multiple epiphyseal dysplasia, and others.
  • achondroplasia a defect in the fibroblast growth factor receptor 3 (FGFR3) gene
  • FGFR3 fibroblast growth factor receptor 3
  • COMP collagen oligomeric matrix protein
  • the present invention relates to an isolated polynucleotide or to a nucleic acid construct that comprises a nucleic acid segment encoding a 3′-phosphoadenosine-5′-phosphosulfate (PAPS) synthetase (PAPSS), particularly, a human PAPSS2 nucleotide sequence of (SEQ. ID. NO.:1) or an orthologous murine Papss2 nucleotide sequence (SEQ. ID. NO.:2), sequences complementary to either one of them, degenerate coding sequences, or gene-specific fragments of (SEQ. ID. NOS.:1 and 2).
  • PAPS 3′-phosphoadenosine-5′-phosphosulfate synthetase
  • the present polynucleotides and nucleic acid constructs containing PAPSS2 and Papss2 nucleotide sequences include RNA; DNA; and chimeric RNA/DNA.
  • Embodiments include probes, primers, and expression vectors containing PAPSS2- and Papss2-specific nucleotide sequences.
  • the present invention also relates to a genetically modified vertebrate cell containing a nucleic acid construct of the present invention and to a non-human vertebrate containing the cell.
  • the present invention also relates to human PAPSS2 and murine Papss2 proteins encoded by the present polynucleotide or nucleic acid construct, including fusion proteins that contain, together with a PAPSS2 or Papss2 amino acid sequence, any other predetermined polypeptide sequence.
  • the present invention also relates to antibodies and antibody fragments that selectively bind the PAPSS2 or Papss2 protein.
  • the present invention is also directed to a method of diagnosing spondyloepimetaphyseal dysplasia (SEMD) in a human subject.
  • the method involves amplifying nucleic acids from a sample that define an PAPSS2 gene sequence, or a gene-specific fragment thereof; and analyzing the amplified nucleic acids for the presence of homozygosity for a variant allele of PAPSS2.
  • the sample is a bodily substance containing human nucleic acid, for example a blood sample, obtained from a human subject having at least one symptom of SEMD.
  • Homozygosity for a variant allele of PAPSS2 is diagnostic for SEMD in the human subject.
  • the present invention also relates to a method of diagnosing SEMD Pakistani-type in a human subject. But the present invention also relates to a method of identifying a heterozygous human carrier of an SEMD-associated allele.
  • the present invention provides a genetic testing kit for diagnosing SEMD or for identifying a human carrier of SEMD, including SEMD Pakistani-type.
  • the genetic testing kit contains oligonucleotide primers of the present invention.
  • nucleic acid constructs of the present invention are used in a method of gene therapy for treating a human subject having an osteoarthritic disorder that is caused or aggravated by deficient enzymatic sulfation activity.
  • the present invention is also related to a protein therapy method for treating a human subject having an osteoarthritic disorder that is caused or aggravated by deficient enzymatic sulfation activity. This method employs the inventive PAPSS2 fusion protein.
  • FIG. 1 shows a genetic map of the interval containing the SEMD disease gene on human chromosome 10. Distances between loci are given in centimorgans (cM).
  • FIG. 2 shows a genetic map of the bm region of mouse chromosome 19. The 0.7 cM interval containing the disease gene and locus D19Mit13 is shown with a darker line.
  • FIG. 3 shows a variant allele of PAPSS2 associated with SEMD Pakistani type. Sequences derived from amplified DNA fragment from an affected family member (SEMD) and from a control (NL) are shown. An arrow at nucleotide +1424 marks the location of a mutation, and the DNA sequence and the implied effect of the mutation on the PAPSS2 protein sequence is summarized below the nucleotide sequence.
  • FIG. 4 compares expression of PAPSS1 and PAPSS2 mRNAs with an actin mRNA control in samples from various human tissues, as visualized by Northern hybridization with specific cDNA probes for each.
  • the present invention relates to an isolated polynucleotide, of natural origin or a nucleic acid construct, that comprises a nucleic acid segment encoding an ATP sulfurylase/APS kinase, i.e., a PAPS synthetase (PAPSS), particularly, a human PAPSS2 nucleotide sequence of (SEQ. ID. NO.:1) or an orthologous murine Papss2 nucleotide sequence (SEQ. ID. NO.:2).
  • PAPSS PAPS synthetase
  • the human PAPSS2 gene is located on chromosome 10 at locus 10q23-24. (ul Haque, M. F., et al. [1998]). More specifically, the PAPSS2 gene region is flanked by microsatellite markers D10S1143 and D10S2470. (See FIG. 1; C. Dib et al., A comprehensive genetic map of the human genome based on 5,264 microsatellites , Nature 380(6570):152-54 [1996]).
  • the cloned human PAPSS2 nucleotide sequence is the following (GenBank accession AF091242; transcriptional start site [underlined] commences at position +1): (SEQ. ID.
  • the nucleic acid segment encoding a human PAPS synthetase comprises a nucleotide sequence defining an open reading frame within SEQ. ID. NO.:1 that extends from nucleotide position +1 through +1845 (SEQ. ID. NO.:9).
  • the orthologous murine Papss2 gene is located in the bm region of mouse chromosome 19, within a 0.7 cM interval near marker D19Mit13. (See, FIG. 2; ul Haque, M. F., et al. [1998]).
  • the cloned murine Papss2 nucleotide sequence is the following (GenBank accession AF085144; transcriptional start site [underlined] commences at position +1): (SEQ. ID.
  • the nucleic acid segment encoding a murine PAPS synthetase comprises a nucleotide sequence defining an open reading frame within SEQ. ID. NO.:2 that extends from nucleotide position +1 through +1851 (SEQ. ID. NO.:10).
  • the nucleic acid segment has a nucleotide sequence complementary to SEQ. ID. NOS.:1, 2, 9, or 10, or comprises a degenerate coding sequence of any of these.
  • the present nucleic acid segment is a gene-specific fragment of SEQ. ID. NOS.:1, 2, 9 or 10, or a gene-specific fragment of a complementary sequence or degenerate coding sequence.
  • Gene-specific fragments are nucleic acid segments having a contiguous nucleotide sequence that is specific to PAPSS2 or Papss2, respectively.
  • a gene-specific fragment of SEQ. ID. NO.:1 is SEQ. ID. NO.:9
  • NO.:2 is SEQ. ID. NO.:10.
  • a genomics data base such as the GenBank database of the National Center for Biotechnology Information (NCBI)
  • NCBI National Center for Biotechnology Information
  • PowerBLAST PowerBLAST, QBLAST, PSI-BLAST, PHI-BLAST, gapped or ungapped BLAST, or the “Align” program through the Baylor College of Medicine server.
  • Altchul Altchul, S. F., et al., Gapped BLAST and PSI - BLAST: a new generation of protein database search programs , Nucleic Acids Res.
  • a gene specific fragment is at least 5 to 30 contiguous nucleotides long, more preferably at least 6 to 15 contiguous nucleotides long, and most preferably at least 7 to 10 contiguous nucleotides long.
  • Embodiments of the isolated polynucleotide or nucleic acid construct of the present invention include nucleic acid segments comprising RNA, DNA, or chimeric RNA/DNA.
  • RNA segments include messenger RNA encoding an PAPSS2 or Papss2 protein, or a degenerate coding sequence, or a RNA sequence complementary to any of these.
  • a complementary RNA segment can be an antisense RNA or a catalytic RNA sequence, such as a “hairpin” or “hammerhead” ribozyme, with a recognition sequence complementary to a gene-specific fragment of SEQ. ID. NOS.:1, 2, 9 or 10, or a degenerate coding sequence of any of these.
  • nucleic acid segments of DNA include nucleic acid segments of DNA.
  • the DNA segment encoding a PAPSS2 or Papss2 protein is operatively linked to a promoter sequence.
  • the promoter sequence can be an autologous PAPSS2 or Papss2 promoter sequence.
  • any suitable promoter sequence can be used, including an autologous promoter, a promoter from a heterologous human or non-human PAPS synthetase gene (e.g., PAPSS1 or Papss1 promoters), or a predetermined promoter sequence from any other human or non-human gene.
  • Useful promoter sequences include constitutive promoters, such as, but not limited to, cytomegalovirus (CMV) promoter, or inducible promoters, such as, but not limited to, the human C-reactive protein (CRP) promoter (e.g., Kanzler, S., et al, TGF - betal in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis , Am. J. Physiol.
  • CMV cytomegalovirus
  • CCP human C-reactive protein
  • IGF-I insulin-like growth factor
  • Useful promoters include those that promote transcription in cells of diverse tissues, such as, but not limited to, an insulin receptor (IR) gene promoter (e.g., Tewari, D. S., et al., Characterization of the promoter region and 3 ′ end of the human insulin receptor gene , J. Biol. Chem.
  • GHR growth hormone receptor
  • P2 or P3 promoters e.g., Jiang, H., et al., Isolation and characterization of a novel promoter for the bovine growth hormone receptor gene , J. Biol. Chem. 274(12):7893-900 [1999]
  • a leptin promoter e.g., Chen, X. L., et al., Analysis of a 762- bp proximal leptin promoter to drive and control regulation of transgene expression of growth hormone receptor in mice , Biochem. Biophys. Res. Commun. 262(1):187-92 [1999]).
  • tissue-selective promoters i.e., promoters from which expression occurs preferentially in cells of a particular kind of tissue, compared to one or more other types of tissue.
  • tissue-selective promoters i.e., promoters from which expression occurs preferentially in cells of a particular kind of tissue, compared to one or more other types of tissue.
  • cartilage-selective promoters for expression in chondrocytes for example, an osteocalcin (OC) promoter (e.g., Newberry, E.
  • a cartilage-derived retinoic acid-sensitive protein (CD-RAP) gene promoter is also useful for cartilage-selective expression by chondrocytes.
  • CD-RAP cartilage-derived retinoic acid-sensitive protein
  • useful promoter sequences include, an albumin gene promoter (e.g., Pastore, L., et al., Use of a liver - specific promoter reduces immune response to the transgene in adenoviral vectors , Hum. Gen. Ther. 10(11): 1773-81 [1999]); a CYP7A or CYP7A1 promoter (e.g., Nitta, M., et al., CPF: an orphan nuclear receptor that regulates liver - specific expression of the human cholesterol 7 alpha - hydroxylase gene , Proc. Natl. Acad. Sci.
  • an albumin gene promoter e.g., Pastore, L., et al., Use of a liver - specific promoter reduces immune response to the transgene in adenoviral vectors , Hum. Gen. Ther. 10(11): 1773-81 [1999]
  • a CYP7A or CYP7A1 promoter
  • TAFI thrombin-activatable fibrinolysis inhibitor
  • useful promoters include a cyclin A1 promoter (e.g., Müller, C., et al., Cloning of the cyclin A 1 genomic structure and characterization of the promoter region , J. Biol. Chem. 276(16):11220-28 [1999]); a CD34 promoter (e.g., Burn, T. C., et al., Hematopoietic stem cell specific gene expression , U.S. Pat. No. 5,556,954); or an integrin alphaIIb promoter (e.g., Wilcox, D.
  • a cyclin A1 promoter e.g., Müller, C., et al., Cloning of the cyclin A 1 genomic structure and characterization of the promoter region , J. Biol. Chem. 276(16):11220-28 [1999]
  • a CD34 promoter e.g., Burn, T. C., et al., Hem
  • operatively linked means that the promoter sequence, is located directly upstream from the PAPSS2 or Papss2 coding sequence, which is in reading frame, and that both sequences are oriented in a 5′ to 3′ manner, forming a transcriptional unit, such that transcription can take place in vitro in the presence of all essential enzymes, transcription factors, co-factors, activators, and reactants, under favorable physical conditions, e.g., suitable pH and temperature. This does not mean that, in any particular cell, conditions will favor transcription.
  • nucleic acid can be used in a genetic replacement therapy for humans to correct clinical disorders derived from defective endogenous expression of PAPSS activity.
  • defective expression can result from, but need not result from, endogenous underexpression of functional PAPSS2 protein, in particular.
  • a reporter gene sequence encoding a reporter protein for facilitating the detection or selection of cells containing the present nucleic acid construct and expressing PAPSS2 or Papss2.
  • the reporter gene encodes a fluorescent protein.
  • Fluorescent proteins include green fluorescent protein (or enhanced green fluorescent protein), yellow fluorescent protein, blue fluorescent protein, a phycobiliprotein, such as phycoerythrin or phycocyanin, or any other protein which fluoresces under suitable wave-lengths of light.
  • Another reporter gene suitable for some applications is a gene encoding a protein that can enzymatically lead to the emission of light from a substrate(s); for purposes of the present invention, such a protein is a “light-emitting protein.”
  • a light-emitting protein includes proteins such as luciferase or apoaequorin.
  • the DNA segment encodes a PAPSS2 or Papss2 gene-specific antisense RNA, such as an antisense RNA that specifically hybridizes to PAPSS2 mRNA or Papss2 mRNA, preventing translation therefrom.
  • a PAPSS2 or Papss2 gene-specific antisense RNA such as an antisense RNA that specifically hybridizes to PAPSS2 mRNA or Papss2 mRNA, preventing translation therefrom.
  • the nucleic acid construct comprises a chimeric RNA/DNA, such as a chimeric RNA/DNA oligonucleotide.
  • RNA/DNA chimers are useful, for example, in altering single nucleotide polymorphisms (SNPs) or other point mutations in an endogenous PAPSS2 gene sequence.
  • SNPs single nucleotide polymorphisms
  • a SNP in PAPSS2 associated with encoding a truncated or otherwise dysfunctional PAPSS2 protein can be stably repaired using a chimeric RNA/DNA oligonucleotide of the present invention.
  • the nucleic acid construct is a probe or primer sequence.
  • the inventive probe is a labeled polynucleotide that is useful in hybridization assays, such as Southern, Northern, or fluorescence in situ (FISH) hybidizations, for detecting the presence in a sample of polynucleotides having a gene-specific PAPSS2 or Papss2 sequence.
  • the probe is fully complementary to SEQ. ID. NOS.:1, 2, 9, or 10, or is complementary to a gene-specific fragment of any of these.
  • the suitable labels for a probe are typically radioisotopes or fluorogens incorporated into or covalently linked to the polynucleotide by methods known in the art, and are detectable by conventional radiation or fluorescence detecting methods.
  • the primer of the present invention is an oligonucleotide sequence that is useful in amplifying a nucleic acid segment from a sample that defines a nucleotide sequence specific to PAPSS2 or Papss2 by known methods of PCR, including RT-PCR.
  • the primer is preferably 15 to 30 nucleotides long, and most preferably 17 to 22 nucleotides long, but primers as short as 7 contiguous nucleotides may be useful for some gene-specific sequences.
  • PCR DNA Cell Biol. 13(1):75-82 [1994]
  • Examples of useful oligonucleotide primer sequences for amplifying PAPSS2-specific nucleic acid segments include primer sequences comprising: (SEQ. ID. NO.:3; forward primer) 5′-TGGACCAAGGATGACGATGT-3′; (SEQ. ID. NO.:4; reverse primer) 5′-CGGAAAGATGGCAACAATGG; (SEQ. ID. NO.:5; forward primer) 5′-CTGGTGCTGGAAAAACAACG-3′; (SEQ. ID. NO.:6; reverse primer) 5′-TGCGAATGGAGAAATAAAGCTG; (SEQ. ID. NO.:11; forward primer) 5′-GCCAGCCAGCATGTCGGGGAT-3′; (SEQ.
  • a complementary nucleotide sequence, or a gene-specific fragment of any of these is also useful; also useful are PAPSS2-specific primer sequences that overlap any of the afore-mentioned primer sequences at 5 or more contiguous nucleotide positions at their 5′ or 3′ end.
  • Useful primers for amplifying Papss2-specific sequences include primer sequences comprising: (SEQ. ID. NO.:19; reverse primer) 5′-TCTGGCACAAAGAGTTCGTG-3′; (SEQ. ID. NO.:20; forward primer) 5′-GCCAGTTTGTAACCGAGTATTC-3′; (SEQ. ID. NO.:21; reverse primer) 5′-GCAATTGGATACAGAGCAGCTA-3′; (SEQ. ID. NO.:22; forward primer) 5′-GACAATGTCCGTCATGGCCTTA-3′; (SEQ. ID. NO.:23; forward primer) 5′-ATTCCCATTGTATTGCCCGTT-3′; (SEQ. ID. ID.
  • reverse primer 5′-AACGGGCAATACAATGGGAAT-3′; (SEQ. ID. NO.:25; reverse primer) 5′-GATAAAGCTGGTGATGCAAACC-3′; (SEQ. ID. NO.:26; reverse primer) 5′-CATGGGATGGCGTGAGATAC-3′; or (SEQ. ID. NO.:27; forward primer) 5′-CATAAGCTTTGCTTTGGAAGAGT-3′,
  • a complementary nucleotide sequence, or a gene-specific fragment of any of these is also useful; also useful are Papss2-specific primer sequences that overlap any of the afore-mentioned primer sequences at 5 or more contiguous nucleotide positions at their 5′ or 3′ end.
  • the present invention also relates to a pair of oligonucleotide primers (i.e., a primer set) comprising at least one forward and at least one reverse oligonucleotide primer, which together are capable of producing detectable nucleic acid amplification products from the 5′ and 3′ ends of a PAPSS2 or Papss2 nucleic acid template in a PCR- or RT-PCR-based nucleic acid amplification method.
  • a pair of oligonucleotide primers i.e., a primer set
  • a primer set comprising at least one forward and at least one reverse oligonucleotide primer, which together are capable of producing detectable nucleic acid amplification products from the 5′ and 3′ ends of a PAPSS2 or Papss2 nucleic acid template in a PCR- or RT-PCR-based nucleic acid amplification method.
  • the amplification products that the pair of primers can amplify include nucleic acid amplification products comprising (SEQ. ID. NO.:1) or (SEQ. ID. NO.:9); a nucleotide sequence complementary to either of those; or a PAPSS2 gene-specific fragment of any of these.
  • Examples of this embodiment of the inventive pair of oligonucleotide primers include pairs containing a forward primer having a nucleotide sequence comprising (SEQ. ID.
  • oligonucleotide primer pairs for amplifying a PAPSS2 gene sequence include (SEQ. ID. NO.:3 and 4) or (SEQ. ID. NO.:5 and 6).
  • the amplification products that the pair of oligonucleotide primers can amplify include nucleic acid amplification products having (SEQ. ID. NO.:2) or (SEQ. ID. NO.:10); a nucleotide sequence complementary to either of those; or a Papss2 gene-specific fragment of any of these.
  • Examples of this embodiment of the inventive primer pair include pairs containing a forward primer having a nucleotide sequence comprising (SEQ. ID.
  • inventive nucleic acid construct include those in which, cloned into an expression vector, is a DNA segment encoding a PAPSS2 or Papss2 protein, operatively linked with any suitable promoter sequence, including a human PAPSS2 promoter, a promoter from another human or non-human PAPS synthetase gene (e.g., PAPSS1, Papss1, or Papss2 promoters), or a predetermined promoter sequence from any other human or non-human gene, as described above.
  • a human PAPSS2 promoter e.g., a promoter from another human or non-human PAPS synthetase gene (e.g., PAPSS1, Papss1, or Papss2 promoters)
  • a predetermined promoter sequence from any other human or non-human gene, as described above.
  • Suitable vector systems include, but are not limited to, viral vectors, for example, adenoviruses, adeno-associated viruses, retroviruses such as human immune-deficiency virus, other lentiviruses, such as Moloney murine leukemia virus and the retrovirus vector derived from Moloney virus called vesicular-stomatitis-virus-glycoprotein (VSV-G)-Moloney murine leukemia virus, mumps virus, and transfecting fragments of any of these viruses, and other viral DNA segments that facilitate the uptake of the desired DNA segment by, and release into, the cytoplasm of cells and mixtures thereof. All of the above viruses may require modification to render them non-pathogenic or less antigenic. Other known vector systems, however, are also suitable for containing the DNA segment.
  • viral vectors for example, adenoviruses, adeno-associated viruses, retroviruses such as human immune-deficiency virus, other lentiviruses, such as
  • the present invention also relates to a genetically modified vertebrate cell containing the nucleic acid construct of the present invention, regardless of the method by which the construct was introduced into the cell.
  • Embodiments include cartilage-forming cells, such as chondrocytes, and liver cells, such as hepatocytes, as well as cells derived from other tissues such as, colon, lung, placenta, aortic or other vascular endothelium, bone marrow, or heart.
  • the genetically modified cells of the present invention can be detected, isolated or selected from unmodified cells with the aid of, for example, a flow-activated cell sorter (FACS), set at the appropriate wavelength(s), or using conventional microscopic technology.
  • FACS flow-activated cell sorter
  • this expression may be linked to a reporter gene that encodes a different fluorescent or light-emitting protein from the reporter gene linked to PAPSS2 or Papss2 expression.
  • a reporter gene that encodes a different fluorescent or light-emitting protein from the reporter gene linked to PAPSS2 or Papss2 expression.
  • Gene delivery to the cell is by any suitable method including in vivo and vitro gene delivery methods.
  • gene delivery involves exposing a cell to a gene delivery mixture that includes preselected genetic material together with an appropriate vector, mixed, for example, with an effective amount of lipid transfecting agent (lipofection).
  • lipofection lipid transfecting agent
  • the amount of each component of the mixture is chosen so that gene delivery to a specific species of cell is optimized. Such optimization requires no more than routine experimentation.
  • the ratio of DNA to lipid is broad, preferably about 1:1, although other proportions may also be utilized depending on the type of lipid agent and the DNA utilized. This proportion is not crucial.
  • Other well known gene delivery methods include electroporation or chemical methods. (E.g., M. Ostresh, No barriers to entry: transfection tools get biomolecules in the door , The Engineer 13(11):21-23 [1999]).
  • Gene delivery agent means a composition of matter added to the genetic material for enhancing the uptake of exogenous DNA segment(s) into a vertebrate cell. The enhancement is measured relative to the uptake in the absence of the gene delivery agent.
  • gene delivery agents include adenovirus-transferrin-polylysine-DNA complexes. These complexes generally augment the uptake of DNA into the cell and reduce its breakdown during its passage through the cytoplasm to the nucleus of the cell.
  • Other preferred gene delivery agents include Lipofectin®, DMRIE C, Cellfectin® or Lipofectamine (Life Technologies), LipoTAXI (Stratagene), Superfect or Effectene (Qiagen). Although these are not as efficient gene delivery agents as viral agents, they have the advantage that they facilitate stable integration of xenogeneic DNA sequence into the vertebrate genome, without size restrictions commonly associated with virus-derived gene delivery agents. A virus, or transfecting fragment thereof, can be used to facilitate the delivery of the genetic material into the cell.
  • viruses examples include adenoviruses, adeno-associated viruses, retroviruses such as human immune-deficiency virus, other lentiviruses, such as Moloney murine leukemia virus and the retrovirus vector derived from Moloney virus called vesicular-stomatitis-virus-glycoprotein (VSV-G)-Moloney murine leukemia virus, mumps virus, and transfecting fragments of any of these viruses, and other viral DNA segments that facilitate the uptake of the desired DNA segment by, and release into, the cytoplasm of cells and mixtures thereof. All of the above viruses may require modification to render them non-pathogenic or less antigenic. Other known vector systems are also useful.
  • the present invention also relates to genetically modified non-human vertebrates comprising the present genetically modified cells, for example, non-human primates, mice, rats, rabbits, gerbils, hamsters, canines, felines or other non-human mammals.
  • Other vertebrates include birds such as chickens, turkeys, ducks, ostriches, emus, geese, guinea fowl, doves, quail, rare and ornamental birds, and the like.
  • a genetically modified vertebrate is one that has had exogenous or foreign DNA permanently introduced into one or more of its cells, whether somatic or germ cells.
  • the present invention also relates to an isolated human PAPS synthetase protein comprising a polypeptide having an amino acid sequence of (SEQ. ID. NO.:7), i.e., the following contiguous amino acid residues, or an antibody binding fragment of the protein at least 6 amino acids long (amino acid residue 475 is in boldface): (SEQ. ID.
  • This polypeptide sequence is encoded for example by (SEQ. ID. NO.:9), but is also encoded by other degenerate coding sequences.
  • the PAPSS2 protein forms part of a PAPSS2 fusion protein along with a second predetermined polypeptide segment, which can have an amino acid sequence related or unrelated to (SEQ. ID. NO.:7).
  • the PAPSS2 fusion protein includes a first PAPSS2 polypeptide segment comprising an amino acid sequence of (SEQ. ID. NO.:7), an enzymatically active fragment thereof, or a gene-specific antibody binding fragment of (SEQ. ID. NO.:7) at least 6 amino acids long; and a second predetermined polypeptide segment.
  • the fusion protein is produced by known recombinant methods, and the second predetermined polypeptide sequence can be any desired polypeptide, for example, a known antigenic sequence, such as a specific goat, rabbit, or HLA antigen to which immunoreagents of commercially available immunoassay systems are directed.
  • a known antigenic sequence such as a specific goat, rabbit, or HLA antigen to which immunoreagents of commercially available immunoassay systems are directed.
  • conventional immunoassay systems can be used “off the shelf” to detect and quantify a PAPSS2 fusion protein by detecting the second polypeptide sequence.
  • the second polypeptide of the fusion protein is a polypeptide that allows the hybrid molecule to enter cells of a target tissue, for example, cartilage, liver, or platelets, whether in vitro or in vivo.
  • a second polypeptide can be chosen that infiltrates the cells of tissues, such as the human immunodeficiency virus (HIV) TAT protein (Schwarze, S.
  • the present invention also relates to an isolated murine Papss2 protein comprising an amino acid sequence of (SEQ. ID. NO.:8), i.e., the following contiguous amino acid residues, or an antibody binding fragment of the protein at least 6 amino acids long: (SEQ. ID.
  • This polypeptide sequence is encoded for example by (SEQ. ID. NO.:10), but is also encoded by other degenerate coding sequences.
  • the Papss2 protein forms part of a Papss2 fusion protein along with a second predetermined polypeptide segment, which can have an amino acid sequence related or unrelated to (SEQ. ID. NO.:8).
  • the Papss2 fusion protein includes a first Papss2 polypeptide segment comprising an amino acid sequence of (SEQ. ID. NO.:8) or a gene-specific antibody binding fragment thereof at least 6 amino acids long; and a second predetermined polypeptide segment.
  • the fusion protein is produced by known recombinant methods, and the second predetermined polypeptide sequence can be any desired polypeptide, for example, a known antigenic sequence, such as a specific goat, rabbit, or HLA antigen to which immunoreagents of commercially available immunoassay systems are directed.
  • a known antigenic sequence such as a specific goat, rabbit, or HLA antigen to which immunoreagents of commercially available immunoassay systems are directed.
  • conventional immunoassay systems can be used “off the shelf” to detect and quantify a Papss2 fusion protein by detecting the second polypeptide sequence.
  • the present invention also relates to an isolated antibody or antibody fragment that selectively binds a PAPS synthetase protein having an amino acid sequence of (SEQ. ID. NO.:7) or (SEQ.ID. NO.8), or selectively binds an antibody binding fragment of either of these at least 6 amino acids long.
  • the antibody or antibody fragment is raised against the PAPSS2 or Papss2 protein of the present invention.
  • the antibody is raised in a mammal, from which it is isolated in serum, or is most preferably produced in a hybridoma cell line, by known methods, and is a monoclonal antibody.
  • Antibody fragments of the present antibody are also useful; these include Fab′, F(ab′)2, or F(v) fragments that are produced by known methods, typically by pepsinization of whole antibody.
  • the present invention also relates to a method of diagnosing spondyloepimetaphyseal dysplasia in a human subject.
  • the method involves amplifying a nucleic acid segment from a sample.
  • the sample is derived from a human subject having at least one symptom of spondyloepimetaphyseal dysplasia, and the sample is of a bodily substance containing human nucleic acid of the subject.
  • the nucleic acid segment defines a sequence from human chromosomal region 10q23-24, between microsatellite markers D10S1143 and D10S2470, to produce amplification products; and analyzing the amplification products for the presence of homozygosity for a variant allele of a PAPSS2 gene, the presence of homozygosity for the variant allele of the gene corroborating a diagnosis of spondyloepimetaphyseal dysplasia in the human subject.
  • Any bodily substance containing human nucleic acids from the subject may be sampled, collected, and/or transported for the purpose of practicing the method.
  • a most preferred and convenient substance for sampling is blood.
  • a sample of hair root, urine, amniotic fluid, chorionic villus biopsy, skin biopsy, vascular or oral epithelium, spinal fluid, or other biopsy sample of any tissue is also useful.
  • the sample is derived from cultured human cells, cell-free extracts, or other specimens indirectly derived from a subject's body, as well as from substances taken directly from a subject's body.
  • Samples may be stored before amplification and/or analysis by well known storage means that will preserve nucleic acids in an analyzable condition, such as quick freezing, or a controlled freezing regime, in the presence of a cryoprotectant, for example, dimethyl sulfoxide (DMSO), glycerol, or propanediol-sucrose. Samples may also be pooled before or after storage for purposes of amplifying their nucleic acids for analysis.
  • DMSO dimethyl sulfoxide
  • glycerol glycerol
  • propanediol-sucrose propanediol-sucrose
  • amplifying a nucleic acid segment” from a tissue sample of a subject “to obtain amplification products” encompasses any conventional means of amassing sufficient nucleic acid material for analysis. This includes, but is not limited to, amplification by conventional polymerase chain reaction methods (e.g., PCR, including RT-PCR). Alternatively, the practitioner can amplify the human subject's nucleic acids by in vitro cell culture and harvest of the subject's cultured cells, or by multiple sampling from the subject's tissues in vivo and pooling of multiple tissue samples from a subject. Nucleic acids thus “amplified,” if they comprise a PAPSS2 gene or a gene-specific part thereof, are “amplification products” for purposes of the present invention.
  • PCR is used for amplifying the subject's nucleic acids, particularly from a PAPSS2 gene.
  • any combination of oligonucleotide primers that will amplify nucleic acid sequences of a PAPSS2 gene, or parts thereof, can be employed.
  • amplification of the subject's nucleic acids can be achieved using PAPSS2-specific oligonucleotide primers and primer pairs of the present invention, as described above.
  • useful primers comprise a nucleotide sequence of (SEQ. ID.
  • a sequence complementary to any of (SEQ. ID. NOS.:3-6, 11-18, or 28) or the PAPSS2-specific fragment, or any PAPSS2-specific nucleotide sequence at least 15 nucleotides long and overlapping at 5 or more contiguous nucleotide positions any of (SEQ. ID. NOS.:3-6, 11-18, or 28) at its 5′ or 3′ end is a useful primer sequence.
  • pairs of oligonucleotide primers useful for practicing the method include primer pairs comprising (SEQ. ID. NOS.:3 and 4) or (SEQ. ID. NOS.:5 and 6), but any of the present PAPSS2-specific primer pairs are useful.
  • nucleotide sequencing of PAPSS2 can be used to analyze the amplification products of the nucleic acids in a human subject's tissue sample to detect a variant allele in a PAPSS2 gene.
  • a variant allele of PAPSS2 can be detected by any nucleotide sequencing means, for example conventional dideoxy sequencing or preferably by using a commercially available automated sequencer, then by comparing the subject's nucleotide sequences to other known human PAPSS2 sequences available in genomic sequence databases, such as GenBank.
  • sequencing of PAPSS2 may be accomplished by using fluorescence-based single strand conformation polymorphism analysis (SSCP), a routine and reliable means of identifying point mutations, small insertions or deletions.
  • SSCP fluorescence-based single strand conformation polymorphism analysis
  • J. S. Ellison Fluorescence - based mutation detection. Single - strand conformation polymorphism analysis [F - SSCP], Mol Biotechnol. 5(1):17-31 [1996]; H. Iwahana et al., Multiple fluorescence - based PCR - SSCP analysis using internal fluorescent labeling of PCR products , Biotechniques 21(3):510-14, 516-19 [1996]; R.
  • F - SSCP fluorescence - based polymerase chain reaction - single - strand conformation polymorphism [PCR - SSCP ], PCR Methods Appl. 2(1):10-13 [1992]).
  • An automated system may be used, such as an Applied Biosystems DNA sequencer, equipped with GENESCAN 672, Genetyper, or another appropriate analytical software package.
  • high throughput analysis is achieved by PCR multiplexing techniques well known in the art. (E.g., Z. Lin et al., Multiplex genotype determination at a large number of gene loci , Proc. Natl. Acad. Sci. USA 93(6):2582-87 [1996]).
  • nucleotide sequencing is unnecessary for analyzing the amplification products.
  • heteroduplex analysis on high resolution gel matrices can be employed by the skilled practitioner to detect even single nucleotide polymorphisms.
  • the PCR/OLA procedure can be used for analyzing amplification products to detect SNPs in PAPSS2.
  • B. R. Glick and J. J. Pasternak Molecular Biotechnology: Principles and Applications of Recombinant DNA , ASM Press, Washington, D.C., pp.
  • Conformation-sensitive gel electrophoresis of amplification products can also be employed as a means of analysis by the skilled artisan in practicing the methods of the present invention.
  • A. Markoff et al. Comparison of conformation - sensitive gel electrophoresis and single strand conformation polymorphism analysis for detection of mutations in the BRCA 1 gene using optimized conformation analysis protocols , Eur. J. Genet. 6(2):145-50 [1998]).
  • electrophoresis for analyzing amplification products is done rapidly and with high sensitivity by using any of various methods of conventional slab or capillary electrophoresis, with which the practitioner can optionally choose to employ any facilitating means of nucleic acid fragment detection, including, but not limited to, the use of radionuclides, biotin, UV-absorbance or laser-induced fluorescence.
  • any facilitating means of nucleic acid fragment detection including, but not limited to, the use of radionuclides, biotin, UV-absorbance or laser-induced fluorescence.
  • any of diverse fluorescent dyes are optionally used to label primers or amplification products for ease of analysis, including but not limited to, fluorescein, SYBR Green I, YO-PRO-1, thiazole orange, Hex (i.e., 6-carboxy-2′,4′,7′,4,7-hexachlorofluoroscein), FAM (i.e., 6-carboxyfluorescein), or TET (i.e., 4,7,2′,7′-tetrachloro-6-carboxyfluoroscein).
  • fluorescein i.e., SYBR Green I, YO-PRO-1, thiazole orange, Hex (i.e., 6-carboxy-2′,4′,7′,4,7-hexachlorofluoroscein), FAM (i.e., 6-carboxyfluorescein), or TET (i.e., 4,7,2′,7′-tetrachloro-6-carboxyflu
  • Analyzing the amplification products can also be done by means of restricting the amplification products with one or more restriction enzymes, for example HincII, followed by separation of the resulting fragments and analysis of fragment length or differential fragment migration in denaturing high-performance liquid chromatography (DHPLC) or gel electrophoresis, as above, including restriction-capillary electrophoresis.
  • restriction enzymes for example HincII
  • this may be achieved by techniques known in the art, such as PCR-restriction fragment-SSCP, which can detect single base substitutions, deletions or insertions.
  • Variant alleles of a PAPSS2 gene may be of any nucleotide sequence defining an open reading frame, or part thereof, that encodes PAPSS2 protein, or of any nucleotide sequence, or part thereof, defining a regulatory region of a PAPSS2 gene.
  • a PAPSS2 regulatory region may include, but is not limited to, a promoter region, an enhancer, a termination sequence, or any other nucleotide sequence, or part thereof, that regulates the transcription of PAPSS2 protein.
  • one variant allele of PAPSS2 characteristic of SEMD Pakistani-type, defines a stop codon instead of a serine codon corresponding to amino acid residue 475 of SEQ. ID. NO.:7, and results in synthesis of a truncated PAPSS2 protein 474 amino acids long. Homozygosity for this variant allele is associated with SEMD Pakistani-type in a human subject, and thus corroborates a diagnosis of SEMD Pakistani type.
  • the present invention also relates to a method of identifying a human carrier of an heritable allele associated with spondyloepimetaphyseal dysplasia.
  • the method of identifying a carrier involves amplifying a nucleic acid segment from a sample derived from a human subject without symptoms of spondyloepimetaphyseal dysplasia, to produce amplification products.
  • the sample is of a bodily substance containing human nucleic acid of the subject.
  • the nucleic acid segment defines a sequence from human chromosomal region 10q23-24, between microsatellite markers D10S1143 and D10S2470.
  • the amplification products are analyzed for the presence of a variant allele of a PAPSS2 gene, which is accomplished as described above.
  • the presence of the variant allele of the gene identifies the human subject as a carrier of an heritable allele associated with spondyloepimetaphyseal dysplasia.
  • a benefit of the present method of identifying a human carrier of an heritable allele associated with SEMD is that couples in which one or both of the spouses is identified as a carrier of a SEMD-associated allele, can make more informed reproductive decisions.
  • the present invention also relates to a gene therapy method for treating a human subject having an osteoarthritic disorder that is caused or aggravated by deficient enzymatic sulfation activity.
  • osteoarthritic disorder that is caused or aggravated by deficient enzymatic sulfation activity.
  • Examples include spondyloepimetaphyseal dysplasia, Stickler syndrome, spondyloepiphyseal dysplasia, and achondrogenesis; achondroplasia; chondrodysplasia; diastrophic dysplasia; the collagen oligomeric matrix protein (COMP) disorders such as pseudoachondroplasia and multiple epiphyseal dysplasia.
  • CIP collagen oligomeric matrix protein
  • the method involves exposing, in vitro, one or more cells derived directly (e.g., biopsied) or indirectly (e.g., cultured) from a tissue of a human subject having at least one symptom of an osteoarthritic disorder caused or aggravated by deficient enzymatic sulfation activity to a gene delivery mixture comprising at least one gene delivery agent and a nucleic acid construct having a nucleic acid segment encoding a PAPS synthetase protein having an amino acid sequence of (SEQ. ID. NO.:7) or (SEQ. ID.
  • nucleic acid construct causing the nucleic acid construct to be taken up by, and released into the cell(s), such that the nucleic acid construct is incorporated into the genome of the cell(s), whereby under appropriate physiological conditions expression of functional PAPS synthetase protein is enhanced in the cell(s), compared to unmodified cells of the same kind.
  • the genetically modified cells are then implanted into the tissue of the human subject, where PAPS synthetase activity is thereby enhanced relative to pre-implantation, and at least one symptom associated with the osteoarthritic disorder in the subject is improved.
  • the human subject is preferably a juvenile, and most preferably a prepubescent juvenile.
  • the human subject is any age.
  • the gene therapy method for treating an osteoarthritic disorder caused or aggravated by deficient enzymatic sulfation activity is directed to symptom(s) related to deficient sulfation activity that may arise in liver cells, e.g., hepatocytes, in platelets, or in vascular tissue, and these symptoms are treated in accordance with the method at any age, depending only on the practitioner's best estimation of the physiologic resilience of the individual patient in facing the stresses of the procedure.
  • cells can be obtained by pertcutaneous or laparoscopic biopsy.
  • cells are also obtained by any other suitable surgical means or from a pre-existing culture derived from a tissue of the subject or other viable sample of the subject's cells.
  • Implantation of the genetically modified cells is accomplished by conventional percutaneous, laparoscopic, stereotactic, or other surgical methods.
  • the method involves genetically modifying a cell(s) derived from a tissue of the subject.
  • a cartilage-forming cell such as a chondrocyte from an epiphyseal region.
  • other cell types can also be genetically modified in accordance with the method to improve osteoarthritic symptoms that may be associated with other tissues, for example hepatocytes, platelets, or vascular endothelium.
  • the cells for example, chondrocytes, hepatocytes, hematopoietic precursor cells, or vascular endothelial cells, are obtained from an appropriate tissue, such as the epiphyses, joints, liver, bone marrow, or vascular tissue.
  • the cell(s) are genetically modified. This can be by any suitable gene delivery method as described above, preferably in vitro, for example by transfection, transduction, or electroporation, but in vivo methods of gene delivery are also contemplated.
  • the cell(s) is exposed to a gene delivery mixture comprising at least one gene delivery agent, as described above, and a nucleic acid construct, preferably DNA, containing a nucleic acid segment encoding a PAPS synthetase protein having an amino acid sequence of (SEQ. ID. NO.:7), for example (SEQ. ID. NO.:9), or containing a nucleic acid segment encoding a PAPS synthetase protein having an amino acid sequence of (SEQ. ID. NO.:8), for example (SEQ. ID. NO.:10), operatively linked, in a transcriptional unit, to a predetermined promoter sequence that operates in the cell.
  • the nucleic acid construct that is used in the present gene therapy method optionally contains a reporter gene for convenient detection, isolation or selection of genetically modified cells expressing PAP synthetase protein from an exogenously supplied gene, as described above.
  • the construct is then taken up by and released into the cell, and is incorporated into the genome of the cell. Under appropriate physiological conditions, transcription of the PAPSS2 or Papss2 encoding region occurs, followed by translation, and thus, expression of PAPSS2 or Papss2 protein is enhanced in the cell, compared to unmodified cells of the same kind.
  • the cell(s) implanted in the tissue of the subject one or more symptoms of the osteoarthritic disorder in the subject are thereby improved due to enhanced enzymatic sulfation in the tissue of biochemicals that require sulfation for bioactivity or have increased bioactivity in humans in a sulfated form.
  • chondrocytes and stem cell precursors of chondrocytes can be obtained from fetal cartilage, can be genetically modified and re-implanted while the subject is in utero.
  • Another embodiment of the gene therapy method of the present invention involves a gene modification strategy employing a chimeric RNA/DNA oligonucleotide construct, particularly useful in repairing SNPs associated with a SEMD phenotype, such as the allele encoding a stop codon instead of serine at position 475 of (SEQ. ID. NO.:7) (e.g., “TAA” instead of “TCA” at nt. +1423 through +1425 of SEQ. ID. NO.:1; see FIG. 3), associated with SEMD Pakistani type. (E.g., Kren, B. T., et al., Gene repair using chimeric RNA/DNA oligonucleotides , Semin. Liver Dis.
  • a SEMD phenotype such as the allele encoding a stop codon instead of serine at position 475 of (SEQ. ID. NO.:7) (e.g., “TAA” instead of “TCA” at nt. +1423
  • this gene modification strategy exploits the recombinogenicity of RNA-DNA hybrids and features the use of chimeric RNA/DNA oligonucleotides with hairpin capped ends that avoid destabilization or destruction by cellular helicases or exonucleases; an RNA/DNA oligonucleotide is designed so that it perfectly aligns with a specific genomic target sequence except for a single mismatched basepair, which is recognized by endogenous DNA repair systems that can then convert the SNP to a desired normal sequence.
  • the cells are exposed to a nucleic acid construct that includes a chimeric RNA/DNA oligonucleotide.
  • This chimeric RNA/DNA comprises a nucleic acid segment of a PAPSS2 gene comprising a nucleotide sequence of (SEQ. ID. NO.:9), (SEQ. ID. NO.:10), or a gene-specific fragment of either of these.
  • the nucleic acid construct is taken up by, and released into, the cell, and the nucleotide sequence of the nucleic acid segment is incorporated into the genome of the cell, whereby expression of functional PAPS synthetase protein is enhanced in the cell.
  • the genetically modified cell(s) is then implanted into the tissue of the human subject, as described above. With the cell(s) implanted in the tissue of the subject, one or more symptoms of the osteoarthritic disorder in the subject are thereby improved due to enhanced enzymatic sulfation in the tissue of biochemicals that require sulfation for bioactivity or have increased bioactivity in humans in a sulfated form.
  • the gene therapy method provides a much needed way to improve or eliminate symptoms of aberrant skeletal growth or joint degeneration associated with osteoarthritic disorders such as SEMD.
  • the method provides a way to improve symptoms resulting from deficient sulfation activity in other cell types, such as hepatocytes, platelets, or vascular epithelium, for example, abnormally long bleeding time.
  • the present invention is also related to a protein therapy method for treating a human subject having an osteoarthritic disorder.
  • the osteoarthritic disorder is one that is caused or aggravated by deficient enzymatic sulfation activity, as described above.
  • the method employs the inventive PAPSS2 fusion protein.
  • the method involves exposing a cell(s) of a tissue of a human subject having the osteoarthritic disorder to a fusion protein comprising a first PAPSS2 polypeptide segment that comprises an amino acid sequence of (SEQ. ID.
  • Exposing the cell(s) is preferably accomplished in vivo, for example by injecting or infusing the fusion protein into the subject.
  • An example of a second polypeptide segment capable of infiltrating a diversity of cell types is an human immunodeficiency virus (HIV) TAT protein. (Schwarze, S. R., et al. [1999]). But a tissue-specific second polypeptide can also be used.
  • HIV human immunodeficiency virus
  • a useful indicator of improvement in symptoms of aberrant skeletal growth is a comparison of the subject's growth rate over a period of months or years after treatment using the method, with the rate of growth before treatment. It is also useful to compare the subject's growth over time after treatment with standard growth curves or tables for humans of the same age and sex. Improvement in joint function, for example reduction in joint pain or enhanced joint movement, or joint appearance on x-ray, are useful indicators. Another useful indicator is improvement in platelet function, which is detected in normalized or shortened bleeding time for the subject.
  • biochemical or molecular methods are employed to detect improvement.
  • assays showing increased sulfation activity in a tissue biopsy sample(s) from the subject are useful in determining the effectiveness of the method.
  • tissue biopsy sample(s) from the subject such as in cartilage, liver, or blood samples and/or extracts
  • assays are based on direct measurement of in vivo and/or in vitro PAPS synthetase enzymatic activity or detecting the assimilation of sulfate into APS (i.e., sulfate activation assay) or into other sulfated metabolites, for example measuring the degree of sulfation of aggrecan side chains.
  • Radiolabeled (e.g., 35 S) sulfate and chromatographic separations are common tools used in such assay methods. Detection of PAPSS2-specific mRNA transcripts in tissue samples, using the probes or primers of the present invention, can also be employed as an indirect measure of improvement.
  • the nucleic acid construct that is used in the present gene therapy method can optionally contain in the transcriptional unit a reporter gene, as described above, for convenient detection of genetically modified cells expressing exogenous PAPSS2 in a tissue biopsy sample(s) from the subject.
  • the present invention is also related to a genetic testing kit for diagnosing SEMD in a human subject.
  • the kit is an assemblage of materials for facilitating amplifying nucleic acids from a human subject comprising PAPSS2 nucleotide sequences and/or analyzing PAPSS2-derived amplification products.
  • a genetic testing kit of the present invention comprises at least one oligonucleotide primer of the present invention and preferably comprises a pair of oligonucleotide primers of the present invention, together with instructions for the practice of the methods of the present invention.
  • a most preferred embodiment of the genetic testing kit of the present invention comprises an inventive pair of oligonucleotide primers, as described above, for example (SEQ. ID.
  • a preferred embodiment of the genetic testing kit of the present invention can incorporate an array of oligonucleotide primers specific for SNPs in human PAPSS2, preassembled in a “DNA chip” (or “gene chip”) configuration for facilitating the amplifying of nucleic acids and the analyzing of amplification products.
  • a “DNA chip” or “gene chip”
  • the present invention also relates to a kit for genetically modifying a vertebrate cell.
  • the kit is a ready assemblage of materials or components for facilitating the genetic modification of a vertebrate cell.
  • the kit includes a polynucleotide comprising a PAPSS2 sequence having SEQ. ID. NOS.:1, or a Papss2 sequence having SEQ. ID. NO.:2, a sequence complementary to either of these, or a degenerate coding sequence thereof (i.e., encoding SEQ. ID. NOS.:7 or 8), or a gene-specific fragment of any of these, as described herein with respect to the nucleic acid construct of the present invention.
  • the polynucleotide includes a transcriptional unit that contains the human PAPSS2- or murine Papss2-encoding nucleic acid segment, operatively linked to a functional promoter sequence, and/or a reporter gene for facilitating detection, isolation, or selection of genetically modified cells from unmodified cells.
  • the kit optionally contains a suitable gene delivery agent. The kit is particularly useful in practicing the gene therapy method for treating a human subject having an osteoarthritic disorder that is caused or aggravated by deficient enzymatic sulfation activity.
  • the kit includes a DNA sequence encoding the PAPSS2 or Papss2 protein, or fragment thereof at least 6 amino acids long, in a sense or antisense orientation, as appropriate for a particular application.
  • the kit includes a PAPSS2- or Papss2-specific chimeric RNA/DNA oligonucleotide, as described above.
  • Some embodiments of the kit are configured for use in practicing the present method of treating a human subject having an osteoarthritic disorder, as described above.
  • the present invention also relates to a kit for practicing the inventive method of protein therapy for treating a human subject having an osteoarthritic disorder that employs the inventive PAPSS2 fusion protein, as described above.
  • the kit contains a fusion protein comprising a first PAPSS2 polypeptide segment that comprises an amino acid sequence of (SEQ. ID. NO.:7), or an enzymatically active fragment thereof, and a second polypeptide segment capable of infiltrating the cell, whereby the fusion protein is taken up by the cell and the PAPSS2 polypeptide segment is enzymatically active within the cell.
  • a second polypeptide segment capable of infiltrating cell(s) is an human immunodeficiency virus (HIV) TAT protein, which can infiltrate diverse cell types, but other polypeptide segments are also useful.
  • HIV human immunodeficiency virus
  • kits for diagnosing SEMD or identifying a carrier of a heritable marker associated with SEMD and kits for genetically modifying a vertebrate cell or for protein therapy can be provided to the practitioner stored in any convenient and suitable ways that preserve their operability and utility.
  • the components can be in dissolved, dehydrated, or lyophilized form; they can be provided at room, refrigerated or frozen temperatures.
  • the kits of the present invention include instructions for using the materials or components effectively for their intended purpose(s).
  • polynucleotides, nucleic acid constructs, primers, primer pairs, and kits of the present invention can be used therapeutically to detect SEMD in patients with specific variant alleles of PAPSS2.
  • variant alleles can be targeted for gene therapy directed at repairing malfunctional PAPSS2 alleles or they may suggest specific chemotherapy directed to enhancing endogenous PAPS synthetase activity or may be directed to other metabolic targets in biochemical pathways mediated by PAPS synthetase activity.
  • Genotyping Synthetic oligonucleotide primers were obtained for genotyping in the SEMD family with polymorphic microsatellite markers from the CHLC Human Screening Set/Weber version 8 (Research Genetics). Additional markers were derived from a physical map of chromosome 10 (Gray, I. C., et al., An integrated physical and genetic map spanning chromosome band 10 q 24, Genomics 43:85-88 [1997]) and databases from the Whitehead Institute for Biomedical Research, the Cooperative Human Linkage Center, and Genethon.
  • SEMD was modeled as an autosomal recessive fully penetrant disease with an allele frequency of 0.0001.
  • LOD scores were summed across the pedigrees.
  • BLAST searches Altschul, S. F., et al., Gapped BLAST and PSI - BLAST: a new generation of protein search programs, Nucleic Acids Res. 25:3389-3402 [1997]
  • determinations of sequence homology were performed using the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/BLAST/) and Baylor College of Medicine (http://dot.imgen.bcm.tmc.edu:933 1/seq-search/nucleic_acid-search.html) servers.
  • the phenoytpic map of the mouse genome was accessed through the Mouse Genome Informatics server (http://www.informatics.jax.org), maintained by the Jackson Laboratory.
  • oligonucleotide primers B SEQ. ID. NO.:12, below
  • E SEQ. ID. NO.:15, below
  • the fragment was hybridized to plaques from a directional human fetal cartilage cDNA library constructed by Stratagene in the lambda ZAP2 vector (D. Krakow and D. Cohn, unpublished).
  • a forward primer SEQ. ID.
  • Primers used for sequence analysis of the cDNA clones were: (SEQ. ID. NO.:11; forward primer) (A) 5′-GCCAGCCAGCATGTCGGGGAT-3′; (SEQ. ID. NO.:12; forward primer) (B) 5′-ACCTGAAACTCCTGAGCGTGTGCT-3′; (SEQ. ID. NO.:13; forward primer) (C) 5′-GATGTGCCTCTAGACTGGCGG-3′; (SEQ. ID. NO.:14; reverse primer) (D) 5′-GAGCACTTCAGAAAGAAACTCTGG-3′; (SEQ. ID.
  • reverse primer E) 5′-CATCCGCCAGTCTAGAGGCAC-3′; (SEQ. ID. NO.:16; reverse primer) (F) 5′-AGGTGTCAGACGGTATTGGTC-3′; (SEQ. ID. NO.:17; reverse primer) (G) 5′-GTCACTCACTGTGGACAAATTGG-3′; and (SEQ. ID. NO.:18; reverse primer) (H) 5′-CACCTCAGCAATCCGGCGGAT-3′.
  • the sequence of 3′ end of the coding region of the mouse Papss2 cDNA was identified by database searching.
  • the 5′ end of the cDNA was isolated from a mouse brain cDNA library, constructed from the C57BL/6 strain in the Uni-ZAP XR vector (Stratagene), by amplification from pooled library DNA using a gene specific primer derived from the sequence at locus D19Mit13 (5′-TCTGGCACAAAGAGTTCGTG-3′ [SEQ. ID. NO.:19; reverse primer]) and a vector-specific primer.
  • oligonucleotide primers from the 5′ ([a] 5′-GCCAGTTTGTAAC CGAGTATTC-3′ [SEQ. ID. NO.:20; forward primer]) and 3′ ([b] 5′-GCAATTGGATACAGAGCAGC TA-3′ [SEQ. ID. NO.:21; reverse primer]) untranslated regions were used. Sequence was determined using the 5′ and 3′ untranslated region primers as well as primers: (SEQ. ID. NO.:22; forward primer) (c) 5′-GACAATGTCCGTCATGGCCTTA-3′; (SEQ. ID.
  • forward primer (d) 5′-ATTCCCATTGTATTGCCCGTT-3′; (SEQ. ID. NO.:24; reverse primer) (e) 5′-AACGGGCAATACAATGGGAAT-3′; and (SEQ. ID. NO.:25; reverse primer) (f) 5′-GATAAAGCTGGTGATGCAAACC-3′.
  • RNA was purified from a lymphoblastoid cell line from an affected family member. RT-PCR using either the primers from the 5′- and 3′-untranslated regions (primers A and D, above) or internal primers were used to amplify cDNA fragments containing the entire coding region. Control fragments were amplified from human cartilage RNA. Direct sequence analysis of the PCR products using the primers listed above was used to identify the mutation. To confirm the mutation and examine segregation in the Pakistani family, we used HincII digestion of a 108 bp genomic DNA fragment amplified with primers 5′-TGGA (SEQ. ID. NO.:3; forward primer) 5′-TGGACCAAGGATGACGATGT-3′ and (SEQ. ID. NO.:4; reverse primer) 5′-CGGAAAGATGGCAACAATGG-3′.
  • RNA was purified from frozen spleen from the brachymorphic mouse and a PWK control. (Rusiniak et al. [1996]).
  • the Papss2 coding region was amplified in two fragments by RT-PCR using primer pair (a) (SEQ. ID. NO.:20; forward primer) plus (g) 5′-CATGG GATGGCGTGAGATAC-3′ (SEQ. ID. NO.:26; reverse primer) and primer pair (b) (SEQ. ID. NO.:21; reverse primer) plus (h) 5′-CATAAGCTTTGCTTT GGAAGAGT-3′ (SEQ. ID. NO.:27; forward primer), and the sequence was determined using the primers (c)-(f) listed above.
  • a pooling strategy was used to carry out a genome-wide search for the chromosomal region containing the disease gene in a large inbred Pakistani SEMD family (Ahmad et al., 1998, incorporated by reference). A total of 381 markers were typed, ultimately achieving an average marker spacing of about 10 cM. Individual genotypes for all studied family members were determined for 83 markers that showed differences in allele distributions between the affected and unaffected pools. For all but three of these markers, D10S1432, D10S2470, and D10S677, linkage to the SEMD phenotype could be excluded. Significant linkage was initially obtained for the marker at locus D10S2470, yielding a maximum two-point lod score of 5.44 at a recombination fraction of 0.01.
  • a proximal boundary at locus D10S1689 was established by the haplotypes of three individuals, VI-2, VI-4 and VIII-2.
  • a distal limit at locus D10S2470 was established by a recombination observed in VIII-15. Together, these recombinant events localized the disease gene within a maximum interval of 8.1 cM, flanked on the proximal side by the marker at locus D10S1689 and on the distal side by the marker at locus D10S2470.
  • the genotype of individual VI-7 provided clear evidence of recombination within the 8.1 cM interval.
  • FIG. 1 shows a genetic map of the interval containing the SEMD disease gene on human chromosome 10.
  • the darker bar identifies the 8.1 cM maximum interval between loci D10S1689 and D10S2470.
  • the 1.7 cM minimum interval is identified by the darkest bar, between loci D10S1143 and D10S2470.
  • the locations of D10S1432 and D10S677 are not drawn to scale.
  • the SEMD interval established by linkage corresponded to chromosomal region 10q23-24, which is syntenic with the region of mouse chromosome 19 to which the recessive mouse skeletal mutant brachymorphic was localized.
  • This regional homology implied that the two phenotypes could be due to mutations in an orthologous pair of genes.
  • Additional recombination mapping using recombinant mice from a large backcross with the brachymorphic mouse showed that only 3 of 25 mice recombinant at the previously defined proximal boundary (Rusiniak, M. E., et al., Molecular markers near the mouse brachymorphic ( bm ) gene, which affects connective tissues and bleeding time , Mamm.
  • Genome 7:98-102 [1996]) the markers at loci D19Mit39 and D19Mit57, were recombinant at locus D19Mit135.
  • the distal limit was not further narrowed by recombination mapping, leaving a total estimated interval of about 0.7 cM, flanked by the markers at loci D19Mit135 and D19Mit64, containing the bm mutation. (FIG. 2).
  • the marker at locus D19Mit13 was the only marker non-recombinant with the brachymorphic phenotype and, because of the large size of the cross, was therefore expected to be extremely close to the disease gene.
  • a BLAST search using D19Mit13 as the query sequence was carried out to test the hypothesis idea that the marker might be within an intron of the bm gene.
  • Sequences on both sides of the D19Mit13 CA repeat element were about 80% homologous to a human expressed sequence tag (EST), zc38a08.r1, which was distinct from but similar to the known PAPS synthetase gene, Papss1.
  • nucleotide sequences of PAPSS2 cDNA clones isolated from a human fetal cartilage cDNA library were determined. The reading frame was determined by comparison with the paralogous human PAPSS1 and mouse Papss1 cDNA sequences. At the 5′ end, an in-frame ATG codon immediately preceded by a sequence that fit the consensus sequence for translation initiation (Kozak, M., An analysis of 5′- noncoding sequences from 699 vertebrate messenger RNAs , Nucleic Acids Res. 15:8125-48 [1987]) was assumed to represent the first translated codon.
  • the coding region of the human PAPSS2 cDNA was amplified by RT-PCR using RNA derived from a lymphoblastoid cell line from an affected member of the Pakistani SEMD family.
  • the data presented here demonstrate that a mutation in a novel gene in the sulfate activation pathway results in a human osteochondrodysplasia phenotype.
  • the PAPSS2 mutation characterized in the Pakistani SEMD family introduced a nonsense mutation at the codon for residue 475 of the 615 amino acid protein. It is unknown whether, as has been observed for many other genes (e.g., Willing, M. C., et al., Premature chain termination is a unifying mechanism for COL 1 A 1 null alleles in osteogenesis imperfecta type I cell strains , Am. J. Hum. Genet. 59:799-809 [1996]), the nonsense mutation leads to destabilization of the transcript, or if a truncated protein, perhaps retaining partial activity, is synthesized.
  • the characterized mutation is the only structural mutation in the coding region that is unique to the brachymorphic mouse.
  • the mutation results in substitution for a highly conserved residue among other Papss proteins and APS kinase domains of species from vertebrates to bacteria, suggesting it is essential for kinase activity.
  • the phenotype of the brachymorphic mouse and the human SEMD family are substantially similar. Both are recessively inherited dwarfing conditions that affect the spine and long bones. (Lane & Dickie [1968]; Ahmad, M., et al. [1998]).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are isolated polynucleotides containing nucleic acid segments encoding human or murine ATP sulfurylase/APS kinase, also known as PAPS synthetase (PAPSS), particularly PAPSS2 and Papss2 proteins. Also disclosed are nucleic acid constructs, including vectors, probes, primers, and primer pairs containing novel PAPSS2 and Papss2 gene sequences. A genetically modified vertebrate cell containing a nucleic acid construct of the present invention and a non-human vertebrate comprising the cell are also disclosed. Based on the present PAPSS2-specific polynucleotides and nucleic acid constructs, are genetic testing kits and methods for diagnosing spondyloepimetaphyseal dysplasia (SEMD) in a human subject, of identifying a human carrier of an heritable allele associated with SEMD, and of gene therapy or protein therapy for treating a human subject having an osteoarthritic disorder, which is caused or aggravated by deficient enzymatic sulfation activity. Also disclosed is a protein therapy method for treating a human subject having an osteoarthritic disorder caused or aggravated by deficient enzymatic sulfation activity that employs an inventive PAPSS2 fusion protein. Also disclosed are an isolated antibody or antibody fragment that selectively binds a PAPSS2 or Papss2 protein.

Description

  • [0001] The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of grants HD22657 and AR02038 awarded by the NIH.
    • BACKGROUND OF THE INVENTION
  • Throughout the application various publications are referenced in parentheses. The disclosures of these publications in their entireties are hereby incorporated by reference in the application in order to more fully describe the state of the art to which this invention pertains. [0002]
  • 1. The Field of the Invention [0003]
  • This invention relates to the medical arts. In particular, it relates to a genetic marker that is useful for diagnosing or treating spondyloepimetaphyseal dysplasia and for identifying genetic carriers of heritable alleles associated with spondyloepimetaphyseal dysplasia. [0004]
  • 2. Discussion of the Related Art [0005]
  • Osteochondrodysplasias are a genetically heterogeneous group of disorders related to cartilage producing cells. Abnormalities in cartilage formation can cause defects in bone deposition, skeletal development, linear growth, and the continued maintenance of cartilage and bone. (Reviewed in Mundlos, S. and Olsen, B. R., [0006] Heritable diseases of the skeleton. Part II: Molecular insights into skeletal development-matrix components and their homeostasis, FASEB J. 11 (4):227-33 [1997]).
  • There are numerous and disparate causes of osteochondrodysplasias. (Horton, W. A., [0007] Molecular genetic basis of the human chondrodysplasias, Endocrinol. Metab. Clin. North Am. 25(3):683-97 [1996]). A significant number are due to defects in the collagen genes themselves. (Reviewed in Williams, C. J. and Jiminez, S. A., Heritable diseases of cartilage caused by mutations in collagen genes, J. Rheumatol. Suppl. 43:28-33 [1995]; Byers, P. H., Molecular genetics of chondrodysplasias, including clues to development, structure, and function, Curr. Opin. Rheumatol. 6(3):345-50 [1994]). In addition to collagen defects, several forms of osteochondrodysplasias are caused by mutations in the cartilage oligomeric matrix protein (COMP). (Ikegawa, S., et al., Novel and recurrent COMP mutations in preudoachondroplasia and epiphyseal dysplasia, Hum. Genet. 103(6):633-8 [1998]; Briggs, M. D., et al, Diverse mutations in the gene for cartilage oligomeric matrix protein in the pseudoachondroplasia-multiple epiphyseal dysplasia disease spectrum, Am. J. Hum. Genet. 62(2):311-9 [1998]; Briggs, M. D., et al., Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage matrix protein gene, Nat. Genet. 10(3):330-6 [1995]; Ballo, R., et al., Multiple epiphyseal dysplasia, ribbing type: a novel point mutation in the COMP gene in a South African family, Am. J. Med. Genet. 68(4):396-400 [1997]).
  • Still other osteochondrodysplasias have been found to be caused by defects in secreted peptide growth factors and their receptors. (E.g., Thomas, J. T., et al., [0008] A human chondroplysplasia due to a mutation in a TGF-β superfamily member, Nat. Genet. 12(3):315-7 [1996]; Bonaventure, J., et al., Common mutations in the gene encoding FGFR-3 account for achondroplasia, hypochondroplasia and thanatophoric dysplasia, Acta Paediatr. Suppl. 417:33-38 [1996]).
  • Finally, mutations in genes which affect protein sulfation cause some forms of osteochondrodysplasia. Protein sulfation is a post-translational modification carried out by all cells. (Lipmann, F., [0009] Biological sulfate activation and transfer, Science 128:575-580 [1958]). The primary source of sulfur for the sulfation pathway is free sulfate, which can be transported into the cytoplasm by one of a variety of transmembrane symporter or antiporter molecules. (Elgavish, A., et al., Sulfate transport in human lung fibroblasts (IMR-90), J. Cell Physiol. 125:243-250 [1985]; Markovich, D., et al., Expression cloning of rat renal Na+/SO 4 (2−) cotransport, Proc. Natl. Acad. Sci. U.S.A. 90:8073-8077 [1993]; Bissig, M., et al., Functional expression cloning of the canalicular sulfate transport system of rat hepatocytes, J. Biol.Chem. 269:3017-3021 [1994]; Hastbacka, J., et al., The diastrophic dysplasia gene encodes a novel sulfate transporter: positional cloning by fine-structure linkage disequilibrium mapping, Cell 78:1073-1087 [1994]; Everett, L. A., et al., Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS), Nat. Genet. 17:411-422 [1997]).
  • Within the cytoplasm, sulfate is activated to a high energy form in two enzymatic steps (Geller, D. H., et al, [0010] Co-purification and characterization of ATP-sulfurylase and adenosine-5′-phosphosulfate kinase from rat chondrosarcoma, J. Biol. Chem. 262:7374-7382 [1987]). First, utilizing ATP and sulfate as substrates, an ATP sulfurylase activity catalyzes the synthesis of adenosine 5′-phosphosulfate (APS). Subsequently, an APS kinase activity catalyzes the phosphorylation of the APS to generate 3′-phosphoadenosine 5′-phosphosulfate (PAPS). PAPS is the universal bioactivated sulfate donor used in all known post-translational sulfation reactions.
  • Secreted extracellular matrix proteins are post-translationally sulfated in the Golgi, and delivery of PAPS to the Golgi is mediated by a PAPS translocase activity. Microsomal proteins with PAPS binding activity have been identified (Mandon, E. C., et al., [0011] Purification of the golgi adenosine 3′-phosphate 5′-phosphosulfate transporter, homodimer within the membrane, Proc.Natl.Acad.Sci.U.S.A. 91:10707-10711 [1994]; Ozeran, J. D., et al, Kinetics of PAPS translocase: evidence for an antiport mechanism, Biochemistry 35:3685-3694 [1996]), but the tissue specificity and the contribution of these proteins to PAPS transport remains unknown. Following transport, sulfation reactions are carried out by substrate-specific sulfotransferases. A major class of sulfation substrates within the Golgi is the side-chains of proteoglycans, which are abundant structural proteins of the extracellular matrices of many tissues. Proteoglycans are particularly abundant in the extracellular matrix of cartilage.
  • Direct evidence that sulfation of extracellular matrix proteins is essential for proper matrix function was revealed by the identification of mutations in the diastrophic dysplasia sulfate transporter, DTDST. (Hastbacka et al. [1994]). Mutations in the DTDST gene produce a spectrum of recessively inherited osteochondrodysplasia phenotypes. (Hastbacka et al. [1994]; Hastbacka, J., et al., [0012] Atelosteogenesis type II is caused by mutations in the diastrophic dyplasia sulfate transporter gene (DTDST): Evidence for a phenotypic series involving three chondrodysplasias, Am. J. Hum. Genet. 58:255-262 [1996]; Superti-Furga, et al., A family of chondrodysplasias caused by mutations in the diastrophic dysplasia transporter gene and associated with impaired sulfation of proteoglycans, Ann. N. Y. Acad. Sci. 785:195-201 [1996]). The severity of the three known disorders, i.e., the moderately severe diastrophic dysplasia phenotype and the lethal forms, atelosteogenesis type II and achondrogenesis type IB, is correlated with the consequences of the mutations on the activity of the transporter. (Superti-Furga, A, et al. Achondrogenesis type IB is caused by mutations in the diastrophic dysplasia sulfate transporter gene, Nature Genet. 12:100-02 (1996). The mutations lead to dramatically reduced proteoglycan sulfation in cartilage, particularly the chondroitin sulfate side chains of aggrecan. However, even in the most severe disorder in the group, some proteoglycan sulfation can be measured. (Rossi, A., et al., Undersulfation of proteoglycans synthesized by chondrocytes from patient with achondrogenesis type IB homozygous for an L483P substitution in the diastrophic dysplasia sulfate transporter, J. Biol. Chem. 271:18456-64 [1996]; Rossi, A., et al., Undersulfation of cartilage proteoglycans ex vivo and increased contribution of amino acid sulfur to sulfation in vitro in McAlister dysplasia/atelosteogenesis type 2, Eur. J. Biochem. 248:741-47 [1997]; Rossi, A., et al., Proteoglycan sulfation in cartilage and cell cultures from patients with sulfate transporter chondrodyplasias: relationship to clinical severity and indications on the role of cellular sulfate production, Matrix Biology 17:361-69[1998]).
  • Biochemical evidence that a defect in another step in the sulfation pathway can produce an osteochondrodysplasia phenotype was provided by studies in the brachymorphic (bm) mouse. The brachymorphic phenotype is characterized by disproportionate short-limb dwarfism, a short spine and tail, and a domed skull. (Lane & Dickie [1968]). The brachymorphic mouse also exhibits an increased bleeding time, but tests of platelet function, including aggregation and secretion, have so far failed to reveal specific functional deficits in brachymorphic platelets. (Rusiniak, M. E., et al., [0013] Molecular markers near the mouse brachymorphic (bm) gene, which affects connective tissues and bleeding time, Mamm. Genome 7:98-102 [1996])
  • In brachymorphic mice, abnormal growth plates with a structurally abnormal cartilage extracellular matrix and short chondrocyte columns, with comparatively unaligned cells, are apparent on histologic analysis. (Lane & Dickie [1968]; Orkin et al. [1976]; Orkin et al.[1977]; Miller, W. A. & Flynn-Miller, K. L., [0014] Achondroplastic, brachymorphic and stubby chondrodystophies in mice,J. Comp. Pathol. 86:349-63 [1976]). Cartilage from this recessively inherited mutant phenotype shows small, diffuse proteoglycan granules and reduced staining for sulfated glycosaminoglycans, consistent with a defect affecting sulfation of the proteoglycans of the cartilage extracellular matrix. (Lane, P. & Dickie, M. M., Three recessive mutations producing diproportionate dwarfing in mice: achondroplasia, brachymorphic, and stubby, J. Hered. 59:300-08 [1968]). In brachymorphic mice, proteoglycan granules show a 50% reduction in size in the reserve zone of the growth plate matrix, and are difficult to identify in the proliferative and hypertrophic zones. (Orkin, R. W., et al., Undersulfated chondroitin sulfate in the cartilage matrix of brachymorphic mice, Dev. Biol. 50:82-94 [1976]; Orkin, R. W., et al., Defects in the cartilaginous growth plates of brachymorphic mice, J. Cell Biol. 73:287-99 [1977]). This suggests that reduced proteoglycan sulfation affects the signals that regulate growth plate chondrocyte maturation. Heparan sulfate proteoglycans have been implicated in the sequestration and presentation of growth factors, particularly fibroblast growth factors, to receptors at the cell surface. (Rapraeger, A. C., et al., Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation, Science 252:1705-08 [1991]; Yayon, A., et al., Cell surface, heparin-like molecules are required for binding of basic Fibroblast Growth Factor to its high-affinity receptor, Cell 64:841-48 [1991]; Schlessinger, J., et al., Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors?, Cell 83:357-60 [1995]). Skeletal defects in mice lacking heparan sulfate 2-sulfotransferase include dwarfism, with shortened long bones, ribs and spine, implying a specific role for heparan sulfate proteoglycans in skeletal development. (Bullock, S. I., et al., Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase, Genes Dev. 12:1894-1906 [1998]).
  • Indeed, reduced activities of both ATP sulfurylase and APS kinase, and decreased synthesis of chondroitin sulfate, have been demonstrated in bm mice. (Schwartz, N. B., et al, [0015] Defective PAPS-synthesis in epiphyseal cartilage from brachymorphic mice, Biochem. Biophys. Res. Commun. 82:173-78 [1978]; Sugahara, K. & Schwartz, N. B., Defect in 3′-phosphoadenosine 5′-phosphosulfate formation in brachymorphic mice. Proc. Natl. Acad. Sci. U.S.A. 76:6615-18 [1979]). The ATP sulfurylase and APS kinase activities in brachymorphic mouse tissues co-purified. (Geller, D. H., et al. [1987]; Lyle, S., et al., Rat chondrosarcoma ATP sulfurylase and adenosine 5′-phosphosulfate kinase reside on a single bifunctional protein, Biochemistry 33:5920-25 [1994]). The functional activity of the APS kinase was reduced to a greater extent than was that of the ATP sulfurylase, suggesting that brachymorphism resulted from a structural mutation that affected channeling APS from the carboxyl-terminal sulfurylase activity to the amino-terminal kinase. (Lyle, S., et al., Sulfate-activating enzymes in normal and brachymorphic mice: evidence for a channeling defect, Biochemistry 34:940-45 [1995]).
  • A cDNA encoding a murine bifunctional ATP-sulfurylase/APS-kinase enzyme (known as Papss1, formerly known as Atpsk1) was isolated from brachymorphic mice and studied by mutational analysis. (Li, H. et al., [0016] The isolation and characterization of cDNA encoding the mouse bifunctional ATP sulfurylase-adenosine 5′-phosphosulfate kinase, J. Biol. Chem. 270(49):29453-59 [1995]; Deyrup, A. T. et al., Deletion and site-directed mutagenesis of the ATP-binding motif (P-loop) in the bifunctional murine ATP-sulfurylase/adenosine 5′-phosphosulfate kinase enzyme, J. Biol. Chem. 273(16):9450-56 [1998]). Subsequently, bifunctional enzymes having ATP-sulfurylase (E. C. 2.7.7.4)/APS-kinase (E.C. 2.7.1.25) activities were designated “PAPS synthetase” (PAPSS; also known as ASAPK and ATPSK).
  • The bm mutation was placed on the mouse phenotypic map by Lane and Dickie (1968). Subsequent application of microsatellite markers to mice from a large backcross localized the bm mutation to a 2.5 cM region located at approximately 32 cM on mouse chromosome 19. (O'Brien, E. P., et al., [0017] Molecular map of chromosome 19 including three genes affecting bleeding time: ep, ru and bm, Mamm. Genome 5:356-60 [1994]; Rusiniak, M. E., et al. [1996]). In addition, a liver cancer susceptibility gene, Hcs6, has been localized near bm in mouse strain C3H/He. (Manenti, G., et al. [1994]).
  • The bm mutation co-localized with a PAPSS gene. (Kurima, K. et al., [0018] A member of a family of sulfate-activating enzymes causes murine brachymorphism, Proc. Natl. Acad. Sci. 95(15):8681-85 [1998]; Sugahara, K. and Schwartz, N. B., Defect in 3′-phosphoadenosine 5′-phosphosulfate formation in brachymorphic mice, Proc. Nat. Acad. Sci. 76(12):6615-18 [1979]). Although brachymorphic mouse liver shows decreased PAPSS activity, the brachymorphic phenotype does not manifest any grossly recognizable liver defects. It has been observed that brachymorphic mouse liver has a decreased ability to esterify xenobiotic carcinogens with sulfate (Lyman, S. D. & Poland, A., Effect of the brachymorphic trait in mice on xenobiotic sulfate ester formation, Biochem. Pharmacol. 32:3345-50 [1983]), which implies that altered susceptibility to such agents could result from defects in a PAPSS gene. Consistent with this hypothesis, brachymorphic mice have decreased susceptibility to carcinogen-induced hepatocarcinoma, presumably due to a decreased ability to generate sulfated carcinogens. (Boberg, E. W., et al., Strong evidence from studies with brachymorphic mice and pentachlorophenol that 1′-sulfooxysafrole is the major ultimate electrophilic and carcinogenic metabolite of 1′-hydroxysafrole in mouse liver, Cancer Res. 43:5163-73 [1983]; Lai, C. C., et al., Initiation of hepatocarcinogenesis in infant male B6C3F1 mice by N-hydroxy-2-aminofluorene depends primarily on metabolism to N-sulfooxy-2-aminofluorene and formation of DNA-(deoxyguanosin-8-yl)-2-aminofluorene adducts, Carcinogenesis 8:471-78 [1987]).
  • PAPSS enzymes have been isolated and characterized in non-murine systems, for example, in association with rat chondrosarcomas. (Rosenthal, E. and Leustek, T., [0019] A multifunctional Urechis caupo protein, PAPS synthetase, has both ATP sulfurylase and APS kinase activities, Gene 165(2):243-48 [1995]; Schwartz, N. B., et al., Sulfate activation and transport in mammals; system components and mechanisms, Chem. Biol Interact. 109(1-3):143-51 [1998]; Lyle, S. et al., Rat chondrosarcoma ATP sulfurylase and adenosine 5′-phosphosulfate kinase reside on a single bifunctional protein, Biochemistry 33(19):5920-25 [1994]; Lyle, S. et al., Intermediate channeling between ATP sulfurylase and adenosine 5′-phosphosulfate kinase from rat chondrosarcoma, Biochemistry 33(22):6822-27 [1994]). Human cDNAs for PAPSS have also been cloned, and their activities have been analyzed biochemically and mutationally. (Yanagisawa, K. et al., cDNA cloning, expression, and characterization of the human bifunctional ATP sulfurylase/adenosine 5′-phosphosulfate kinase enzyme, Biosci. Biotechnol. Biochem. 62(5):1037-40 [1998]; Girard, J. P., et al., Sulfation in high endothelial venules: cloning and expression of the human PAPS synthetase, FASEB J. 12(7):603-12 [1998]; Venkatachalam, K. V. et al., Molecular cloning, expression, and characterization of human bifunctional 3′-phosphoadenosine 5′-phosphosulfate synthase and its functional domains, J. Biol. Chem. 273(30):19311-20 [1998]; Ventkatachalam, K. V., et al., Site-selected mutagenesis of a conserved nucleotide binding HXGH motif located in the ATP sulfurylase domain of human bifunctional 3′-phosphoadenosine 5′-phosphosulfate synthase, J. Biol. Chem. 274(5):2601-04 [1999]).
  • Phenotypically analogous to murine brachymorphism, is spondyloepimetaphyseal dysplasia (SEMD) in humans. SEMD is a subgroup of osteochondrodysplasias affecting skeletal development, linear bone and cartilage growth, and bone and cartilage maintenance. Effects of SEMD can include dwarfism, stunted or malformed limbs, enlarged joints, kyphoscoliosis (spinal warping), and brachydactyly (short fingers and toes). SEMD typically runs in families, and can be inherited in autosomal dominant or recessive manners. (Ahmad, M. et al., [0020] Distinct, autosomal recessive form of spondyloepimetaphyseal dysplasia segregating in an inbred Pakistani kindred, Am. J. Med. Genet. 78(5):468-73 [1998]; Figuera, L. E., et al., Spondyloepimetaphyseal dysplasia (SEMD) Shohat type, Am. J. Med. Genet. 51(3):213-15 [1994]; Shohat, M. et al., New form of spondyloepimetaphyseal dysplasia (SEMD) in Jewish family of Iraqi origin, Am. J. Med. Genet. 46(4):358-62, [1993]; Whyte, M. P. et al., Hypotrichosis with spondyloepimetaphyseal dysplasia in three generations; a new autosomal dominant syndrome, Am. J. Med. Genet. 36(3):288-91 [1990]; Gertner, J. M., et al., Linkage studies of a Missouri kindred with autosomal dominant spondyloepimetaphyseal dysplasia (SEMD) indicate genetic heterogeneity, J. Bone Miner. Res. 12(8):1204-9, [1997]).
  • A nonsense mutation in a novel, cartilage-specific human PAPSS (PAPSS2, formerly ATPSK2), has been indicated as the cause of a recessive form of SEMD in an inbred Pakistani family. (Ahmad, M., et al., [0021] A distinct, autosomal recessive form of spondyloepimetaphyseal dysplasia segregating in an inbred Pakistani kindred, Am. J. Med. Genet. 78:468-73 [1998]; ul Haque, M. F., et al., Mutations in orthologous genes in human spondyloepimetaphyseal dysplasia and the brachymorphic mouse, Nat. Genet. 20(2):157-62 [1998]). Genome-wide linkage studies localized the disease gene for this dwarfing condition to chromosome 10q23-24, in a region syntenic with the locus for the bm locus on mouse chromosome 19. (ul Haque, M. F., et al. [1998]). This disorder, designated SEMD Pakistani type, is characterized by short, bowed lower limbs, enlarged knee joints, kyphoscoliosis, a mild generalized brachydactyly, and early-onset degenerative joint disease in the hands and knees. Radiographs of patients with SEMD Pakistani type show delayed epiphyseal ossification, especially at the hips and knees, and platyspondyly.
  • Currently, there are only a few methods of detecting bone related diseases. (Eg., Klock, J. C., [0022] Chondroitin sulfate as a marker for bone resorption, U.S. Pat. No. 5,869,273; Takeshita, S. et al., Bone-related sulfatase-like protein and process for its production, U.S. Pat. No. 5,627,050). DNA-based diagnostic approaches have been suggested for some type 2 collagen disorders, such as Stickler syndrome, spondyloepiphyseal dysplasia, and achondrogenesis; achondroplasia (a defect in the fibroblast growth factor receptor 3 (FGFR3) gene); the collagen oligomeric matrix protein (COMP) disorders pseudoachondroplasia and multiple epiphyseal dysplasia, and others. (E.g., Ritvaniemi, Arthritis and Rheumatism 38:999-1004 [1995]; Shiang et al., Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia, Cell 78:335-42 [1994]; Briggs et al., Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage of oligomeric matrix protein gene, Nature Genetics 10:330-36 [1995]; Superti-Ferga et al., Recessively inherited multiple epiphyseal dysplasia with normal stature, club foot, and double layered patella caused by DTDST mutation, J. Med. Genet. 36:621-24 [1999]). But most reported diagnostic methods relate to osteogenic proteins. (E.g., Khandke, K. M., et al., Chromatographic process for the copurification of chondroitinase I and II proteins from Proteus vulgaris, U.S. Pat. No. 5,525,500; Parsons, T. F., et al., Osteogenic Factors, U.S. Pat. No. 5,106,626; Oppermann, H., et al., Cartilage and bone-inducing proteins, U.S. Pat. No. 5,750,651).
  • Accordingly, a reliable method is still needed for diagnosing SEMD, detecting the presence of SEMD in recessive carriers, and for treating osteoarthritic disorders, including osteochondrodysplasias, that are caused or aggravated by deficient PAPS synthetase activity. The present invention provides these and other advantages, as described herein. [0023]
    • SUMMARY OF THE INVENTION
  • The present invention relates to an isolated polynucleotide or to a nucleic acid construct that comprises a nucleic acid segment encoding a 3′-phosphoadenosine-5′-phosphosulfate (PAPS) synthetase (PAPSS), particularly, a human PAPSS2 nucleotide sequence of (SEQ. ID. NO.:1) or an orthologous murine Papss2 nucleotide sequence (SEQ. ID. NO.:2), sequences complementary to either one of them, degenerate coding sequences, or gene-specific fragments of (SEQ. ID. NOS.:1 and 2). The present polynucleotides and nucleic acid constructs containing PAPSS2 and Papss2 nucleotide sequences include RNA; DNA; and chimeric RNA/DNA. Embodiments include probes, primers, and expression vectors containing PAPSS2- and Papss2-specific nucleotide sequences. [0024]
  • The present invention also relates to a genetically modified vertebrate cell containing a nucleic acid construct of the present invention and to a non-human vertebrate containing the cell. The present invention also relates to human PAPSS2 and murine Papss2 proteins encoded by the present polynucleotide or nucleic acid construct, including fusion proteins that contain, together with a PAPSS2 or Papss2 amino acid sequence, any other predetermined polypeptide sequence. The present invention also relates to antibodies and antibody fragments that selectively bind the PAPSS2 or Papss2 protein. [0025]
  • The present invention is also directed to a method of diagnosing spondyloepimetaphyseal dysplasia (SEMD) in a human subject. The method involves amplifying nucleic acids from a sample that define an PAPSS2 gene sequence, or a gene-specific fragment thereof; and analyzing the amplified nucleic acids for the presence of homozygosity for a variant allele of PAPSS2. The sample is a bodily substance containing human nucleic acid, for example a blood sample, obtained from a human subject having at least one symptom of SEMD. Homozygosity for a variant allele of PAPSS2 is diagnostic for SEMD in the human subject. In particular, the present invention also relates to a method of diagnosing SEMD Pakistani-type in a human subject. But the present invention also relates to a method of identifying a heterozygous human carrier of an SEMD-associated allele. [0026]
  • The present invention provides a genetic testing kit for diagnosing SEMD or for identifying a human carrier of SEMD, including SEMD Pakistani-type. The genetic testing kit contains oligonucleotide primers of the present invention. [0027]
  • Also, nucleic acid constructs of the present invention are used in a method of gene therapy for treating a human subject having an osteoarthritic disorder that is caused or aggravated by deficient enzymatic sulfation activity. The present invention is also related to a protein therapy method for treating a human subject having an osteoarthritic disorder that is caused or aggravated by deficient enzymatic sulfation activity. This method employs the inventive PAPSS2 fusion protein.[0028]
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows a genetic map of the interval containing the SEMD disease gene on human chromosome 10. Distances between loci are given in centimorgans (cM). [0029]
  • FIG. 2 shows a genetic map of the bm region of mouse chromosome 19. The 0.7 cM interval containing the disease gene and locus D19Mit13 is shown with a darker line. [0030]
  • FIG. 3 shows a variant allele of PAPSS2 associated with SEMD Pakistani type. Sequences derived from amplified DNA fragment from an affected family member (SEMD) and from a control (NL) are shown. An arrow at nucleotide +1424 marks the location of a mutation, and the DNA sequence and the implied effect of the mutation on the PAPSS2 protein sequence is summarized below the nucleotide sequence. [0031]
  • FIG. 4 compares expression of PAPSS1 and PAPSS2 mRNAs with an actin mRNA control in samples from various human tissues, as visualized by Northern hybridization with specific cDNA probes for each.[0032]
    • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • _tx0 The present invention relates to an isolated polynucleotide, of natural origin or a nucleic acid construct, that comprises a nucleic acid segment encoding an ATP sulfurylase/APS kinase, i.e., a PAPS synthetase (PAPSS), particularly, a human PAPSS2 nucleotide sequence of (SEQ. ID. NO.:1) or an orthologous murine Papss2 nucleotide sequence (SEQ. ID. NO.:2). [0033]
  • The human PAPSS2 gene is located on chromosome 10 at locus 10q23-24. (ul Haque, M. F., et al. [1998]). More specifically, the PAPSS2 gene region is flanked by microsatellite markers D10S1143 and D10S2470. (See FIG. 1; C. Dib et al., [0034] A comprehensive genetic map of the human genome based on 5,264 microsatellites, Nature 380(6570):152-54 [1996]). The cloned human PAPSS2 nucleotide sequence is the following (GenBank accession AF091242; transcriptional start site [underlined] commences at position +1):
    (SEQ. ID. NO.:1)
    −80 CTGCTGCCGC CGCCGCCGCC GCCGTCCCTG CGTCCTTCGG TCTCTGCTCC CGGGACCCGG
    −20 CTCCGCCGCA GCCAGCCAGC ATGTCGGGGA TCAAGAAGCA AAAGACGGAG AACCAGCAGA
    +41 AATCCACCAA TGTAGTCTAT CAGGCCCACC ATGTGAGCAG GAATAAGAGA GGGCAAGTGG
    +101 TTGGAACAAG GGGTGGGTTC CGAGGATGTA CCGTGTGGCT AACAGGTCTC TCTGGTGCTG
    +161 GAAAAACAAC GATAAGTTTT GCCCTGGAGG AGTACCTTGT CTCCCATGCC ATCCCTTGTT
    +221 ACTCCCTGGA TGGGGACAAT GTCCGTCATG GCCTTAACAG AAATCTCGGA TTCTCTCCTG
    +281 GGGACAGAGA GGAAAATATC CGCCGGATTG CTGAGGTGGC TAAGCTGTTT GCTGATGCTG
    +341 GTCTGGTCTG CATTACCAGC TTTATTTCTC CATTCGCAAA GGATCGTGAG AATGCCCGCA
    +401 AAATACATGA ATCAGCAGGG CTGCCATTCT TTGAAATATT TGTAGATGCA CCTCTAAATA
    +461 TTTGTGAAAG CAGAGACGTA AAAGGCCTCT ATAAAAGGGC CAGAGCTGGG GAGATTAAAG
    +521 GATTTACAGG TATTGATTCT GATTATGAGA AACCTGAAAC TCCTGAGCGT GTGCTTAAAA
    +581 CCAATTTGTC CACAGTGAGT GACTGTGTCC ACCAGGTAGT GGAACTTCTG CAAGAGCAGA
    +641 ACATTGTACC CTATACTATA ATCAAAGATA TCCACGAACT CTTTGTGCCG GAAAACAAAC
    +701 TTGACCACGT CCGAGCTGAG GCTGAAACTC TCCCTTCATT ATCAATTACT AAGCTGGATC
    +761 TCCAGTGGGT CCAGGTTTTG AGCGAAGGCT GGGCCACTCC CCTCAAAGGT TTCATGCGGG
    +821 AGAAGGAGTA CTTACAGGTT ATGCACTTTG ACACCCTGCT AGATGATGGC GTGATCAACA
    +881 TGAGCATCCC CATTGTACTG CCCGTCTCTG CAGAGGATAA GACACGGCTG GAAGGGTGCA
    +941 GCAAGTTTGT CCTGGCACAT GGTGGACGGA GGGTAGCTAT CTTACGAGAC GCTGAATTCT
    +1001 ATGAACACAG AAAAGAGGAA CGCTGTTCCC GTGTTTGGGG GACAACATGT ACAAAACACC
    +1061 CCCATATCAA AATGGTGATG GAAAGTGGGG ACTGGCTGGT TGGTGGAGAC CTTCAGGTGC
    +1121 TGGAGAAAAT AAGATGGAAT GATGGGCTGG ACCAATACCG TCTGACACCT CTGGAGCTCA
    +1181 AACAGAAATG TAAAGAAATG AATGCTGATG CGGTGTTTGC ATTCCAGTTG CGCAATCCTG
    +1241 TCCACAATGG CCATGCCCTG TTGATGCAGG ACACCTGCCG CAGGCTCCTA GAGAGGGGCT
    +1301 ACAAGCACCC GGTCCTCCTA CTACACCCTC TGGGCGGCTG GACCAAGGAT GACGATGTGC
    +1361 CTCTAGACTG GCGGATGAAG CAGCACGCGG CTGTGCTCGA GGAAGGGGTC CTGGATCCCA
    +1421 AGTCAACCAT TGTTGCCATC TTTCCGTCTC CCATGTTATA TGCTGGCCCC ACAGAGGTCC
    +1481 AGTGGCACTG CAGGTCCCGG ATGATTGCGG GTGCCAATTT CTACATTGTG GGGAGGGACC
    +1541 CTGCAGGAAT GCCCCATCCT GAAACCAAGA AGGATCTGTA TGAACCCACT CATGGGGGCA
    +1601 AGGTCTTGAG CATGGCCCCT GGCCTCACCT CTGTGGAAAT CATTCCATTC CGAGTGGCTG
    +1661 CCTACAACAA AGCCAAAAAA GCCATGGACT TCTATGATCC AGCAAGGCAC AATGAGTTTG
    +1721 ACTTCATCTC AGGAACTCGA ATGAGGAAGC TCGCCCGGGA AGGAGAGAAT CCCCCAGATG
    +1781 GCTTCATGGC CCCCAAAGCA TGGAAGGTCC TGACAGATTA TTACAGGTCC CTGGAGAAGA
    +1841 ACTAAGCCTT TGGGTCCAGA GTTTCTTTCT GAAGTGCTCT TTGATTACCT TTTCTATTTT
    +1901 TATGATTAGA TGCTTTGTAT TAAATTGCTT CTCA//.
  • Preferably, the nucleic acid segment encoding a human PAPS synthetase, specifically PAPSS2, comprises a nucleotide sequence defining an open reading frame within SEQ. ID. NO.:1 that extends from nucleotide position +1 through +1845 (SEQ. ID. NO.:9). [0035]
  • The orthologous murine Papss2 gene is located in the bm region of mouse chromosome 19, within a 0.7 cM interval near marker D19Mit13. (See, FIG. 2; ul Haque, M. F., et al. [1998]). The cloned murine Papss2 nucleotide sequence is the following (GenBank accession AF085144; transcriptional start site [underlined] commences at position +1): [0036]
    (SEQ. ID. NO.:2)
    −60 GTATTCTCAA CATCAGATAT CATGTCTTGG AGGAAGTTAC CTAAACTCTG AAGAATTATC
    +1 ATGTCTGCAA ATTTCAAAAT GAACCATAAA AGAGACCAGC AAAAATCCAC CAATGTGGTC
    +61 TACCAGGCCC ATCATGTGAG CAGGAACAAG AGAGGACAAG TGGTTGGAAC CAGGGGAGGA
    +121 TTCCGAGGAT GTACCGTGTG GCTAACAGGT CTCTCTGGTG CTGGGAAAAC AACCATAAGC
    +181 TTTGCTTTGG AAGAGTACCT TGTATCTCAC GCCATCCCAT GTTACTCCCT GGATGGGGAC
    +241 AATGTCCGTC ATGGCCTTAA TAAGAACCTG GGATTCTCTG CCGGGGACCG AGAAGAGAAT
    +301 ATCCGCCGGA TCGCGGAGGT GGCCAAGCTC TTTGCCGACG CCGGCCTGGT TTGCATCACC
    +361 AGCTTTATCT CTCCTTTTGC AAAGGATCGT GAGAATGCCC GAAAAATCCA CGAATCAGCA
    +421 GGACTCCCGT TCTTTGAGAT CTTTGTAGAT GCGCCTTTAA ATATCTGTGA AAGCCGAGAC
    +481 GTAAAAGGAC TCTACAAACG AGCCCGAGCA GGAGAGATTA AAGGGTTTAC AGGCATCGAT
    +541 TCTGACTATG AGAAACCTGA AACTCCAGAG TGTGTGCTGA AGACCAACTT GTCTTCAGTA
    +601 AGCGACTGTG TGCAACAGGT GGTGGAACTT TTGCAGGAGC AGAACATTGT ACCCCACACC
    +661 AGCGACTGTG TGCAACAGGT GGTGGAACTT TTGCAGGAGC AGAACATTGT ACCCCACACC
    +721 GAGGCAGAGA CTCTCCCATC ACTACCAATT ACCAAGCTGG ATCTGCAGTG GGTGCAGATT
    +781 CTGAGTGAAG GCTGGGCCAC TCCCCTCAAA GGCTTTATGC GGGAGAAGGA ATACTTGCAA
    +841 ACTCTACACT TCGACACTCT ACTGGACGAT GGAGTCATCA ACATGAGTAT TCCCATTGTA
    +901 TTGCCCGTTT CTGCGGATGA CAAGGCACGG CTCGAAGGGT GCAGCAAATT TGCCTTGATG
    +961 TACGAAGGTC GGAGGGTCGC TCTATTACAG GACCCTGAAT TCTATGAGCA TAGGAAAGAG
    +1021 GAGCGTTGTT CTCGTGTGTG GGGAACAGCC ACTGCAAAGC ACCCCCATAT CAAAATGGTG
    +1081 ATGGAAAGTG GGGACTGGCT TGTTGGTGGA GACCTACAGG TGCTAGAGAG AATAAGGTGG
    +1141 GACGATGGGC TGGACCAATA CCGCCTTACG CCTCTGGAAC TCAAACAGAA GTGTAAAGAC
    +1201 ATGAATGCTG ATGCCGTGTT TGCATTCDAG TTGCGCAATC CTGTCCACAA TGGTCATGCC
    +1261 CTCCTGATGC AGGACACCCG CCGCAGGCTC CTGGAGAGGG GTTACAAGCA CCCAGTCCTC
    +1321 CTGCTCCACC CTCTTGGGGG CTGGACCAAG GACGATGACG TACCTCTGGA ATGGAGGATG
    +1381 AAACAGCATG CAGCTGTACT GGAGGAAAGG GTCCTGGATC CCAAGTCAAC TATTGTTGCC
    +1441 ATCTTTCCAT CTCCTATGTT ATACGCTGGT CCCACAGAGG TCCAGTGGCA TTGCAGATGC
    +1501 CGGATGATTG CAGGAGCCAA TTTCTACATT GTGGGTAGGG ATCCCGCAGG AATGCCCCAT
    +1561 CCTGAGACAA AGAAAGACCT ATATGAACCC ACCCACGGGG GCAAGGTCTT GAGTATGGCC
    +1621 CCTGGCCTTA CCTCTGTGGA AATAATTCCG TTCCGAGTGG CTGCCTACAA TAAAATTAAA
    +1681 AAGGCCATGG ACTTTTATGA TCCAGCAAGG CACGAGGAGT TTGACTTCAT CTCAGGAACT
    +1741 CGCATGAGGA AGCTCGCCCG GGAAGGAGAA GATCCCCCAG ATGGCTTCAT GGCCCCGAAA
    +1801 GCGTGGAAAG TGTTGACAGA TTACTACAGG TCTCTGGAGA AGACCAACTA GGTGCTCCTG
    +1861 GCTCTGGCTT CTTCCTCAAG TGCTCTCTGA CGATTTTTTT TTTCTATTTT TGTGATTTAG
    +1921 CTGCTCTGTA TCCAATTGCA //.
  • Preferably, the nucleic acid segment encoding a murine PAPS synthetase, specifically Papss2, comprises a nucleotide sequence defining an open reading frame within SEQ. ID. NO.:2 that extends from nucleotide position +1 through +1851 (SEQ. ID. NO.:10). [0037]
  • In other embodiments, the nucleic acid segment has a nucleotide sequence complementary to SEQ. ID. NOS.:1, 2, 9, or 10, or comprises a degenerate coding sequence of any of these. Alternatively, the present nucleic acid segment is a gene-specific fragment of SEQ. ID. NOS.:1, 2, 9 or 10, or a gene-specific fragment of a complementary sequence or degenerate coding sequence. Gene-specific fragments are nucleic acid segments having a contiguous nucleotide sequence that is specific to PAPSS2 or Papss2, respectively. For example, a gene-specific fragment of SEQ. ID. NO.:1 is SEQ. ID. NO.:9, and a gene-specific fragment of SEQ. ID. NO.:2 is SEQ. ID. NO.:10. The skilled artisan can readily determine other gene-specific fragments by conducting a sequence similarity search of a genomics data base, such as the GenBank database of the National Center for Biotechnology Information (NCBI), using a computerized algorithm, such as PowerBLAST, QBLAST, PSI-BLAST, PHI-BLAST, gapped or ungapped BLAST, or the “Align” program through the Baylor College of Medicine server. (E.g., Altchul, S. F., et al., [0038] Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, Nucleic Acids Res. 25(17):3389-402 [1997]; Zhang, J., & Madden, T. L., PowerBLAST: a new network BLAST application for interactive or automated sequence analysis and annotation, Genome Res. 7(6):649-56 [1997]; Madden, T. L., et al., Applications of network BLAST server, Methods Enzymol. 266:131-41 [1996]; Altschul, S. F., et al., Basic local alignment search tool, J. Mol. Biol. 215(3):403-10 [1990]). Preferably, a gene specific fragment is at least 5 to 30 contiguous nucleotides long, more preferably at least 6 to 15 contiguous nucleotides long, and most preferably at least 7 to 10 contiguous nucleotides long. Embodiments of the isolated polynucleotide or nucleic acid construct of the present invention include nucleic acid segments comprising RNA, DNA, or chimeric RNA/DNA.
  • RNA segments include messenger RNA encoding an PAPSS2 or Papss2 protein, or a degenerate coding sequence, or a RNA sequence complementary to any of these. A complementary RNA segment can be an antisense RNA or a catalytic RNA sequence, such as a “hairpin” or “hammerhead” ribozyme, with a recognition sequence complementary to a gene-specific fragment of SEQ. ID. NOS.:1, 2, 9 or 10, or a degenerate coding sequence of any of these. [0039]
  • Other embodiments of the isolated polynucleotide or nucleic acid construct include nucleic acid segments of DNA. In some embodiments, the DNA segment encoding a PAPSS2 or Papss2 protein is operatively linked to a promoter sequence. The promoter sequence can be an autologous PAPSS2 or Papss2 promoter sequence. Alternatively, in a nucleic acid construct of the present invention, any suitable promoter sequence can be used, including an autologous promoter, a promoter from a heterologous human or non-human PAPS synthetase gene (e.g., PAPSS1 or Papss1 promoters), or a predetermined promoter sequence from any other human or non-human gene. Useful promoter sequences include constitutive promoters, such as, but not limited to, cytomegalovirus (CMV) promoter, or inducible promoters, such as, but not limited to, the human C-reactive protein (CRP) promoter (e.g., Kanzler, S., et al, [0040] TGF-betal in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis, Am. J. Physiol. 276(4Pt 1):G1059-68 [1999]), or the insulin-like growth factor (IGF-I) promoter (e.g., Meton I., et al., Growth hormone induces insulin-like growth factor-I gene transcription by synergistic action of STAT5 and HNF-lalpha, FEBS Lett. 444(2-3):155-59 [1999]). Useful promoters include those that promote transcription in cells of diverse tissues, such as, but not limited to, an insulin receptor (IR) gene promoter (e.g., Tewari, D. S., et al., Characterization of the promoter region and 3′ end of the human insulin receptor gene, J. Biol. Chem. 264(27):16238-45 [1989]); growth hormone receptor (GHR) P2 or P3 promoters (e.g., Jiang, H., et al., Isolation and characterization of a novel promoter for the bovine growth hormone receptor gene, J. Biol. Chem. 274(12):7893-900 [1999]); or a leptin promoter (e.g., Chen, X. L., et al., Analysis of a 762-bp proximal leptin promoter to drive and control regulation of transgene expression of growth hormone receptor in mice, Biochem. Biophys. Res. Commun. 262(1):187-92 [1999]).
  • Also useful for various applications are tissue-selective promoters, i.e., promoters from which expression occurs preferentially in cells of a particular kind of tissue, compared to one or more other types of tissue. These include, cartilage-selective promoters for expression in chondrocytes, for example, an osteocalcin (OC) promoter (e.g., Newberry, E. P., et al., [0041] The RRM domain of MINT, a novel Msx2 binding protein, recognizes and regulates the rat osteocalcin promoter, Biochemistry 38(33):10678-90 [1999]); a SOX9 promoter, aggrecan gene promoter (AGC1), or collagen oligomeric matrix protein (COMP) gene promoter (e.g., Kanai, Y. & Koopman, P., Structural and functional characterization of the mouse Sox9 promoter: implications for campomelic dysplasia, Hum. Mol. Genet. 8(4):691-96 [1999]; Newton et al, Characterization of human and mouse cartilage oligomeric matrix protein, Genomics 24:435-39 [1994); or a promoter from a collagen gene, such as, but not limited to promoters for COL2A1, COL9A1, or COL10A1. (e.g., Ganguly, A., et al., Targeted insertions of two exogenous collagen genes into both alleles of their endogenous loci in cultured human cells: the insertions are directed by relatively short fragments containing the promoters and the 5′ ends of the genes, Proc Natl Acad Sci USA 91(15):7365-9 [1994]; Dharmavaram, R. M., et al., Detection and characterization of Sp1 binding activity in human chondrocytes and its alterations during chondrocyte dedifferentiation, J. Biol Chem 272(43):26918-25 [1997]; Zhou, G., et al., Three high mobility group-like sequences within a 48-base pair enhancer of the Col2a1 gene are required for cartilage-specific expression in vivo, J. Biol Chem 273(24): 14989-97 [1998]; Seghatoleslami, M. R., et al., Differential regulation of COL2A1 expression in developing and mature chondrocytes, Matrix Biol 14(9):753-64 [1995]; Lefebvre, V., et al., An 18-base-pair sequence in the mouse proalphal(II) collagen gene is sufficient for expression in cartilage and binds nuclear proteins that are selectively expressed in chondrocytes, Mol Cell Biol 16(8):4512-23 [1996]; Zhou, G., et al., A 182 bp fragment of the mouse pro alpha 1(II) collagen gene is sufficient to direct chondrocyte expression in transgenic mice, J. Cell Sci, 108(Pt 12):3677-84 [3677-84]; Mukhopadhyay, K., et al., Use of a new rat chondrosarcoma cell line to delineate a 119-base pair chondrocyte-specific enhancer element and to define active promoter segments in the mouse pro-alpha 1(II) collagen gene, J. Biol Chem 270(46):27711-9 [1995]; Vikkula, M., et al., Structural analysis of the regulatory elements of the tyupe-II procollagen gene. Conservation of promoter and first intron sequences between human and mouse, Biochem J 285(Pt 1):287-94 [1992]; Beier, F., et al., Localization of silencer and enhancer elements in the human type X collagen gene, J Cell Biochem 662(2):210-8 [1997]; Thomas, J. T., Sequence comparison of three mammalian type-X collagen promoters and preliminary functional analysis of the human promoter, Gene 160(2):291-6 [1995]; Apte, S. S., Characterization of the mouse type X collagen gene, Matrix 13(2):165-79 [1993]). A cartilage-derived retinoic acid-sensitive protein (CD-RAP) gene promoter is also useful for cartilage-selective expression by chondrocytes. (e.g., Xie, W. F., et al., Transactivation of the mouse cartilage derived retinoic acid-sensitive protein gene by Sox9, J. Bone Miner. Res. 14(5):757-63 [1999]).
  • For liver-selective expression in hepatocytes, useful promoter sequences include, an albumin gene promoter (e.g., Pastore, L., et al., [0042] Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors, Hum. Gen. Ther. 10(11): 1773-81 [1999]); a CYP7A or CYP7A1 promoter (e.g., Nitta, M., et al., CPF: an orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7alpha-hydroxylase gene, Proc. Natl. Acad. Sci. USA 96(12):6660-65 [1999]; Chen, J., et al., Hepatocyte nuclear factor 1 binds to and transactivates the human but not the rat CYP7A1 promoter, Biochem. Biophys. Res. Commun. 260(3):829-34 [1999]); a GHR P1 promoter (e.g., Zou, L., et al., Isolation of a liver-specific promoter for human growth hormone receptor gene, Endocrinology 138(4):1771-74 [1997]; Jiang, H., et al. [1999]; Adams, T. E., Differential expression of growth hormone receptor messenger RNA from a second promoter, Mol. Cell Endocrinol. 108(1-2):23-33 [1995]); or a thrombin-activatable fibrinolysis inhibitor (TAFI) promoter (e.g., Boffa, M. B., et al., Characterization of the gene encoding human TAFI [thrombin-activatable fibrinolysis inhibitor; plasma procarboxypeptidase B], Biochemistry 38(20):6547-58 [1999]).
  • For hematopoietic tissue-selective expression in hematopoietic precursor cells, useful promoters include a cyclin A1 promoter (e.g., Müller, C., et al., [0043] Cloning of the cyclin A1 genomic structure and characterization of the promoter region, J. Biol. Chem. 276(16):11220-28 [1999]); a CD34 promoter (e.g., Burn, T. C., et al., Hematopoietic stem cell specific gene expression, U.S. Pat. No. 5,556,954); or an integrin alphaIIb promoter (e.g., Wilcox, D. A., et al., Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells, Proc. Natl. Acad. Sci. USA 96(17):9654-59 [1999]).
  • The foregoing examples of useful promoter sequences are not an exhaustive list, but are merely illustrative of the promoters available to the skilled artisan in practicing the present invention. [0044]
  • For purposes of the present invention, “operatively linked” means that the promoter sequence, is located directly upstream from the PAPSS2 or Papss2 coding sequence, which is in reading frame, and that both sequences are oriented in a 5′ to 3′ manner, forming a transcriptional unit, such that transcription can take place in vitro in the presence of all essential enzymes, transcription factors, co-factors, activators, and reactants, under favorable physical conditions, e.g., suitable pH and temperature. This does not mean that, in any particular cell, conditions will favor transcription. [0045]
  • By way of example, transcription of the DNA sequence encoding a PAPSS2 protein produces mRNA transcript, which is translatable into PAPSS2 protein, or a functional fragment thereof Thus, one benefit of the present invention is that the nucleic acid can be used in a genetic replacement therapy for humans to correct clinical disorders derived from defective endogenous expression of PAPSS activity. Such defective expression can result from, but need not result from, endogenous underexpression of functional PAPSS2 protein, in particular. [0046]
  • Other preferred embodiments of the present nucleic acid construct also include, operatively linked as part of the transcriptional unit, a reporter gene sequence encoding a reporter protein for facilitating the detection or selection of cells containing the present nucleic acid construct and expressing PAPSS2 or Papss2. Preferably, but not necessarily, the reporter gene encodes a fluorescent protein. Fluorescent proteins include green fluorescent protein (or enhanced green fluorescent protein), yellow fluorescent protein, blue fluorescent protein, a phycobiliprotein, such as phycoerythrin or phycocyanin, or any other protein which fluoresces under suitable wave-lengths of light. Another reporter gene suitable for some applications is a gene encoding a protein that can enzymatically lead to the emission of light from a substrate(s); for purposes of the present invention, such a protein is a “light-emitting protein.” For example, a light-emitting protein includes proteins such as luciferase or apoaequorin. [0047]
  • Alternatively, the DNA segment encodes a PAPSS2 or Papss2 gene-specific antisense RNA, such as an antisense RNA that specifically hybridizes to PAPSS2 mRNA or Papss2 mRNA, preventing translation therefrom. [0048]
  • In another embodiment, the nucleic acid construct comprises a chimeric RNA/DNA, such as a chimeric RNA/DNA oligonucleotide. Such RNA/DNA chimers are useful, for example, in altering single nucleotide polymorphisms (SNPs) or other point mutations in an endogenous PAPSS2 gene sequence. For example, a SNP in PAPSS2 associated with encoding a truncated or otherwise dysfunctional PAPSS2 protein can be stably repaired using a chimeric RNA/DNA oligonucleotide of the present invention. [0049]
  • In other embodiments, the nucleic acid construct is a probe or primer sequence. The inventive probe is a labeled polynucleotide that is useful in hybridization assays, such as Southern, Northern, or fluorescence in situ (FISH) hybidizations, for detecting the presence in a sample of polynucleotides having a gene-specific PAPSS2 or Papss2 sequence. The probe is fully complementary to SEQ. ID. NOS.:1, 2, 9, or 10, or is complementary to a gene-specific fragment of any of these. The suitable labels for a probe are typically radioisotopes or fluorogens incorporated into or covalently linked to the polynucleotide by methods known in the art, and are detectable by conventional radiation or fluorescence detecting methods. [0050]
  • The primer of the present invention is an oligonucleotide sequence that is useful in amplifying a nucleic acid segment from a sample that defines a nucleotide sequence specific to PAPSS2 or Papss2 by known methods of PCR, including RT-PCR. The primer is preferably 15 to 30 nucleotides long, and most preferably 17 to 22 nucleotides long, but primers as short as 7 contiguous nucleotides may be useful for some gene-specific sequences. (E.g., Vincent, J., et al., [0051] Oligonucleonucleotides as short as 7-mers can be used for PCR amplification, DNA Cell Biol. 13(1):75-82 [1994]).
  • Examples of useful oligonucleotide primer sequences for amplifying PAPSS2-specific nucleic acid segments include primer sequences comprising: [0052]
    (SEQ. ID. NO.:3; forward primer)
    5′-TGGACCAAGGATGACGATGT-3′;
    (SEQ. ID. NO.:4; reverse primer)
    5′-CGGAAAGATGGCAACAATGG;
    (SEQ. ID. NO.:5; forward primer)
    5′-CTGGTGCTGGAAAAACAACG-3′;
    (SEQ. ID. NO.:6; reverse primer)
    5′-TGCGAATGGAGAAATAAAGCTG;
    (SEQ. ID. NO.:11; forward primer)
    5′-GCCAGCCAGCATGTCGGGGAT-3′;
    (SEQ. ID. NO.:12, forward primer)
    5′-ACCTGAAACTCCTGAGCGTGTGCT-3′;
    (SEQ. ID. NO.:13; forward primer)
    5′-GATGTGCCTCTAGACTGGCGG-3′;
    (SEQ. ID. NO.:14; reverse primer)
    5′-GAGCACTTCAGAAAGAAACTCTGG-3′;
    (SEQ. ID. NO.:15; reverse primer)
    5′-CATCCGCCAGTCTAGAGGCAC-3′;
    (SEQ. ID. NO.:16; reverse primer)
    5′-AGGTGTCAGACGGTATTGGTC-3′;
    (SEQ. ID. NO.:17; reverse primer)
    5′-GTCACTCACTGTGGACAAATTGG-3′;
    (SEQ. ID. NO.:18; reverse primer)
    5′-CACCTCAGCAATCCGGCGGAT-3′; or
    (SEQ. ID. NO.:28; reverse primer)
    5′-GCATGTCCAGACAGACACCAC-3′,
  • but a complementary nucleotide sequence, or a gene-specific fragment of any of these is also useful; also useful are PAPSS2-specific primer sequences that overlap any of the afore-mentioned primer sequences at 5 or more contiguous nucleotide positions at their 5′ or 3′ end. [0053]
  • Useful primers for amplifying Papss2-specific sequences include primer sequences comprising: [0054]
    (SEQ. ID. NO.:19; reverse primer)
    5′-TCTGGCACAAAGAGTTCGTG-3′;
    (SEQ. ID. NO.:20; forward primer)
    5′-GCCAGTTTGTAACCGAGTATTC-3′;
    (SEQ. ID. NO.:21; reverse primer)
    5′-GCAATTGGATACAGAGCAGCTA-3′;
    (SEQ. ID. NO.:22; forward primer)
    5′-GACAATGTCCGTCATGGCCTTA-3′;
    (SEQ. ID. NO.:23; forward primer)
    5′-ATTCCCATTGTATTGCCCGTT-3′;
    (SEQ. ID. NO.:24; reverse primer)
    5′-AACGGGCAATACAATGGGAAT-3′;
    (SEQ. ID. NO.:25; reverse primer)
    5′-GATAAAGCTGGTGATGCAAACC-3′;
    (SEQ. ID. NO.:26; reverse primer)
    5′-CATGGGATGGCGTGAGATAC-3′; or
    (SEQ. ID. NO.:27; forward primer)
    5′-CATAAGCTTTGCTTTGGAAGAGT-3′,
  • but a complementary nucleotide sequence, or a gene-specific fragment of any of these is also useful; also useful are Papss2-specific primer sequences that overlap any of the afore-mentioned primer sequences at 5 or more contiguous nucleotide positions at their 5′ or 3′ end. [0055]
  • The present invention also relates to a pair of oligonucleotide primers (i.e., a primer set) comprising at least one forward and at least one reverse oligonucleotide primer, which together are capable of producing detectable nucleic acid amplification products from the 5′ and 3′ ends of a PAPSS2 or Papss2 nucleic acid template in a PCR- or RT-PCR-based nucleic acid amplification method. [0056]
  • In some embodiments, the amplification products that the pair of primers can amplify include nucleic acid amplification products comprising (SEQ. ID. NO.:1) or (SEQ. ID. NO.:9); a nucleotide sequence complementary to either of those; or a PAPSS2 gene-specific fragment of any of these. Examples of this embodiment of the inventive pair of oligonucleotide primers include pairs containing a forward primer having a nucleotide sequence comprising (SEQ. ID. NOS.: 3, 5, or any of 11-13), a complementary nucleotide sequence, a gene-specific fragment of either of these, or a nucleotide sequence overlapping at 5 or more contiguous nucleotide positions any sequence of those afore-mentioned at its 5′ or 3′ end; and containing a reverse primer having a nucleotide sequence comprising (SEQ. ID. NO.: 4, 6, 14-18, or 28), a complementary nucleotide sequence, a gene-specific fragment of either of these; or a nucleotide sequence overlapping at 5 or more contiguous nucleotide positions any sequence of those afore-mentioned at its 5′ or 3′ end. For example, useful oligonucleotide primer pairs for amplifying a PAPSS2 gene sequence include (SEQ. ID. NO.:3 and 4) or (SEQ. ID. NO.:5 and 6). [0057]
  • In other embodiments, the amplification products that the pair of oligonucleotide primers can amplify include nucleic acid amplification products having (SEQ. ID. NO.:2) or (SEQ. ID. NO.:10); a nucleotide sequence complementary to either of those; or a Papss2 gene-specific fragment of any of these. Examples of this embodiment of the inventive primer pair include pairs containing a forward primer having a nucleotide sequence comprising (SEQ. ID. NO.:20, 22, 23, or 27), a complementary nucleotide sequence, a gene-specific fragment of either of these, or a nucleotide sequence overlapping at 5 or more contiguous nucleotide positions any sequence of those afore-mentioned at its 5′ or 3′ end; and containing a reverse primer having a nucleotide sequence comprising (SEQ. ID. NOS.: 19, 21, or any of 24-26), a complementary nucleotide sequence, a gene-specific fragment of either of these; or a nucleotide sequence overlapping at 5 or more contiguous nucleotide positions any sequence of those afore-mentioned at its 5′ or 3′ end. [0058]
  • Other embodiments of the inventive nucleic acid construct include those in which, cloned into an expression vector, is a DNA segment encoding a PAPSS2 or Papss2 protein, operatively linked with any suitable promoter sequence, including a human PAPSS2 promoter, a promoter from another human or non-human PAPS synthetase gene (e.g., PAPSS1, Papss1, or Papss2 promoters), or a predetermined promoter sequence from any other human or non-human gene, as described above. Suitable vector systems include, but are not limited to, viral vectors, for example, adenoviruses, adeno-associated viruses, retroviruses such as human immune-deficiency virus, other lentiviruses, such as Moloney murine leukemia virus and the retrovirus vector derived from Moloney virus called vesicular-stomatitis-virus-glycoprotein (VSV-G)-Moloney murine leukemia virus, mumps virus, and transfecting fragments of any of these viruses, and other viral DNA segments that facilitate the uptake of the desired DNA segment by, and release into, the cytoplasm of cells and mixtures thereof. All of the above viruses may require modification to render them non-pathogenic or less antigenic. Other known vector systems, however, are also suitable for containing the DNA segment. [0059]
  • The present invention also relates to a genetically modified vertebrate cell containing the nucleic acid construct of the present invention, regardless of the method by which the construct was introduced into the cell. Embodiments include cartilage-forming cells, such as chondrocytes, and liver cells, such as hepatocytes, as well as cells derived from other tissues such as, colon, lung, placenta, aortic or other vascular endothelium, bone marrow, or heart. [0060]
  • If the nucleic acid construct includes a fluorescent reporter gene, as described above, the genetically modified cells of the present invention can be detected, isolated or selected from unmodified cells with the aid of, for example, a flow-activated cell sorter (FACS), set at the appropriate wavelength(s), or using conventional microscopic technology. [0061]
  • In particular applications involving a genetically modified cell that expresses additional xenogeneic genes from any promoter, this expression may be linked to a reporter gene that encodes a different fluorescent or light-emitting protein from the reporter gene linked to PAPSS2 or Papss2 expression. Thus, multiple reporters fluorescing or emitting at different wavelengths can be chosen and cell selections based on the expression of multiple traits can be made. [0062]
  • Gene delivery to the cell is by any suitable method including in vivo and vitro gene delivery methods. (E.g., D. T. Curiel et al., U.S. Pat. Nos. 5,521,291 and 5,547,932). Typically, gene delivery involves exposing a cell to a gene delivery mixture that includes preselected genetic material together with an appropriate vector, mixed, for example, with an effective amount of lipid transfecting agent (lipofection). The amount of each component of the mixture is chosen so that gene delivery to a specific species of cell is optimized. Such optimization requires no more than routine experimentation. The ratio of DNA to lipid is broad, preferably about 1:1, although other proportions may also be utilized depending on the type of lipid agent and the DNA utilized. This proportion is not crucial. Other well known gene delivery methods include electroporation or chemical methods. (E.g., M. Ostresh, [0063] No barriers to entry: transfection tools get biomolecules in the door, The Scientist 13(11):21-23 [1999]).
  • “Gene delivery agent”, as used herein, means a composition of matter added to the genetic material for enhancing the uptake of exogenous DNA segment(s) into a vertebrate cell. The enhancement is measured relative to the uptake in the absence of the gene delivery agent. Examples of gene delivery agents include adenovirus-transferrin-polylysine-DNA complexes. These complexes generally augment the uptake of DNA into the cell and reduce its breakdown during its passage through the cytoplasm to the nucleus of the cell. [0064]
  • Other preferred gene delivery agents include Lipofectin®, DMRIE C, Cellfectin® or Lipofectamine (Life Technologies), LipoTAXI (Stratagene), Superfect or Effectene (Qiagen). Although these are not as efficient gene delivery agents as viral agents, they have the advantage that they facilitate stable integration of xenogeneic DNA sequence into the vertebrate genome, without size restrictions commonly associated with virus-derived gene delivery agents. A virus, or transfecting fragment thereof, can be used to facilitate the delivery of the genetic material into the cell. Examples of suitable viruses include adenoviruses, adeno-associated viruses, retroviruses such as human immune-deficiency virus, other lentiviruses, such as Moloney murine leukemia virus and the retrovirus vector derived from Moloney virus called vesicular-stomatitis-virus-glycoprotein (VSV-G)-Moloney murine leukemia virus, mumps virus, and transfecting fragments of any of these viruses, and other viral DNA segments that facilitate the uptake of the desired DNA segment by, and release into, the cytoplasm of cells and mixtures thereof. All of the above viruses may require modification to render them non-pathogenic or less antigenic. Other known vector systems are also useful. [0065]
  • The present invention also relates to genetically modified non-human vertebrates comprising the present genetically modified cells, for example, non-human primates, mice, rats, rabbits, gerbils, hamsters, canines, felines or other non-human mammals. Other vertebrates include birds such as chickens, turkeys, ducks, ostriches, emus, geese, guinea fowl, doves, quail, rare and ornamental birds, and the like. Broadly speaking, a genetically modified vertebrate is one that has had exogenous or foreign DNA permanently introduced into one or more of its cells, whether somatic or germ cells. [0066]
  • The present invention also relates to an isolated human PAPS synthetase protein comprising a polypeptide having an amino acid sequence of (SEQ. ID. NO.:7), i.e., the following contiguous amino acid residues, or an antibody binding fragment of the protein at least 6 amino acids long (amino acid residue 475 is in boldface): [0067]
    (SEQ. ID. NO.:7)
    MSGIKKQKTENQQKSTNVVYQAHHVSRNKRGQVVGTRGGFRGCTVWLTGL
    SGAGKTTISFALEEYLVSHAIPCYSLDGDNVRHGLNRNLGFSPGDREENI
    RRIAEVAKLFADAGLVCITSFISPFAKDRENARKIHESAGLPFFEIFVDA
    PLNICESRDVKGLYKRARAGEIKGFTGIDSDYEKPETPERVLKTNLSTVS
    DCVHQVVELLQEQNIVPYTIIKDIHELFVPENKLDHVRAEAETLPSLSIT
    KLDLQWVQVLSEGWATPLKGFMREKEYLQVMHFDTLLDDGVINMSIPIVL
    PVSAEDKTRLEGCSKFVLAHGGRRVAILRDAEFYEHRKEERCSRVWGTTC
    TKHPHIKMVMESGDWLVGGDLQVLEKIRWNDGLDQYRLTPLELKQKCKEM
    NADAVFAFQLRNPVHNGHALLMQDTCRRLLERGYKHPVLLLHPLGGWTKD
    DDVPLDWRMKQHAAVLEEGVLDPKSTIVAIFPSPMLYAGPTEVQWHCRSR
    MIAGANFYIVGRDPAGMPHPETKKDLYEPTHGGKVLSMAPGLTSVEIIPF
    RVAAYNKAKKAMDFYDPARHNEFDFISGTRMRKLAREGENPPDGFMAPKA
    WKVLTDYYRSEMDKN//.
  • This polypeptide sequence is encoded for example by (SEQ. ID. NO.:9), but is also encoded by other degenerate coding sequences. [0068]
  • In one embodiment, the PAPSS2 protein forms part of a PAPSS2 fusion protein along with a second predetermined polypeptide segment, which can have an amino acid sequence related or unrelated to (SEQ. ID. NO.:7). The PAPSS2 fusion protein includes a first PAPSS2 polypeptide segment comprising an amino acid sequence of (SEQ. ID. NO.:7), an enzymatically active fragment thereof, or a gene-specific antibody binding fragment of (SEQ. ID. NO.:7) at least 6 amino acids long; and a second predetermined polypeptide segment. The fusion protein is produced by known recombinant methods, and the second predetermined polypeptide sequence can be any desired polypeptide, for example, a known antigenic sequence, such as a specific goat, rabbit, or HLA antigen to which immunoreagents of commercially available immunoassay systems are directed. Thus, in some applications, conventional immunoassay systems can be used “off the shelf” to detect and quantify a PAPSS2 fusion protein by detecting the second polypeptide sequence. [0069]
  • In other applications, for example in protein therapy for the treatment of osteoarthritic disorders related to deficient enzymatic sulfation, the second polypeptide of the fusion protein is a polypeptide that allows the hybrid molecule to enter cells of a target tissue, for example, cartilage, liver, or platelets, whether in vitro or in vivo. For example, a second polypeptide can be chosen that infiltrates the cells of tissues, such as the human immunodeficiency virus (HIV) TAT protein (Schwarze, S. R., et al., [0070] In vivo protein transduction: delivery of a biologically active protein into the mouse, Science 285:1569-72 [1999]), and once within the cells, the PAPSS2 polypeptide segment of the fusion protein becomes enzymatically active in the sulfation pathway within the cells.
  • The present invention also relates to an isolated murine Papss2 protein comprising an amino acid sequence of (SEQ. ID. NO.:8), i.e., the following contiguous amino acid residues, or an antibody binding fragment of the protein at least 6 amino acids long: [0071]
    (SEQ. ID. NO.:8)
    MSANFKMNHKRDQQKSTNVVYQAHHVSRNKRGQVVGTRGGFRGCTVWLTG
    LSGAGKTTISFALEEYLVSHAIPCYSLDGDNVRHGLNKNLGFSAGDREEN
    IRRIAEVAKLFADAGLVCITSFISPFAKDRENARKIHESAGLPFFEIFVD
    APLNICESRDVKGLYKRARAGEIKGFTGIDSDYEKPETPECVLKTNLSSV
    SDCVQQVVELLQEQNIVPHTTIKGIHELFVPENKVDQIRAEAETLPSLPI
    TKLDLQWVQILSEGWATPLKGFMREKEYLQTLHFDTLLDDGVINMSIPIV
    LPVSADDKARLEGCSKFALMYEGRRVALLQDPEFVEHRKEERCSRVWGTA
    TAKHPHIKMVMESGDWLVGGDLQVLERIRWDDGLDQYRLTPLELKQKCKD
    MNADAVFAFQLRNPVHNGHALLMQDTRRRLLERGYKHPVLLLHPLGGWTK
    DDDVPLEWRMKQHAAVLEERVLDPKSTIVAIFPSPMLYAGPTEVQWHCRC
    RMIAGANFYIVGRDPAGMPHPETKKDLYEPTHGGKVLSMAPGLTSVEIIP
    FRVAAYNKIKKAMDFYDPARHEEFDFISGTRMRKLAREGEDPPDGFMAPK
    AWKVLTDYYRSEMDKTN//.
  • This polypeptide sequence is encoded for example by (SEQ. ID. NO.:10), but is also encoded by other degenerate coding sequences. [0072]
  • In one embodiment, the Papss2 protein forms part of a Papss2 fusion protein along with a second predetermined polypeptide segment, which can have an amino acid sequence related or unrelated to (SEQ. ID. NO.:8). The Papss2 fusion protein includes a first Papss2 polypeptide segment comprising an amino acid sequence of (SEQ. ID. NO.:8) or a gene-specific antibody binding fragment thereof at least 6 amino acids long; and a second predetermined polypeptide segment. As above, the fusion protein is produced by known recombinant methods, and the second predetermined polypeptide sequence can be any desired polypeptide, for example, a known antigenic sequence, such as a specific goat, rabbit, or HLA antigen to which immunoreagents of commercially available immunoassay systems are directed. Thus, in some applications, conventional immunoassay systems can be used “off the shelf” to detect and quantify a Papss2 fusion protein by detecting the second polypeptide sequence. [0073]
  • The present invention also relates to an isolated antibody or antibody fragment that selectively binds a PAPS synthetase protein having an amino acid sequence of (SEQ. ID. NO.:7) or (SEQ.ID. NO.8), or selectively binds an antibody binding fragment of either of these at least 6 amino acids long. These are useful for detection and visualization of PAPSS2 or Papss2 proteins in various applications. The antibody or antibody fragment is raised against the PAPSS2 or Papss2 protein of the present invention. The antibody is raised in a mammal, from which it is isolated in serum, or is most preferably produced in a hybridoma cell line, by known methods, and is a monoclonal antibody. Antibody fragments of the present antibody are also useful; these include Fab′, F(ab′)2, or F(v) fragments that are produced by known methods, typically by pepsinization of whole antibody. [0074]
  • The present invention also relates to a method of diagnosing spondyloepimetaphyseal dysplasia in a human subject. The method involves amplifying a nucleic acid segment from a sample. The sample is derived from a human subject having at least one symptom of spondyloepimetaphyseal dysplasia, and the sample is of a bodily substance containing human nucleic acid of the subject. The nucleic acid segment defines a sequence from human chromosomal region 10q23-24, between microsatellite markers D10S1143 and D10S2470, to produce amplification products; and analyzing the amplification products for the presence of homozygosity for a variant allele of a PAPSS2 gene, the presence of homozygosity for the variant allele of the gene corroborating a diagnosis of spondyloepimetaphyseal dysplasia in the human subject. [0075]
  • Any bodily substance containing human nucleic acids from the subject may be sampled, collected, and/or transported for the purpose of practicing the method. A most preferred and convenient substance for sampling is blood. However, a sample of hair root, urine, amniotic fluid, chorionic villus biopsy, skin biopsy, vascular or oral epithelium, spinal fluid, or other biopsy sample of any tissue is also useful. The sample is derived from cultured human cells, cell-free extracts, or other specimens indirectly derived from a subject's body, as well as from substances taken directly from a subject's body. Samples may be stored before amplification and/or analysis by well known storage means that will preserve nucleic acids in an analyzable condition, such as quick freezing, or a controlled freezing regime, in the presence of a cryoprotectant, for example, dimethyl sulfoxide (DMSO), glycerol, or propanediol-sucrose. Samples may also be pooled before or after storage for purposes of amplifying their nucleic acids for analysis. [0076]
  • For purposes of the present invention “amplifying a nucleic acid segment” from a tissue sample of a subject “to obtain amplification products” encompasses any conventional means of amassing sufficient nucleic acid material for analysis. This includes, but is not limited to, amplification by conventional polymerase chain reaction methods (e.g., PCR, including RT-PCR). Alternatively, the practitioner can amplify the human subject's nucleic acids by in vitro cell culture and harvest of the subject's cultured cells, or by multiple sampling from the subject's tissues in vivo and pooling of multiple tissue samples from a subject. Nucleic acids thus “amplified,” if they comprise a PAPSS2 gene or a gene-specific part thereof, are “amplification products” for purposes of the present invention. [0077]
  • In a most preferred embodiment of the present method, PCR is used for amplifying the subject's nucleic acids, particularly from a PAPSS2 gene. If PCR is used, any combination of oligonucleotide primers that will amplify nucleic acid sequences of a PAPSS2 gene, or parts thereof, can be employed. Most preferably, amplification of the subject's nucleic acids can be achieved using PAPSS2-specific oligonucleotide primers and primer pairs of the present invention, as described above. For example, useful primers comprise a nucleotide sequence of (SEQ. ID. NOS.:3-6, 11-18, or 28) or a PAPSS2-specific fragment of any of these at least 15 nucleotides long. In addition a sequence complementary to any of (SEQ. ID. NOS.:3-6, 11-18, or 28) or the PAPSS2-specific fragment, or any PAPSS2-specific nucleotide sequence at least 15 nucleotides long and overlapping at 5 or more contiguous nucleotide positions any of (SEQ. ID. NOS.:3-6, 11-18, or 28) at its 5′ or 3′ end, is a useful primer sequence. Examples of pairs of oligonucleotide primers useful for practicing the method include primer pairs comprising (SEQ. ID. NOS.:3 and 4) or (SEQ. ID. NOS.:5 and 6), but any of the present PAPSS2-specific primer pairs are useful. [0078]
  • In a preferred embodiment of the method of the present invention, nucleotide sequencing of PAPSS2 can be used to analyze the amplification products of the nucleic acids in a human subject's tissue sample to detect a variant allele in a PAPSS2 gene. A variant allele of PAPSS2 can be detected by any nucleotide sequencing means, for example conventional dideoxy sequencing or preferably by using a commercially available automated sequencer, then by comparing the subject's nucleotide sequences to other known human PAPSS2 sequences available in genomic sequence databases, such as GenBank. [0079]
  • In a most preferred embodiment of the present method that employs nucleotide sequencing, sequencing of PAPSS2 may be accomplished by using fluorescence-based single strand conformation polymorphism analysis (SSCP), a routine and reliable means of identifying point mutations, small insertions or deletions. (J. S. Ellison, [0080] Fluorescence-based mutation detection. Single-strand conformation polymorphism analysis [F-SSCP], Mol Biotechnol. 5(1):17-31 [1996]; H. Iwahana et al., Multiple fluorescence-based PCR-SSCP analysis using internal fluorescent labeling of PCR products, Biotechniques 21(3):510-14, 516-19 [1996]; R. Makino et al., F-SSCP: fluorescence-based polymerase chain reaction-single-strand conformation polymorphism [PCR-SSCP], PCR Methods Appl. 2(1):10-13 [1992]). An automated system may be used, such as an Applied Biosystems DNA sequencer, equipped with GENESCAN 672, Genetyper, or another appropriate analytical software package.
  • Optionally, high throughput analysis is achieved by PCR multiplexing techniques well known in the art. (E.g., Z. Lin et al., [0081] Multiplex genotype determination at a large number of gene loci, Proc. Natl. Acad. Sci. USA 93(6):2582-87 [1996]).
  • In another preferred embodiment of the present method, nucleotide sequencing is unnecessary for analyzing the amplification products. For example, heteroduplex analysis on high resolution gel matrices can be employed by the skilled practitioner to detect even single nucleotide polymorphisms. (M. T. Hauser et al., [0082] Generation of co-dominant PCR-based markers by duplex analysis on high resolution gels, Plant. J. 16(1):117-25 [1998]). The PCR/OLA procedure can be used for analyzing amplification products to detect SNPs in PAPSS2. (B. R. Glick and J. J. Pasternak, Molecular Biotechnology: Principles and Applications of Recombinant DNA, ASM Press, Washington, D.C., pp. 197-200 [1994]). Conformation-sensitive gel electrophoresis of amplification products can also be employed as a means of analysis by the skilled artisan in practicing the methods of the present invention. (A. Markoff et al., Comparison of conformation-sensitive gel electrophoresis and single strand conformation polymorphism analysis for detection of mutations in the BRCA1 gene using optimized conformation analysis protocols, Eur. J. Genet. 6(2):145-50 [1998]).
  • A skilled practitioner will know that electrophoresis for analyzing amplification products is done rapidly and with high sensitivity by using any of various methods of conventional slab or capillary electrophoresis, with which the practitioner can optionally choose to employ any facilitating means of nucleic acid fragment detection, including, but not limited to, the use of radionuclides, biotin, UV-absorbance or laser-induced fluorescence. (K. Keparnik et al., [0083] Fast detection of a (CA) 18 microsatellite repeat in the Ig E receptor gene by capillary electrophoresis with laser-induced fluorescence detection, Electrophoresis 19(2);249-55 [1998]; H. Inoue et al., Enhanced separation of DNA sequencing products by capillary electrophoresis using a stepwise gradient of electric field strength, J. Chromatogr. A. 802(1):179-84 [1998]; N. J. Dovichi, DNA sequencing by capillary electrophoresis, Electrophoresis 18(12-13):2393-99 [1997]; H. Arakawa et al., Analysis of single-strand conformation polymorphisms by capillary electrophoresis with laser induced fluorescence detection, J. Pharm. Biomed. Anal. 15(9-10):1537-44 [1997]; Y. Baba, Analysis of disease-causing genes and DNA-based drugs by capillary electrophoresis. Towards DNA diagnosis and gene therapy for human diseases, J. Chromatgr B. Biomed. Appl. 687(2):271-302 [1996]; K. C. Chan et al., High-speed electrophoretic separation of DNA fragments using a short capillary, J. Chromatogr B. Biomed. Sci. Appl. 695(1):13-15 [1997]).
  • Any of diverse fluorescent dyes are optionally used to label primers or amplification products for ease of analysis, including but not limited to, fluorescein, SYBR Green I, YO-PRO-1, thiazole orange, Hex (i.e., 6-carboxy-2′,4′,7′,4,7-hexachlorofluoroscein), FAM (i.e., 6-carboxyfluorescein), or TET (i.e., 4,7,2′,7′-tetrachloro-6-carboxyfluoroscein). (E.g., J. Skeidsvoll and P. M. Ueland, [0084] Analysis of double-stranded DNA by capillary electrophoresis with laser-induced fluorescence detection using the monomeric dye SYBR green I, Anal. Biochem. 231(20):359-65 [1995]; H. Iwahana et al., Multiple fluorescence-based PCR-SSCP analysis using internal fluorescent labeling of PCR products, Biotechniques 21(30:510-14, 516-19 [1996]).
  • Analyzing the amplification products can also be done by means of restricting the amplification products with one or more restriction enzymes, for example HincII, followed by separation of the resulting fragments and analysis of fragment length or differential fragment migration in denaturing high-performance liquid chromatography (DHPLC) or gel electrophoresis, as above, including restriction-capillary electrophoresis. For example, this may be achieved by techniques known in the art, such as PCR-restriction fragment-SSCP, which can detect single base substitutions, deletions or insertions. (M. Tawata et al., [0085] A mass screening device of genome by polymerase chain reaction-restriction fragment-single strand conformation polymorphism analysis, Genet. Anal. 12(3-4):125-27 [1996]; H. H. Lee et al., Mutational analysis by a combined application of the multiple restriction fragment-single strand conformation polymorphism and the direct linear amplification DNA sequencing protocols, Anal. Biochem. 205(2);289-93 [1992]).
  • Variant alleles of a PAPSS2 gene may be of any nucleotide sequence defining an open reading frame, or part thereof, that encodes PAPSS2 protein, or of any nucleotide sequence, or part thereof, defining a regulatory region of a PAPSS2 gene. A PAPSS2 regulatory region may include, but is not limited to, a promoter region, an enhancer, a termination sequence, or any other nucleotide sequence, or part thereof, that regulates the transcription of PAPSS2 protein. Any mutation or polymorphism in a PAPSS2 gene that results in a loss of PAPSS2 expression or a decrease in PAPSS2 functional activity relative to a normal activity range, or which could do so if it were not masked by the presence in vivo of a fully functional PAPSS2 allele or by another compensatory physiologic mechanism, are contemplated by the present invention. [0086]
  • For example, one variant allele of PAPSS2, characteristic of SEMD Pakistani-type, defines a stop codon instead of a serine codon corresponding to amino acid residue 475 of SEQ. ID. NO.:7, and results in synthesis of a truncated PAPSS2 protein 474 amino acids long. Homozygosity for this variant allele is associated with SEMD Pakistani-type in a human subject, and thus corroborates a diagnosis of SEMD Pakistani type. [0087]
  • However, detecting heterozygosity for a variant PAPSS2 allele is also useful, for genetic counseling purposes. Consequently, the present invention also relates to a method of identifying a human carrier of an heritable allele associated with spondyloepimetaphyseal dysplasia. As in the present method of diagnosing spondyloepimetaphyseal dysplasia, the method of identifying a carrier involves amplifying a nucleic acid segment from a sample derived from a human subject without symptoms of spondyloepimetaphyseal dysplasia, to produce amplification products. As described above, the sample is of a bodily substance containing human nucleic acid of the subject. The nucleic acid segment defines a sequence from human chromosomal region 10q23-24, between microsatellite markers D10S1143 and D10S2470. The amplification products are analyzed for the presence of a variant allele of a PAPSS2 gene, which is accomplished as described above. The presence of the variant allele of the gene identifies the human subject as a carrier of an heritable allele associated with spondyloepimetaphyseal dysplasia. A benefit of the present method of identifying a human carrier of an heritable allele associated with SEMD, is that couples in which one or both of the spouses is identified as a carrier of a SEMD-associated allele, can make more informed reproductive decisions. [0088]
  • The present invention also relates to a gene therapy method for treating a human subject having an osteoarthritic disorder that is caused or aggravated by deficient enzymatic sulfation activity. Examples include spondyloepimetaphyseal dysplasia, Stickler syndrome, spondyloepiphyseal dysplasia, and achondrogenesis; achondroplasia; chondrodysplasia; diastrophic dysplasia; the collagen oligomeric matrix protein (COMP) disorders such as pseudoachondroplasia and multiple epiphyseal dysplasia. In one embodiment, the method involves exposing, in vitro, one or more cells derived directly (e.g., biopsied) or indirectly (e.g., cultured) from a tissue of a human subject having at least one symptom of an osteoarthritic disorder caused or aggravated by deficient enzymatic sulfation activity to a gene delivery mixture comprising at least one gene delivery agent and a nucleic acid construct having a nucleic acid segment encoding a PAPS synthetase protein having an amino acid sequence of (SEQ. ID. NO.:7) or (SEQ. ID. NO.:8); causing the nucleic acid construct to be taken up by, and released into the cell(s), such that the nucleic acid construct is incorporated into the genome of the cell(s), whereby under appropriate physiological conditions expression of functional PAPS synthetase protein is enhanced in the cell(s), compared to unmodified cells of the same kind. The genetically modified cells are then implanted into the tissue of the human subject, where PAPS synthetase activity is thereby enhanced relative to pre-implantation, and at least one symptom associated with the osteoarthritic disorder in the subject is improved. [0089]
  • For purposes of treating symptoms of aberrant skeletal growth, the human subject is preferably a juvenile, and most preferably a prepubescent juvenile. However, for purposes of treating symptoms of joint degeneration associated with osteoarthritic disorders, such as SEMD or chondrodysplasia, and for stabilizing the cartilage matrix, the human subject is any age. In one embodiment, the gene therapy method for treating an osteoarthritic disorder caused or aggravated by deficient enzymatic sulfation activity is directed to symptom(s) related to deficient sulfation activity that may arise in liver cells, e.g., hepatocytes, in platelets, or in vascular tissue, and these symptoms are treated in accordance with the method at any age, depending only on the practitioner's best estimation of the physiologic resilience of the individual patient in facing the stresses of the procedure. [0090]
  • These stresses are typically minimal, as cells can be obtained by pertcutaneous or laparoscopic biopsy. However, cells are also obtained by any other suitable surgical means or from a pre-existing culture derived from a tissue of the subject or other viable sample of the subject's cells. Implantation of the genetically modified cells is accomplished by conventional percutaneous, laparoscopic, stereotactic, or other surgical methods. [0091]
  • The method involves genetically modifying a cell(s) derived from a tissue of the subject. Preferably, but not necessarily, this is a cartilage-forming cell, such as a chondrocyte from an epiphyseal region. However, other cell types can also be genetically modified in accordance with the method to improve osteoarthritic symptoms that may be associated with other tissues, for example hepatocytes, platelets, or vascular endothelium. The cells, for example, chondrocytes, hepatocytes, hematopoietic precursor cells, or vascular endothelial cells, are obtained from an appropriate tissue, such as the epiphyses, joints, liver, bone marrow, or vascular tissue. [0092]
  • The cell(s) are genetically modified. This can be by any suitable gene delivery method as described above, preferably in vitro, for example by transfection, transduction, or electroporation, but in vivo methods of gene delivery are also contemplated. The cell(s) is exposed to a gene delivery mixture comprising at least one gene delivery agent, as described above, and a nucleic acid construct, preferably DNA, containing a nucleic acid segment encoding a PAPS synthetase protein having an amino acid sequence of (SEQ. ID. NO.:7), for example (SEQ. ID. NO.:9), or containing a nucleic acid segment encoding a PAPS synthetase protein having an amino acid sequence of (SEQ. ID. NO.:8), for example (SEQ. ID. NO.:10), operatively linked, in a transcriptional unit, to a predetermined promoter sequence that operates in the cell. [0093]
  • The nucleic acid construct that is used in the present gene therapy method optionally contains a reporter gene for convenient detection, isolation or selection of genetically modified cells expressing PAP synthetase protein from an exogenously supplied gene, as described above. [0094]
  • The construct is then taken up by and released into the cell, and is incorporated into the genome of the cell. Under appropriate physiological conditions, transcription of the PAPSS2 or Papss2 encoding region occurs, followed by translation, and thus, expression of PAPSS2 or Papss2 protein is enhanced in the cell, compared to unmodified cells of the same kind. With the cell(s) implanted in the tissue of the subject, one or more symptoms of the osteoarthritic disorder in the subject are thereby improved due to enhanced enzymatic sulfation in the tissue of biochemicals that require sulfation for bioactivity or have increased bioactivity in humans in a sulfated form. [0095]
  • Under some circumstances, the practitioner may deem it desirable to apply the present gene therapy method to a fetal subject that has been identified as being homozygous for a variant allele of a PAPSS2 gene by the present method of diagnosing spondyloepimetaphyseal dysplasia. In such instances, chondrocytes and stem cell precursors of chondrocytes can be obtained from fetal cartilage, can be genetically modified and re-implanted while the subject is in utero. [0096]
  • Another embodiment of the gene therapy method of the present invention involves a gene modification strategy employing a chimeric RNA/DNA oligonucleotide construct, particularly useful in repairing SNPs associated with a SEMD phenotype, such as the allele encoding a stop codon instead of serine at position 475 of (SEQ. ID. NO.:7) (e.g., “TAA” instead of “TCA” at nt. +1423 through +1425 of SEQ. ID. NO.:1; see FIG. 3), associated with SEMD Pakistani type. (E.g., Kren, B. T., et al., [0097] Gene repair using chimeric RNA/DNA oligonucleotides, Semin. Liver Dis. 19(1):93-104 [1999]; Alexeev, V. & Yoon, K., Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA-DNA oligonucleotide, Nat. Biotechnol. 16(13):1343-46 [1998]; Cole-Strauss, A.., et al., Targeted gene repair directed by the chimeric RNA/DNA oligonucleotide in a mammalian cell free extract, Nucleic Acids Res. 27(5):1323-30 [1999], Xiang, Y., et al., Targeted gene conversion in a mammalian CD34+-enriched cell population using a chimeric RNA/DNA oligonucleotide, J. Mol. Med. 75(11-12):829-35 [1997]; Cole-Strauss, A.., et al., Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide, Science 273(5280):1386-89 [1996]; Yoon, K., et al., Targeted gene correction of episomal DNA in mammalian cells mediated by a chimeric RNA.DNA oligonucleotide, Proc. Natl. Acad. Sci. USA 93(5):2071-76 [1996]). Briefly, this gene modification strategy exploits the recombinogenicity of RNA-DNA hybrids and features the use of chimeric RNA/DNA oligonucleotides with hairpin capped ends that avoid destabilization or destruction by cellular helicases or exonucleases; an RNA/DNA oligonucleotide is designed so that it perfectly aligns with a specific genomic target sequence except for a single mismatched basepair, which is recognized by endogenous DNA repair systems that can then convert the SNP to a desired normal sequence.
  • In this embodiment, the cells are exposed to a nucleic acid construct that includes a chimeric RNA/DNA oligonucleotide. This chimeric RNA/DNA comprises a nucleic acid segment of a PAPSS2 gene comprising a nucleotide sequence of (SEQ. ID. NO.:9), (SEQ. ID. NO.:10), or a gene-specific fragment of either of these. The nucleic acid construct is taken up by, and released into, the cell, and the nucleotide sequence of the nucleic acid segment is incorporated into the genome of the cell, whereby expression of functional PAPS synthetase protein is enhanced in the cell. Under appropriate physiological conditions, transcription of the PAPSS2 or Papss2 encoding region occurs, followed by translation, and thus, expression of PAPS synthetase protein is enhanced in the cell, compared to unmodified cells of the same kind. The genetically modified cell(s) is then implanted into the tissue of the human subject, as described above. With the cell(s) implanted in the tissue of the subject, one or more symptoms of the osteoarthritic disorder in the subject are thereby improved due to enhanced enzymatic sulfation in the tissue of biochemicals that require sulfation for bioactivity or have increased bioactivity in humans in a sulfated form. [0098]
  • Thus, the gene therapy method provides a much needed way to improve or eliminate symptoms of aberrant skeletal growth or joint degeneration associated with osteoarthritic disorders such as SEMD. The method provides a way to improve symptoms resulting from deficient sulfation activity in other cell types, such as hepatocytes, platelets, or vascular epithelium, for example, abnormally long bleeding time. [0099]
  • The present invention is also related to a protein therapy method for treating a human subject having an osteoarthritic disorder. The osteoarthritic disorder is one that is caused or aggravated by deficient enzymatic sulfation activity, as described above. The method employs the inventive PAPSS2 fusion protein. The method involves exposing a cell(s) of a tissue of a human subject having the osteoarthritic disorder to a fusion protein comprising a first PAPSS2 polypeptide segment that comprises an amino acid sequence of (SEQ. ID. NO.:7), or an enzymatically active fragment thereof, and a second polypeptide segment capable of infiltrating the cell, whereby the fusion protein is taken up by the cell and the PAPSS2 polypeptide segment is enzymatically active within the cell. Exposing the cell(s) is preferably accomplished in vivo, for example by injecting or infusing the fusion protein into the subject. An example of a second polypeptide segment capable of infiltrating a diversity of cell types is an human immunodeficiency virus (HIV) TAT protein. (Schwarze, S. R., et al. [1999]). But a tissue-specific second polypeptide can also be used. [0100]
  • The skilled artisan is aware of suitable means of detecting an improvement in the subject's symptom(s) resulting from treatment by the inventive genetic or protein therapy methods. For example, a useful indicator of improvement in symptoms of aberrant skeletal growth is a comparison of the subject's growth rate over a period of months or years after treatment using the method, with the rate of growth before treatment. It is also useful to compare the subject's growth over time after treatment with standard growth curves or tables for humans of the same age and sex. Improvement in joint function, for example reduction in joint pain or enhanced joint movement, or joint appearance on x-ray, are useful indicators. Another useful indicator is improvement in platelet function, which is detected in normalized or shortened bleeding time for the subject. [0101]
  • Alternatively, biochemical or molecular methods are employed to detect improvement. For example, assays showing increased sulfation activity in a tissue biopsy sample(s) from the subject, such as in cartilage, liver, or blood samples and/or extracts, are useful in determining the effectiveness of the method. Commonly, such assays are based on direct measurement of in vivo and/or in vitro PAPS synthetase enzymatic activity or detecting the assimilation of sulfate into APS (i.e., sulfate activation assay) or into other sulfated metabolites, for example measuring the degree of sulfation of aggrecan side chains. Radiolabeled (e.g., [0102] 35S) sulfate and chromatographic separations are common tools used in such assay methods. Detection of PAPSS2-specific mRNA transcripts in tissue samples, using the probes or primers of the present invention, can also be employed as an indirect measure of improvement.
  • Alternatively, the nucleic acid construct that is used in the present gene therapy method can optionally contain in the transcriptional unit a reporter gene, as described above, for convenient detection of genetically modified cells expressing exogenous PAPSS2 in a tissue biopsy sample(s) from the subject. [0103]
  • The present invention is also related to a genetic testing kit for diagnosing SEMD in a human subject. The kit is an assemblage of materials for facilitating amplifying nucleic acids from a human subject comprising PAPSS2 nucleotide sequences and/or analyzing PAPSS2-derived amplification products. A genetic testing kit of the present invention comprises at least one oligonucleotide primer of the present invention and preferably comprises a pair of oligonucleotide primers of the present invention, together with instructions for the practice of the methods of the present invention. A most preferred embodiment of the genetic testing kit of the present invention comprises an inventive pair of oligonucleotide primers, as described above, for example (SEQ. ID. NOS.:3 and 4) or (SEQ. ID. NOS.:5 and 6). A preferred embodiment of the genetic testing kit of the present invention can incorporate an array of oligonucleotide primers specific for SNPs in human PAPSS2, preassembled in a “DNA chip” (or “gene chip”) configuration for facilitating the amplifying of nucleic acids and the analyzing of amplification products. (E.g., J. G. Hacia et al., [0104] Enhanced high density oligonucleotide array-based sequence analysis using modified nucleoside triphosphates, Nucleic Acids Res. 26(2):4975-82 [1998]; R. W. Wallace, DNA on a chip: serving up the genome for diagnostics and research, Mol. Med. Today 3(9):384-89 [1997]; T. Pastinen et al., Minisequencing: a specific tool for DNA analysis and diagnostics on oligonucleotide arrays, Genome Res. 7(6):606-14 [1997]; M. T. Cronin et al., Cystic fibrosis mutation detection by hybridization to light-generated DNA probe arrays, Hum. Mutat. 7(3):244-55 [1996]; A. C. Pease et al., Light-generated oligonucleotide arrays for rapid DNA sequence analysis, Proc. Natl. Acad. Sci. USA 91(11):5022-26 [1994]; E. M. Southern et al., Arrays of complementary oligonucleotides for analyzing the hybridisation behaviour of nucleic acids, Nucleic Acids Res. 22(8):1368-73 [1994]).
  • The present invention also relates to a kit for genetically modifying a vertebrate cell. The kit is a ready assemblage of materials or components for facilitating the genetic modification of a vertebrate cell. The kit includes a polynucleotide comprising a PAPSS2 sequence having SEQ. ID. NOS.:1, or a Papss2 sequence having SEQ. ID. NO.:2, a sequence complementary to either of these, or a degenerate coding sequence thereof (i.e., encoding SEQ. ID. NOS.:7 or 8), or a gene-specific fragment of any of these, as described herein with respect to the nucleic acid construct of the present invention. Preferably the polynucleotide includes a transcriptional unit that contains the human PAPSS2- or murine Papss2-encoding nucleic acid segment, operatively linked to a functional promoter sequence, and/or a reporter gene for facilitating detection, isolation, or selection of genetically modified cells from unmodified cells. The kit optionally contains a suitable gene delivery agent. The kit is particularly useful in practicing the gene therapy method for treating a human subject having an osteoarthritic disorder that is caused or aggravated by deficient enzymatic sulfation activity. [0105]
  • However, in several embodiments, the kit includes a DNA sequence encoding the PAPSS2 or Papss2 protein, or fragment thereof at least 6 amino acids long, in a sense or antisense orientation, as appropriate for a particular application. Alternatively, the kit includes a PAPSS2- or Papss2-specific chimeric RNA/DNA oligonucleotide, as described above. Some embodiments of the kit are configured for use in practicing the present method of treating a human subject having an osteoarthritic disorder, as described above. [0106]
  • The present invention also relates to a kit for practicing the inventive method of protein therapy for treating a human subject having an osteoarthritic disorder that employs the inventive PAPSS2 fusion protein, as described above. The kit contains a fusion protein comprising a first PAPSS2 polypeptide segment that comprises an amino acid sequence of (SEQ. ID. NO.:7), or an enzymatically active fragment thereof, and a second polypeptide segment capable of infiltrating the cell, whereby the fusion protein is taken up by the cell and the PAPSS2 polypeptide segment is enzymatically active within the cell. An example of a second polypeptide segment capable of infiltrating cell(s) is an human immunodeficiency virus (HIV) TAT protein, which can infiltrate diverse cell types, but other polypeptide segments are also useful. [0107]
  • The materials or components assembled in the present kits for diagnosing SEMD or identifying a carrier of a heritable marker associated with SEMD and kits for genetically modifying a vertebrate cell or for protein therapy can be provided to the practitioner stored in any convenient and suitable ways that preserve their operability and utility. For example the components can be in dissolved, dehydrated, or lyophilized form; they can be provided at room, refrigerated or frozen temperatures. The kits of the present invention include instructions for using the materials or components effectively for their intended purpose(s). [0108]
  • It is contemplated that the polynucleotides, nucleic acid constructs, primers, primer pairs, and kits of the present invention can be used therapeutically to detect SEMD in patients with specific variant alleles of PAPSS2. These variant alleles can be targeted for gene therapy directed at repairing malfunctional PAPSS2 alleles or they may suggest specific chemotherapy directed to enhancing endogenous PAPS synthetase activity or may be directed to other metabolic targets in biochemical pathways mediated by PAPS synthetase activity. [0109]
  • The foregoing descriptions of the isolated polynucleotides, nucleic acid constructs, genetically modified cells and vertebrates, methods, and kits of the present invention are illustrative and by no means exhaustive. The invention will now be described in greater detail by reference to the following non-limiting examples. [0110]
    • EXAMPLES Example 1
  • Methods. [0111]
  • Genotyping. Synthetic oligonucleotide primers were obtained for genotyping in the SEMD family with polymorphic microsatellite markers from the CHLC Human Screening Set/Weber version 8 (Research Genetics). Additional markers were derived from a physical map of chromosome 10 (Gray, I. C., et al., [0112] An integrated physical and genetic map spanning chromosome band 10q24, Genomics 43:85-88 [1997]) and databases from the Whitehead Institute for Biomedical Research, the Cooperative Human Linkage Center, and Genethon.
  • Similar methods were used for analysis of microsatellite markers in the brachymorphic mice, using DNA samples from backcross animals recombinant in the bm region. (Rusiniak, M. E., et al., [0113] Molecular markers near the mouse brachymorphic (bm) gene, which affects connective tissues and bleeding time, Mamm. Genome 7:98-102 [1996]). Markers were derived from the Whitehead Institute for Biomedical Research mouse genetic and physical mapping database (http://www-genome.wi.mit.edu/cgi-bin/mouse/index).
  • Linkage Calculations. Two-point linkage analyses were conducted for eight markers in the region of D10S1143 (see FIGS. 1 and 2 and Table 1). LOD scores were calculated with the MLINK subroutine of the LINKAGE 5.1 package (Terwilliger, J. D. & Ott, J., [0114] Handbook of human genetic linkage, Baltimore:John Hopkins University Press [1994]) using a Pentium PC. Because of the computational problems introduced by extensive inbreeding and multiple generations with no genotyping or phenotyping data, the SEMD pedigree was divided into three separate sub-pedigrees. Individuals in the three nuclear families from the most recent generation, including each of their ancestors back to the founding couple as well as all inbreeding loops, were analyzed separately. The genotypes of each individual were analyzed only once.
  • SEMD was modeled as an autosomal recessive fully penetrant disease with an allele frequency of 0.0001. LOD scores were summed across the pedigrees. The LOD scores of −□ reflect recombinations within nuclear families for markers D10S2470 and D10S1753. Other markers did not recombine within the nuclear families, so that q=0.0 could not be ruled out for them, although parsimony indicates that recombination has probably occurred within the pedigree for each of these markers. The maximum LOD scores for markers D10S1143 and D10S2470 at q=0.01 were consistent with the results of the haplotype analysis. Because marker allele frequencies in the Pakistani population are unknown, for each marker, the allele frequencies were set at 1/N, where N was the number of observed alleles in the pedigree. [0115]
  • Radiation Hybrid Mapping. DNA from the Genebridge 4 Radiation Hybrid (RH) panel was obtained from Research Genetics. For the PAPSS2 gene, a 236 bp PCR product was amplified using primers 5′-CTGGTGCTGGAAAAACAACG-3′ (SEQ. ID. NO.:5; forward primer) and 5′-TGCGAATGGAGAA ATAAAGCTG-3′ (SEQ. ID. NO.:6; reverse primer). RH data were submitted to the Whitehead server (http://www-genome.wi.mit.edu/cgi-bin/contig/rhmapper.p1) for placement on the the RH map. [0116]
  • Computer Methods. BLAST searches (Altschul, S. F., et al., [0117] Gapped BLAST and PSI-BLAST: a new generation of protein search programs, Nucleic Acids Res. 25:3389-3402 [1997]) and determinations of sequence homology were performed using the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/BLAST/) and Baylor College of Medicine (http://dot.imgen.bcm.tmc.edu:933 1/seq-search/nucleic_acid-search.html) servers. The phenoytpic map of the mouse genome was accessed through the Mouse Genome Informatics server (http://www.informatics.jax.org), maintained by the Jackson Laboratory.
  • cDNA library analysis. To isolate the human PAPSS2 cDNA clones, oligonucleotide primers B (SEQ. ID. NO.:12, below) and E (SEQ. ID. NO.:15, below) were designed from the EST sequences identified by BLAST searching to amplify an 826 bp cDNA fragment by RT-PCR from human fetal cartilage RNA. The fragment was hybridized to plaques from a directional human fetal cartilage cDNA library constructed by Stratagene in the lambda ZAP2 vector (D. Krakow and D. Cohn, unpublished). Alternatively, a forward primer (SEQ. ID. NO.:11, below) and a reverse primer 5′-GCATGTCCAGACAGACACCAC-3′ (SEQ. ID. NO.:28) were used to produce, from fetal cartilage RNA, a cDNA sequence 1940 base pairs long, including the entire PAPSS2 coding region and flanking regions, which nucleic acid segment was then used as a hybridization probe of the fetal cartilage cDNA library. [0118]
  • Primers used for sequence analysis of the cDNA clones were: [0119]
    (SEQ. ID. NO.:11; forward primer)
    (A) 5′-GCCAGCCAGCATGTCGGGGAT-3′;
    (SEQ. ID. NO.:12; forward primer)
    (B) 5′-ACCTGAAACTCCTGAGCGTGTGCT-3′;
    (SEQ. ID. NO.:13; forward primer)
    (C) 5′-GATGTGCCTCTAGACTGGCGG-3′;
    (SEQ. ID. NO.:14; reverse primer)
    (D) 5′-GAGCACTTCAGAAAGAAACTCTGG-3′;
    (SEQ. ID. NO.:15; reverse primer)
    (E) 5′-CATCCGCCAGTCTAGAGGCAC-3′;
    (SEQ. ID. NO.:16; reverse primer)
    (F) 5′-AGGTGTCAGACGGTATTGGTC-3′;
    (SEQ. ID. NO.:17; reverse primer)
    (G) 5′-GTCACTCACTGTGGACAAATTGG-3′; and
    (SEQ. ID. NO.:18; reverse primer)
    (H) 5′-CACCTCAGCAATCCGGCGGAT-3′.
  • The sequence of 3′ end of the coding region of the mouse Papss2 cDNA was identified by database searching. The 5′ end of the cDNA was isolated from a mouse brain cDNA library, constructed from the C57BL/6 strain in the Uni-ZAP XR vector (Stratagene), by amplification from pooled library DNA using a gene specific primer derived from the sequence at locus D19Mit13 (5′-TCTGGCACAAAGAGTTCGTG-3′ [SEQ. ID. NO.:19; reverse primer]) and a vector-specific primer. To amplify the entire coding region of Papss2, oligonucleotide primers from the 5′ ([a] 5′-GCCAGTTTGTAAC CGAGTATTC-3′ [SEQ. ID. NO.:20; forward primer]) and 3′ ([b] 5′-GCAATTGGATACAGAGCAGC TA-3′ [SEQ. ID. NO.:21; reverse primer]) untranslated regions were used. Sequence was determined using the 5′ and 3′ untranslated region primers as well as primers: [0120]
    (SEQ. ID. NO.:22; forward primer)
    (c) 5′-GACAATGTCCGTCATGGCCTTA-3′;
    (SEQ. ID. NO.:23; forward primer)
    (d) 5′-ATTCCCATTGTATTGCCCGTT-3′;
    (SEQ. ID. NO.:24; reverse primer)
    (e) 5′-AACGGGCAATACAATGGGAAT-3′; and
    (SEQ. ID. NO.:25; reverse primer)
    (f) 5′-GATAAAGCTGGTGATGCAAACC-3′.
  • Mutation analysis. To define the human mutation, RNA was purified from a lymphoblastoid cell line from an affected family member. RT-PCR using either the primers from the 5′- and 3′-untranslated regions (primers A and D, above) or internal primers were used to amplify cDNA fragments containing the entire coding region. Control fragments were amplified from human cartilage RNA. Direct sequence analysis of the PCR products using the primers listed above was used to identify the mutation. To confirm the mutation and examine segregation in the Pakistani family, we used HincII digestion of a 108 bp genomic DNA fragment amplified with primers 5′-TGGA [0121]
    (SEQ. ID. NO.:3; forward primer)
    5′-TGGACCAAGGATGACGATGT-3′ and
    (SEQ. ID. NO.:4; reverse primer)
    5′-CGGAAAGATGGCAACAATGG-3′.
  • To define the mouse mutation, RNA was purified from frozen spleen from the brachymorphic mouse and a PWK control. (Rusiniak et al. [1996]). The Papss2 coding region was amplified in two fragments by RT-PCR using primer pair (a) (SEQ. ID. NO.:20; forward primer) plus (g) 5′-CATGG GATGGCGTGAGATAC-3′ (SEQ. ID. NO.:26; reverse primer) and primer pair (b) (SEQ. ID. NO.:21; reverse primer) plus (h) 5′-CATAAGCTTTGCTTT GGAAGAGT-3′ (SEQ. ID. NO.:27; forward primer), and the sequence was determined using the primers (c)-(f) listed above. [0122]
    • Example 2
  • Linkage of SEMD Pakistani Type to Markers on Human Chromosome 10. [0123]
  • A pooling strategy was used to carry out a genome-wide search for the chromosomal region containing the disease gene in a large inbred Pakistani SEMD family (Ahmad et al., 1998, incorporated by reference). A total of 381 markers were typed, ultimately achieving an average marker spacing of about 10 cM. Individual genotypes for all studied family members were determined for 83 markers that showed differences in allele distributions between the affected and unaffected pools. For all but three of these markers, D10S1432, D10S2470, and D10S677, linkage to the SEMD phenotype could be excluded. Significant linkage was initially obtained for the marker at locus D10S2470, yielding a maximum two-point lod score of 5.44 at a recombination fraction of 0.01. [0124]
  • Saturation genotyping with additional markers from the region confirmed the initial linkage result. Two-point lod scores for all markers are shown in Table 1, with the highest lod score of 5.51 at a recombination fraction of 0.01, obtained for the marker at locus D10S1143. [0125]
    TABLE 1
    Linkage Analysis of Chromosome 10 Markers and SEMD.
    LOD Score at q =
    Marker 0.0 0.001 0.01 0.05 0.1 0.2 0.3 0.4
    D10S1689 −0.20 −0.12 0.19 0.45 0.41 0.20 0.10 0.02
    D10S1717 2.85 3.02 3.52 3.62 3.26 2.39 1.50 0.66
    D10S1644 4.28 4.44 4.88 4.76 4.12 2.78 1.63 0.67
    D10S1687 4.23 4.41 4.87 4.77 4.18 2.85 1.66 0.67
    D10S1739 2.16 2.43 3.02 3.08 2.69 1.81 1.02 0.34
    D10S1143 4.89 5.06 5.51 5.35 4.66 3.14 1.79 0.71
    D10S2470 −∞ 4.63 5.44 5.31 4.60 3.04 1.67 0.67
    D10S1753 −∞ −0.57 1.02 1.80 1.74 1.20 0.66 0.20
  • A proximal boundary at locus D10S1689 was established by the haplotypes of three individuals, VI-2, VI-4 and VIII-2. A distal limit at locus D10S2470 was established by a recombination observed in VIII-15. Together, these recombinant events localized the disease gene within a maximum interval of 8.1 cM, flanked on the proximal side by the marker at locus D10S1689 and on the distal side by the marker at locus D10S2470. The genotype of individual VI-7 provided clear evidence of recombination within the 8.1 cM interval. Compatible with the recessive inheritance pattern for the disease, he was homozygous for the marker at only one locus, D10S2470, within the maximum interval. Together with the distal boundary of the larger interval established by the recombination in individual VIII-15, the data showed that the disease gene was contained within the 1.7 cM separating the markers at loci D10S1143 and D10S2470. [0126]
  • FIG. 1 shows a genetic map of the interval containing the SEMD disease gene on human chromosome 10. The darker bar identifies the 8.1 cM maximum interval between loci D10S1689 and D10S2470. The 1.7 cM minimum interval is identified by the darkest bar, between loci D10S1143 and D10S2470. The locations of D10S1432 and D10S677 are not drawn to scale. [0127]
    • Example 3
  • A Novel ATP Sulfurylase/Kinase Gene in Mice and Humans. [0128]
  • The SEMD interval established by linkage corresponded to chromosomal region 10q23-24, which is syntenic with the region of mouse chromosome 19 to which the recessive mouse skeletal mutant brachymorphic was localized. This regional homology implied that the two phenotypes could be due to mutations in an orthologous pair of genes. Additional recombination mapping using recombinant mice from a large backcross with the brachymorphic mouse showed that only 3 of 25 mice recombinant at the previously defined proximal boundary (Rusiniak, M. E., et al., [0129] Molecular markers near the mouse brachymorphic (bm) gene, which affects connective tissues and bleeding time, Mamm. Genome 7:98-102 [1996]), the markers at loci D19Mit39 and D19Mit57, were recombinant at locus D19Mit135. The distal limit was not further narrowed by recombination mapping, leaving a total estimated interval of about 0.7 cM, flanked by the markers at loci D19Mit135 and D19Mit64, containing the bm mutation. (FIG. 2).
  • As in prior genetic mapping studies (Rusiniak et al. [1996]), the marker at locus D19Mit13 was the only marker non-recombinant with the brachymorphic phenotype and, because of the large size of the cross, was therefore expected to be extremely close to the disease gene. A BLAST search using D19Mit13 as the query sequence was carried out to test the hypothesis idea that the marker might be within an intron of the bm gene. Sequences on both sides of the D19Mit13 CA repeat element were about 80% homologous to a human expressed sequence tag (EST), zc38a08.r1, which was distinct from but similar to the known PAPS synthetase gene, Papss1. Comparison of the EST sequence with D19Mit13 revealed that the CA repeat was contained within a 180 base pair intron bordered by consensus splice donor and splice acceptor sequences (data not shown). Further sequential BLAST searches using both the human PAPSS1 and murine Papss1 cDNA sequences, as well as EST sequences derived from each search, identified sets of overlapping ESTs from both species that could be used to assemble partial cDNA sequences. The ESTs were derived from a variety of tissue and cell types, including colon, lung, placenta, aortic endothelium, and fetal heart, suggesting a widely expressed gene. (FIG. 4). [0130]
  • To complete the human cDNA sequence, the nucleotide sequences of PAPSS2 cDNA clones isolated from a human fetal cartilage cDNA library were determined. The reading frame was determined by comparison with the paralogous human PAPSS1 and mouse Papss1 cDNA sequences. At the 5′ end, an in-frame ATG codon immediately preceded by a sequence that fit the consensus sequence for translation initiation (Kozak, M., [0131] An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs, Nucleic Acids Res. 15:8125-48 [1987]) was assumed to represent the first translated codon. Conceptual translation of the 615 codon open reading frame predicted a molecular weight of 69,448 Da for the unmodified protein. The coding regions of the human PAPSS2 and PAPSS1 cDNA sequences were 71% identical and the primary translation products were 78% identical. Radiation hybrid mapping localized PAPSS2 at 519 cR on the chromosome 10 map, between loci AFM225YD12 and D10S583, and within the SEMD region defined by linkage.
  • Sequential BLAST searching and sequence analysis of PCR products from a mouse brain cDNA library was used to complete the coding sequence of the mouse Papss2 cDNA. At the 5′ end, there were two in-frame ATG codons, each preceded by a possible consensus sequence for translation initiation. An in-frame stop codon was located just upstream from the first ATG, further supporting the inference that one or both of the two ATG codons represent the site(s) of translation initiation. For purposes of comparison with the human orthologue, we have assumed that the first ATG is used. The open reading frame contains 617 codons and a molecular weight of 69,814 Da was calculated for the encoded protein. The coding regions of the human PAPSS2 and mouse Papss2 genes were 86% identical at the cDNA level and 93% identical at the protein level. [0132]
    • Example 4
  • A Stop Codon in the Human PAPSS2 Gene in the Pakistani SEMD Family. [0133]
  • The coding region of the human PAPSS2 cDNA was amplified by RT-PCR using RNA derived from a lymphoblastoid cell line from an affected member of the Pakistani SEMD family. The only sequence change relative to the control fragment, amplified from human fetal cartilage RNA, was a point mutation that predicted a stop codon in place of the serine codon for residue 475 of the protein. (FIG. 3). The mutation thus predicted truncation of the protein from 615 to 474 amino acids. The mutation disrupted a HincII restriction endonuclease cleavage site, and analysis of an amplified genomic DNA fragment containing the site of the mutation by HincII digestion demonstrated cosegregation of the mutation and the phenotype in the family; all affected individuals were homozygous for the mutation, and all obligate carriers (unaffected offspring of affected individuals and unaffected parents of affected individuals) were heterozygous for the mutation (data not shown). None of a panel of 43 DNA samples from individuals of Pakistani origin carried the mutation. [0134]
  • The data presented here demonstrate that a mutation in a novel gene in the sulfate activation pathway results in a human osteochondrodysplasia phenotype. The PAPSS2 mutation characterized in the Pakistani SEMD family introduced a nonsense mutation at the codon for residue 475 of the 615 amino acid protein. It is unknown whether, as has been observed for many other genes (e.g., Willing, M. C., et al., [0135] Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains, Am. J. Hum. Genet. 59:799-809 [1996]), the nonsense mutation leads to destabilization of the transcript, or if a truncated protein, perhaps retaining partial activity, is synthesized.
  • Even though the PAPSS2 gene is expressed in a wide variety of tissues (FIG. 4), the mutation produces an exclusively skeletal phenotype. Thus, similar to the disproportionate effect on cartilage of mutations in the gene encoding the widely expressed sulfate transporter DTDST (Hastbacka, J., et al. [1994]; Rossi, A., et al. [1998]), the cartilage-specificity of phenotypic expression is likely the result of the high demand for sulfation of extracellular matrix molecules in cartilage. Differences in levels of expression of the ATPSK1 and PAPSS2 transcripts among different tissues (unpublished data) suggest that this may also influence the tissue-specificity of the phenotype. In cartilage, both PAPSS1 and PAPSS2 transcripts are expressed (unpublished data), but the relative abundances of the proteins in vivo, and their contributions to net PAPS synthesis, are unknown. The milder effect of a mutation in PAPSS2 as compared with DTDST mutations implies that PAPSS1 partially compensates for the PAPSS2 defect by providing a physiologically significant level of PAPS synthesis in cartilage. [0136]
    • Example 5
  • An Papss2 Missense Mutation in the Brachymorphic Mouse. [0137]
  • Complete sequence analysis of the Papss2 coding region from the brachymorphic mouse and the PWK strain used in the backcross identified ten single nucleotide sequence differences between the strains [A at base 295 (A295), G342, G386, C649, G881, C1086, G1239, T1524, G1557, and T1815]. Of these, only two implied sequence differences at the protein level, predicting G79R and K109R substitutions, both within the APS kinase domain of the protein. As the normal mouse strain C57BL/6 was also homozygous for arginine at residue 109, the G79R was the likely pathogenic substitution. A glycine codon is present in the same position among APS kinase domains of eucaryotic Papss genes as well as among APS kinases of bacteria, suggesting it is essential for APS kinase activity. [0138]
  • The conclusion that the G79R Papss2 substitution produces the brachymorphic phenotype is supported by the following evidence. First, the biochemical defect in PAPS synthetase activity measured in brachymorphic cartilage and liver tissue extracts, showing markedly decreased APS kinase activity and a lesser effect on ATP sulfurylase activity, predicts a structural defect affecting the kinase domain of the protein. As the G79R substitution is within the kinase domain, these data are compatible with the biochemical evidence and the hypothesis that the abnormal enzyme does not properly channel APS to the kinase. (Lyle, S., et al., Sulfate-activating enzymes in normal and brachymorphic mice: evidence for a channeling defect, Biochemistry 34:940-45 [1995]). Second, the decrease in Papss activity in liver and cartilage (Schwartz, N. B., et al. [1978]; Sugahara, K. & Schwartz, N. B. [1979]; Sugahara, K. & Schwartz, N. B., [0139] Defect in 3′-phosphoadenosine 5′-phosphosulfate synthesis in brachymorphic mice. II. tissue distribution of the defect, Arch. Biochem. Biophys. 214:602-09 [1982]) is correlated with the human tissues in which Papss2 is highly expressed (unpublished data). Third, the characterized mutation is the only structural mutation in the coding region that is unique to the brachymorphic mouse. Fourth, the mutation results in substitution for a highly conserved residue among other Papss proteins and APS kinase domains of species from vertebrates to bacteria, suggesting it is essential for kinase activity. Fifth, the phenotype of the brachymorphic mouse and the human SEMD family are substantially similar. Both are recessively inherited dwarfing conditions that affect the spine and long bones. (Lane & Dickie [1968]; Ahmad, M., et al. [1998]). Both phenotypes are evident at birth, but disproportion increases postnatally. Radiographic studies in SEMD Pakistani type (Ahmad, M., et al. [1998]) and histologic analysis of brachymorphic mice (Orkin et al. [1977]) demonstrate that both phenotypes are characterized by a primarily epiphyseal dysplasia with only mild metaphyseal abnormalities. Although brachymorphism is produced by a missense mutation and SEMD by a nonsense mutation, the phenotypic similarity argues that an Papss2 null allele is likely to produce a mouse osteochondrodysplasia phenotype very similar or equivalent to brachymorphic.
  • The foregoing examples being illustrative but not an exhaustive description of the embodiments of the present invention, the following claims are presented. [0140]
  • 1 28 1 2014 DNA Homo sapiens 1 ctgctgccgc cgccgccgcc gccgtccctg cgtccttcgg tctctgctcc cgggacccgg 60 ctccgccgca gccagccagc atgtcgggga tcaagaagca aaagacggag aaccagcaga 120 aatccaccaa tgtagtctat caggcccacc atgtgagcag gaataagaga gggcaagtgg 180 ttggaacaag gggtgggttc cgaggatgta ccgtgtggct aacaggtctc tctggtgctg 240 gaaaaacaac gataagtttt gccctggagg agtaccttgt ctcccatgcc atcccttgtt 300 actccctgga tggggacaat gtccgtcatg gccttaacag aaatctcgga ttctctcctg 360 gggacagaga ggaaaatatc cgccggattg ctgaggtggc taagctgttt gctgatgctg 420 gtctggtctg cattaccagc tttatttctc cattcgcaaa ggatcgtgag aatgcccgca 480 aaatacatga atcagcaggg ctgccattct ttgaaatatt tgtagatgca cctctaaata 540 tttgtgaaag cagagacgta aaaggcctct ataaaagggc cagagctggg gagattaaag 600 gatttacagg tattgattct gattatgaga aacctgaaac tcctgagcgt gtgcttaaaa 660 ccaatttgtc cacagtgagt gactgtgtcc accaggtagt ggaacttctg caagagcaga 720 acattgtacc ctatactata atcaaagata tccacgaact ctttgtgccg gaaaacaaac 780 ttgaccacgt ccgagctgag gctgaaactc tcccttcatt atcaattact aagctggatc 840 tccagtgggt ccaggttttg agcgaaggct gggccactcc cctcaaaggt ttcatgcggg 900 agaaggagta cttacaggtt atgcactttg acaccctgct agatgatggc gtgatcaaca 960 tgagcatccc cattgtactg cccgtctctg cagaggataa gacacggctg gaagggtgca 1020 gcaagtttgt cctggcacat ggtggacgga gggtagctat cttacgagac gctgaattct 1080 atgaacacag aaaagaggaa cgctgttccc gtgtttgggg gacaacatgt acaaaacacc 1140 cccatatcaa aatggtgatg gaaagtgggg actggctggt tggtggagac cttcaggtgc 1200 tggagaaaat aagatggaat gatgggctgg accaataccg tctgacacct ctggagctca 1260 aacagaaatg taaagaaatg aatgctgatg cggtgtttgc attccagttg cgcaatcctg 1320 tccacaatgg ccatgccctg ttgatgcagg acacctgccg caggctccta gagaggggct 1380 acaagcaccc ggtcctccta ctacaccctc tgggcggctg gaccaaggat gacgatgtgc 1440 ctctagactg gcggatgaag cagcacgcgg ctgtgctcga ggaaggggtc ctggatccca 1500 agtcaaccat tgttgccatc tttccgtctc ccatgttata tgctggcccc acagaggtcc 1560 agtggcactg caggtcccgg atgattgcgg gtgccaattt ctacattgtg gggagggacc 1620 ctgcaggaat gccccatcct gaaaccaaga aggatctgta tgaacccact catgggggca 1680 aggtcttgag catggcccct ggcctcacct ctgtggaaat cattccattc cgagtggctg 1740 cctacaacaa agccaaaaaa gccatggact tctatgatcc agcaaggcac aatgagtttg 1800 acttcatctc aggaactcga atgaggaagc tcgcccggga aggagagaat cccccagatg 1860 gcttcatggc ccccaaagca tggaaggtcc tgacagatta ttacaggtcc ctggagaaga 1920 actaagcctt tgggtccaga gtttctttct gaagtgctct ttgattacct tttctatttt 1980 tatgattaga tgctttgtat taaattgctt ctca 2014 2 2000 DNA Mus musculus 2 gtattctcaa catcagatat catgtcttgg aggaagttac ctaaactctg aagaattatc 60 atgtctgcaa atttcaaaat gaaccataaa agagaccagc aaaaatccac caatgtggtc 120 taccaggccc atcatgtgag caggaacaag agaggacaag tggttggaac caggggagga 180 ttccgaggat gtaccgtgtg gctaacaggt ctctctggtg ctgggaaaac aaccataagc 240 tttgctttgg aagagtacct tgtatctcac gccatcccat gttactccct ggatggggac 300 aatgtccgtc atggccttaa taagaacctg ggattctctg ccggggaccg agaagagaat 360 atccgccgga tcgcggaggt ggccaagctc tttgccgacg ccggcctggt ttgcatcacc 420 agctttatct ctccttttgc aaaggatcgt gagaatgccc gaaaaatcca cgaatcagca 480 ggactcccgt tctttgagat ctttgtagat gcgcctttaa atatctgtga aagccgagac 540 gtaaaaggac tctacaaacg agcccgagca ggagagatta aagggtttac aggcatcgat 600 tctgactatg agaaacctga aactccagag tgtgtgctga agaccaactt gtcttcagta 660 agcgactgtg tgcaacaggt ggtggaactt ttgcaggagc agaacattgt accccacacc 720 accatcaaag gcatccacga actctttgtg ccagaaaaca aagtcgatca aatccgagct 780 gaggcagaga ctctcccatc actaccaatt accaagctgg atctgcagtg ggtgcagatt 840 ctgagtgaag gctgggccac tcccctcaaa ggctttatgc gggagaagga atacttgcaa 900 actctacact tcgacactct actggacgat ggagtcatca acatgagtat tcccattgta 960 ttgcccgttt ctgcggatga caaggcacgg ctcgaagggt gcagcaaatt tgccttgatg 1020 tacgaaggtc ggagggtcgc tctattacag gaccctgaat tctatgagca taggaaagag 1080 gagcgttgtt ctcgtgtgtg gggaacagcc actgcaaagc acccccatat caaaatggtg 1140 atggaaagtg gggactggct tgttggtgga gacctacagg tgctagagag aataaggtgg 1200 gacgatgggc tggaccaata ccgccttacg cctctggaac tcaaacagaa gtgtaaagac 1260 atgaatgctg atgccgtgtt tgcattccag ttgcgcaatc ctgtccacaa tggtcatgcc 1320 ctcctgatgc aggacacccg ccgcaggctc ctggagaggg gttacaagca cccagtcctc 1380 ctgctccacc ctcttggggg ctggaccaag gacgatgacg tacctctgga atggaggatg 1440 aaacagcatg cagctgtact ggaggaaagg gtcctggatc ccaagtcaac tattgttgcc 1500 atctttccat ctcctatgtt atacgctggt cccacagagg tccagtggca ttgcagatgc 1560 cggatgattg caggagccaa tttctacatt gtgggtaggg atcccgcagg aatgccccat 1620 cctgagacaa agaaagacct atatgaaccc acccacgggg gcaaggtctt gagtatggcc 1680 cctggcctta cctctgtgga aataattccg ttccgagtgg ctgcctacaa taaaattaaa 1740 aaggccatgg acttttatga tccagcaagg cacgaggagt ttgacttcat ctcaggaact 1800 cgcatgagga agctcgcccg ggaaggagaa gatcccccag atggcttcat ggccccgaaa 1860 gcgtggaaag tgttgacaga ttactacagg tctctggaga agaccaacta ggtgctcctg 1920 gctctggctt cttcctcaag tgctctctga cgattttttt tttctatttt tgtgatttag 1980 ctgctctgta tccaattgca 2000 3 20 DNA Homo sapiens 3 tggaccaagg atgacgatgt 20 4 20 DNA Homo sapiens 4 cggaaagatg gcaacaatgg 20 5 20 DNA Homo sapiens 5 ctggtgctgg aaaaacaacg 20 6 22 DNA Homo sapiens 6 tgcgaatgga gaaataaagc tg 22 7 615 PRT Homo sapiens 7 Met Ser Gly Ile Lys Lys Gln Lys Thr Glu Asn Gln Gln Lys Ser Thr 1 5 10 15 Asn Val Val Tyr Gln Ala His His Val Ser Arg Asn Lys Arg Gly Gln 20 25 30 Val Val Gly Thr Arg Gly Gly Phe Arg Gly Cys Thr Val Trp Leu Thr 35 40 45 Gly Leu Ser Gly Ala Gly Lys Thr Thr Ile Ser Phe Ala Leu Glu Glu 50 55 60 Tyr Leu Val Ser His Ala Ile Pro Cys Tyr Ser Leu Asp Gly Asp Asn 65 70 75 80 Val Arg His Gly Leu Asn Arg Asn Leu Gly Phe Ser Pro Gly Asp Arg 85 90 95 Glu Glu Asn Ile Arg Arg Ile Ala Glu Val Ala Lys Leu Phe Ala Asp 100 105 110 Ala Gly Leu Val Cys Ile Thr Ser Phe Ile Ser Pro Phe Ala Lys Asp 115 120 125 Arg Glu Asn Ala Arg Lys Ile His Glu Ser Ala Gly Leu Pro Phe Phe 130 135 140 Glu Ile Phe Val Asp Ala Pro Leu Asn Ile Cys Glu Ser Arg Asp Val 145 150 155 160 Lys Gly Leu Tyr Lys Arg Ala Arg Ala Gly Glu Ile Lys Gly Phe Thr 165 170 175 Gly Ile Asp Ser Asp Tyr Glu Lys Pro Glu Thr Pro Glu Arg Val Leu 180 185 190 Lys Thr Asn Leu Ser Thr Val Ser Asp Cys Val His Gln Val Val Glu 195 200 205 Leu Leu Gln Glu Gln Asn Ile Val Pro Tyr Thr Ile Ile Lys Asp Ile 210 215 220 His Glu Leu Phe Val Pro Glu Asn Lys Leu Asp His Val Arg Ala Glu 225 230 235 240 Ala Glu Thr Leu Pro Ser Leu Ser Ile Thr Lys Leu Asp Leu Gln Trp 245 250 255 Val Gln Val Leu Ser Glu Gly Trp Ala Thr Pro Leu Lys Gly Phe Met 260 265 270 Arg Glu Lys Glu Tyr Leu Gln Val Met His Phe Asp Thr Leu Leu Asp 275 280 285 Asp Gly Val Ile Asn Met Ser Ile Pro Ile Val Leu Pro Val Ser Ala 290 295 300 Glu Asp Lys Thr Arg Leu Glu Gly Cys Ser Lys Phe Val Leu Ala His 305 310 315 320 Gly Gly Arg Arg Val Ala Ile Leu Arg Asp Ala Glu Phe Tyr Glu His 325 330 335 Arg Lys Glu Glu Arg Cys Ser Arg Val Trp Gly Thr Thr Cys Thr Lys 340 345 350 His Pro His Ile Lys Met Val Met Glu Ser Gly Asp Trp Leu Val Gly 355 360 365 Gly Asp Leu Gln Val Leu Glu Lys Ile Arg Trp Asn Asp Gly Leu Asp 370 375 380 Gln Tyr Arg Leu Thr Pro Leu Glu Leu Lys Gln Lys Cys Lys Glu Met 385 390 395 400 Asn Ala Asp Ala Val Phe Ala Phe Gln Leu Arg Asn Pro Val His Asn 405 410 415 Gly His Ala Leu Leu Met Gln Asp Thr Cys Arg Arg Leu Leu Glu Arg 420 425 430 Gly Tyr Lys His Pro Val Leu Leu Leu His Pro Leu Gly Gly Trp Thr 435 440 445 Lys Asp Asp Asp Val Pro Leu Asp Trp Arg Met Lys Gln His Ala Ala 450 455 460 Val Leu Glu Glu Gly Val Leu Asp Pro Lys Ser Thr Ile Val Ala Ile 465 470 475 480 Phe Pro Ser Pro Met Leu Tyr Ala Gly Pro Thr Glu Val Gln Trp His 485 490 495 Cys Arg Ser Arg Met Ile Ala Gly Ala Asn Phe Tyr Ile Val Gly Arg 500 505 510 Asp Pro Ala Gly Met Pro His Pro Glu Thr Lys Lys Asp Leu Tyr Glu 515 520 525 Pro Thr His Gly Gly Lys Val Leu Ser Met Ala Pro Gly Leu Thr Ser 530 535 540 Val Glu Ile Ile Pro Phe Arg Val Ala Ala Tyr Asn Lys Ala Lys Lys 545 550 555 560 Ala Met Asp Phe Tyr Asp Pro Ala Arg His Asn Glu Phe Asp Phe Ile 565 570 575 Ser Gly Thr Arg Met Arg Lys Leu Ala Arg Glu Gly Glu Asn Pro Pro 580 585 590 Asp Gly Phe Met Ala Pro Lys Ala Trp Lys Val Leu Thr Asp Tyr Tyr 595 600 605 Arg Ser Glu Met Asp Lys Asn 610 615 8 617 PRT Mus musculus 8 Met Ser Ala Asn Phe Lys Met Asn His Lys Arg Asp Gln Gln Lys Ser 1 5 10 15 Thr Asn Val Val Tyr Gln Ala His His Val Ser Arg Asn Lys Arg Gly 20 25 30 Gln Val Val Gly Thr Arg Gly Gly Phe Arg Gly Cys Thr Val Trp Leu 35 40 45 Thr Gly Leu Ser Gly Ala Gly Lys Thr Thr Ile Ser Phe Ala Leu Glu 50 55 60 Glu Tyr Leu Val Ser His Ala Ile Pro Cys Tyr Ser Leu Asp Gly Asp 65 70 75 80 Asn Val Arg His Gly Leu Asn Lys Asn Leu Gly Phe Ser Ala Gly Asp 85 90 95 Arg Glu Glu Asn Ile Arg Arg Ile Ala Glu Val Ala Lys Leu Phe Ala 100 105 110 Asp Ala Gly Leu Val Cys Ile Thr Ser Phe Ile Ser Pro Phe Ala Lys 115 120 125 Asp Arg Glu Asn Ala Arg Lys Ile His Glu Ser Ala Gly Leu Pro Phe 130 135 140 Phe Glu Ile Phe Val Asp Ala Pro Leu Asn Ile Cys Glu Ser Arg Asp 145 150 155 160 Val Lys Gly Leu Tyr Lys Arg Ala Arg Ala Gly Glu Ile Lys Gly Phe 165 170 175 Thr Gly Ile Asp Ser Asp Tyr Glu Lys Pro Glu Thr Pro Glu Cys Val 180 185 190 Leu Lys Thr Asn Leu Ser Ser Val Ser Asp Cys Val Gln Gln Val Val 195 200 205 Glu Leu Leu Gln Glu Gln Asn Ile Val Pro His Thr Thr Ile Lys Gly 210 215 220 Ile His Glu Leu Phe Val Pro Glu Asn Lys Val Asp Gln Ile Arg Ala 225 230 235 240 Glu Ala Glu Thr Leu Pro Ser Leu Pro Ile Thr Lys Leu Asp Leu Gln 245 250 255 Trp Val Gln Ile Leu Ser Glu Gly Trp Ala Thr Pro Leu Lys Gly Phe 260 265 270 Met Arg Glu Lys Glu Tyr Leu Gln Thr Leu His Phe Asp Thr Leu Leu 275 280 285 Asp Asp Gly Val Ile Asn Met Ser Ile Pro Ile Val Leu Pro Val Ser 290 295 300 Ala Asp Asp Lys Ala Arg Leu Glu Gly Cys Ser Lys Phe Ala Leu Met 305 310 315 320 Tyr Glu Gly Arg Arg Val Ala Leu Leu Gln Asp Pro Glu Phe Tyr Glu 325 330 335 His Arg Lys Glu Glu Arg Cys Ser Arg Val Trp Gly Thr Ala Thr Ala 340 345 350 Lys His Pro His Ile Lys Met Val Met Glu Ser Gly Asp Trp Leu Val 355 360 365 Gly Gly Asp Leu Gln Val Leu Glu Arg Ile Arg Trp Asp Asp Gly Leu 370 375 380 Asp Gln Tyr Arg Leu Thr Pro Leu Glu Leu Lys Gln Lys Cys Lys Asp 385 390 395 400 Met Asn Ala Asp Ala Val Phe Ala Phe Gln Leu Arg Asn Pro Val His 405 410 415 Asn Gly His Ala Leu Leu Met Gln Asp Thr Arg Arg Arg Leu Leu Glu 420 425 430 Arg Gly Tyr Lys His Pro Val Leu Leu Leu His Pro Leu Gly Gly Trp 435 440 445 Thr Lys Asp Asp Asp Val Pro Leu Glu Trp Arg Met Lys Gln His Ala 450 455 460 Ala Val Leu Glu Glu Arg Val Leu Asp Pro Lys Ser Thr Ile Val Ala 465 470 475 480 Ile Phe Pro Ser Pro Met Leu Tyr Ala Gly Pro Thr Glu Val Gln Trp 485 490 495 His Cys Arg Cys Arg Met Ile Ala Gly Ala Asn Phe Tyr Ile Val Gly 500 505 510 Arg Asp Pro Ala Gly Met Pro His Pro Glu Thr Lys Lys Asp Leu Tyr 515 520 525 Glu Pro Thr His Gly Gly Lys Val Leu Ser Met Ala Pro Gly Leu Thr 530 535 540 Ser Val Glu Ile Ile Pro Phe Arg Val Ala Ala Tyr Asn Lys Ile Lys 545 550 555 560 Lys Ala Met Asp Phe Tyr Asp Pro Ala Arg His Glu Glu Phe Asp Phe 565 570 575 Ile Ser Gly Thr Arg Met Arg Lys Leu Ala Arg Glu Gly Glu Asp Pro 580 585 590 Pro Asp Gly Phe Met Ala Pro Lys Ala Trp Lys Val Leu Thr Asp Tyr 595 600 605 Tyr Arg Ser Glu Met Asp Lys Thr Asn 610 615 9 1845 DNA Homo sapiens 9 atgtcgggga tcaagaagca aaagacggag aaccagcaga aatccaccaa tgtagtctat 60 caggcccacc atgtgagcag gaataagaga gggcaagtgg ttggaacaag gggtgggttc 120 cgaggatgta ccgtgtggct aacaggtctc tctggtgctg gaaaaacaac gataagtttt 180 gccctggagg agtaccttgt ctcccatgcc atcccttgtt actccctgga tggggacaat 240 gtccgtcatg gccttaacag aaatctcgga ttctctcctg gggacagaga ggaaaatatc 300 cgccggattg ctgaggtggc taagctgttt gctgatgctg gtctggtctg cattaccagc 360 tttatttctc cattcgcaaa ggatcgtgag aatgcccgca aaatacatga atcagcaggg 420 ctgccattct ttgaaatatt tgtagatgca cctctaaata tttgtgaaag cagagacgta 480 aaaggcctct ataaaagggc cagagctggg gagattaaag gatttacagg tattgattct 540 gattatgaga aacctgaaac tcctgagcgt gtgcttaaaa ccaatttgtc cacagtgagt 600 gactgtgtcc accaggtagt ggaacttctg caagagcaga acattgtacc ctatactata 660 atcaaagata tccacgaact ctttgtgccg gaaaacaaac ttgaccacgt ccgagctgag 720 gctgaaactc tcccttcatt atcaattact aagctggatc tccagtgggt ccaggttttg 780 agcgaaggct gggccactcc cctcaaaggt ttcatgcggg agaaggagta cttacaggtt 840 atgcactttg acaccctgct agatgatggc gtgatcaaca tgagcatccc cattgtactg 900 cccgtctctg cagaggataa gacacggctg gaagggtgca gcaagtttgt cctggcacat 960 ggtggacgga gggtagctat cttacgagac gctgaattct atgaacacag aaaagaggaa 1020 cgctgttccc gtgtttgggg gacaacatgt acaaaacacc cccatatcaa aatggtgatg 1080 gaaagtgggg actggctggt tggtggagac cttcaggtgc tggagaaaat aagatggaat 1140 gatgggctgg accaataccg tctgacacct ctggagctca aacagaaatg taaagaaatg 1200 aatgctgatg cggtgtttgc attccagttg cgcaatcctg tccacaatgg ccatgccctg 1260 ttgatgcagg acacctgccg caggctccta gagaggggct acaagcaccc ggtcctccta 1320 ctacaccctc tgggcggctg gaccaaggat gacgatgtgc ctctagactg gcggatgaag 1380 cagcacgcgg ctgtgctcga ggaaggggtc ctggatccca agtcaaccat tgttgccatc 1440 tttccgtctc ccatgttata tgctggcccc acagaggtcc agtggcactg caggtcccgg 1500 atgattgcgg gtgccaattt ctacattgtg gggagggacc ctgcaggaat gccccatcct 1560 gaaaccaaga aggatctgta tgaacccact catgggggca aggtcttgag catggcccct 1620 ggcctcacct ctgtggaaat cattccattc cgagtggctg cctacaacaa agccaaaaaa 1680 gccatggact tctatgatcc agcaaggcac aatgagtttg acttcatctc aggaactcga 1740 atgaggaagc tcgcccggga aggagagaat cccccagatg gcttcatggc ccccaaagca 1800 tggaaggtcc tgacagatta ttacaggtcc ctggagaaga actaa 1845 10 1851 DNA Mus musculus 10 atgtctgcaa atttcaaaat gaaccataaa agagaccagc aaaaatccac caatgtggtc 60 taccaggccc atcatgtgag caggaacaag agaggacaag tggttggaac caggggagga 120 ttccgaggat gtaccgtgtg gctaacaggt ctctctggtg ctgggaaaac aaccataagc 180 tttgctttgg aagagtacct tgtatctcac gccatcccat gttactccct ggatggggac 240 aatgtccgtc atggccttaa taagaacctg ggattctctg ccggggaccg agaagagaat 300 atccgccgga tcgcggaggt ggccaagctc tttgccgacg ccggcctggt ttgcatcacc 360 agctttatct ctccttttgc aaaggatcgt gagaatgccc gaaaaatcca cgaatcagca 420 ggactcccgt tctttgagat ctttgtagat gcgcctttaa atatctgtga aagccgagac 480 gtaaaaggac tctacaaacg agcccgagca ggagagatta aagggtttac aggcatcgat 540 tctgactatg agaaacctga aactccagag tgtgtgctga agaccaactt gtcttcagta 600 agcgactgtg tgcaacaggt ggtggaactt ttgcaggagc agaacattgt accccacacc 660 accatcaaag gcatccacga actctttgtg ccagaaaaca aagtcgatca aatccgagct 720 gaggcagaga ctctcccatc actaccaatt accaagctgg atctgcagtg ggtgcagatt 780 ctgagtgaag gctgggccac tcccctcaaa ggctttatgc gggagaagga atacttgcaa 840 actctacact tcgacactct actggacgat ggagtcatca acatgagtat tcccattgta 900 ttgcccgttt ctgcggatga caaggcacgg ctcgaagggt gcagcaaatt tgccttgatg 960 tacgaaggtc ggagggtcgc tctattacag gaccctgaat tctatgagca taggaaagag 1020 gagcgttgtt ctcgtgtgtg gggaacagcc actgcaaagc acccccatat caaaatggtg 1080 atggaaagtg gggactggct tgttggtgga gacctacagg tgctagagag aataaggtgg 1140 gacgatgggc tggaccaata ccgccttacg cctctggaac tcaaacagaa gtgtaaagac 1200 atgaatgctg atgccgtgtt tgcattccag ttgcgcaatc ctgtccacaa tggtcatgcc 1260 ctcctgatgc aggacacccg ccgcaggctc ctggagaggg gttacaagca cccagtcctc 1320 ctgctccacc ctcttggggg ctggaccaag gacgatgacg tacctctgga atggaggatg 1380 aaacagcatg cagctgtact ggaggaaagg gtcctggatc ccaagtcaac tattgttgcc 1440 atctttccat ctcctatgtt atacgctggt cccacagagg tccagtggca ttgcagatgc 1500 cggatgattg caggagccaa tttctacatt gtgggtaggg atcccgcagg aatgccccat 1560 cctgagacaa agaaagacct atatgaaccc acccacgggg gcaaggtctt gagtatggcc 1620 cctggcctta cctctgtgga aataattccg ttccgagtgg ctgcctacaa taaaattaaa 1680 aaggccatgg acttttatga tccagcaagg cacgaggagt ttgacttcat ctcaggaact 1740 cgcatgagga agctcgcccg ggaaggagaa gatcccccag atggcttcat ggccccgaaa 1800 gcgtggaaag tgttgacaga ttactacagg tctctggaga agaccaacta g 1851 11 21 DNA Homo sapiens 11 gccagccagc atgtcgggga t 21 12 24 DNA Homo sapiens 12 acctgaaact cctgagcgtg tgct 24 13 21 DNA Homo sapiens 13 gatgtgcctc tagactggcg g 21 14 24 DNA Homo sapiens 14 gagcacttca gaaagaaact ctgg 24 15 21 DNA Homo sapiens 15 catccgccag tctagaggca c 21 16 21 DNA Homo sapiens 16 aggtgtcaga cggtattggt c 21 17 23 DNA Homo sapiens 17 gtcactcact gtggacaaat tgg 23 18 21 DNA Homo sapiens 18 cacctcagca atccggcgga t 21 19 20 DNA Mus musculus 19 tctggcacaa agagttcgtg 20 20 22 DNA Mus musculus 20 gccagtttgt aaccgagtat tc 22 21 22 DNA Mus musculus 21 gcaattggat acagagcagc ta 22 22 22 DNA Mus musculus 22 gacaatgtcc gtcatggcct ta 22 23 21 DNA Mus musculus 23 attcccattg tattgcccgt t 21 24 21 DNA Mus musculus 24 aacgggcaat acaatgggaa t 21 25 22 DNA Mus musculus 25 gataaagctg gtgatgcaaa cc 22 26 20 DNA Mus musculus 26 catgggatgg cgtgagatac 20 27 23 DNA Mus musculus 27 cataagcttt gctttggaag agt 23 28 21 DNA Homo sapiens 28 gcatgtccag acagacacca c 21

Claims (108)

We claim:
1. An isolated polynucleotide comprising a nucleic acid segment encoding a human PAPS synthetase, said nucleic acid segment having a nucleotide sequence of (SEQ. ID. NO.:1), a nucleotide sequence complementary thereto, a degenerate coding sequence thereof, or a gene-specific fragment of any of these.
2. The polynucleotide of claim 1, wherein the nucleic acid segment is a gene-specific fragment comprising the nucleotide sequence of (SEQ. ID. NO.:9).
3. The polynucleotide of claim 1, wherein the nucleic acid segment is a DNA.
4. The polynucleotide of claim 1, wherein the nucleic acid segment is an RNA.
5. The polynucleotide of claim 1, wherein the nucleic acid segment is a chimeric RNA/DNA.
6. A nucleic acid construct comprising a nucleic acid segment comprising:
(A) a nucleotide sequence of (SEQ. ID. NO.:1), a nucleotide sequence complementary thereto, a degenerate coding sequence thereof, or a gene-specific fragment of any of these; or
(B) a nucleic acid segment encoding a human PAPSS2 protein having an amino acid sequence of (SEQ. ID. NO.:7).
7. The nucleic acid construct of claim 6, wherein the nucleic acid segment has the nucleotide sequence of (SEQ. ID. NO.:9) or a sequence complementary thereto.
8. The nucleic acid construct of claim 6, wherein the nucleic acid segment is a probe or primer.
9. The nucleic acid construct of claim 6, wherein the nucleic acid segment is a DNA.
10. The nucleic acid construct of claim 6, wherein the nucleic acid segment is an RNA.
11. The nucleic acid construct of claim 6, wherein the nucleic acid segment is a chimeric RNA/DNA.
12. The nucleic acid construct of claim 6, wherein the nucleic acid segment is cloned into an expression vector.
13. The nucleic acid construct of claim 8, wherein the nucleic acid segment has a nucleotide sequence comprising 5′-TGGACCAAGGATGACGATGT-3′ (SEQ. ID. NO.: 3), a complementary nucleotide sequence, or a PAPSS2-specific sequence overlapping either of these at 5 or more contiguous nucleotides at its 5′ or 3′ end.
14. The nucleic acid construct of claim 8, wherein the nucleic acid segment has a nucleotide sequence comprising 5′-CGGAAAGATGGCAACAATGG (SEQ. ID. NO.: 4), a complementary nucleotide sequence, or a PAPSS2-specific sequence overlapping either of these at 5 or more contiguous nucleotides at its 5′ or 3′ end.
15. The nucleic acid construct of claim 8, wherein the nucleic acid segment has a nucleotide sequence comprising 5′-CTGGTGCTGGAAAAACAACG-3′ (SEQ. ID. NO.: 5), a complementary nucleotide sequence, or a PAPSS2-specific sequence overlapping either of these at 5 or more contiguous nucleotides at its 5′ or 3′ end.
16. The nucleic acid construct of claim 8, wherein the nucleic acid segment has a nucleotide sequence comprising 5′-TGCGAATGGAGAAATAAAGCTG (SEQ. ID. NO.: 6), a complementary nucleotide sequence, or a PAPSS2-specific sequence overlapping either of these at 5 or more contiguous nucleotides at its 5′ or 3′ end.
17. An isolated polynucleotide comprising a nucleic acid segment encoding a murine PAPS synthetase, said nucleic acid segment having a nucleotide sequence of (SEQ. ID. NO.:2), a nucleotide sequence complementary thereto, a degenerate coding sequence thereof, or a gene-specific fragment of any of these.
18. The polynucleotide of claim 17, wherein the nucleic acid segment is a gene-specific fragment comprising the nucleotide sequence of (SEQ. ID. NO.:10).
19. The polynucleotide of claim 17, wherein the nucleic acid segment is a DNA.
20. The polynucleotide of claim 17, wherein the nucleic acid segment is an RNA.
21. The polynucleotide of claim 17, wherein the nucleic acid segment is a chimeric RNA/DNA.
22. A nucleic acid construct, comprising a nucleic acid segment comprising:
(A) a nucleotide sequence of (SEQ. ID. NO.:2), a nucleotide sequence complementary thereto, a degenerate coding sequence thereof, or a gene-specific fragment of any of these; or
(B) a nucleic acid segment encoding a human PAPSS2 protein having an amino acid sequence of(SEQ. ID. NO.:8).
23. The nucleic acid construct of claim 22, wherein the nucleic acid segment is a gene-specific fragment having the nucleotide sequence of (SEQ. ID. NO.:10).
24. The nucleic acid construct of claim 22, wherein the nucleic acid segment is a probe or primer.
25. The nucleic acid construct of claim 22, wherein the nucleic acid segment is a DNA.
26. The nucleic acid construct of claim 22, wherein the nucleic acid segment is an RNA.
27. The nucleic acid construct of claim 22, wherein the nucleic acid segment is a chimeric RNA/DNA.
28. An oligonucleotide primer for amplifying a PAPSS2-specific nucleic acid segment, comprising:
(A) (SEQ. ID. NO.:3),  (SEQ. ID. NO.:4), (SEQ. ID. NO.:5),  (SEQ. ID. NO.:6), (SEQ. ID. NO.:11), (SEQ. ID. NO.:12), (SEQ. ID. NO.:13), (SEQ. ID. NO.:14), (SEQ. ID. NO.:15), (SEQ. ID. NO.:16), (SEQ. ID. NO.:17), (SEQ. ID. NO.:18), or (SEQ. ID. NO.:28);
(B) a nucleotide sequence complementary to (A);
(C) a PAPSS2-specific fragment of (A) or (B) at least 15 nucleotides long; or
(D) a PAPSS2-specific nucleotide sequence overlapping at 5 or more contiguous nucleotide positions any sequence of (A) or (B) at its 5′ or 3′ end.
29. An oligonucleotide primer for amplifying a Papss2-specific nucleic acid segment, comprising:
(A) (SEQ. ID. NO.:19), (SEQ. ID. NO.:20), (SEQ. ID. NO.:21), (SEQ. ID. NO.:22), (SEQ. ID. NO.:23), (SEQ. ID. NO.:24), (SEQ. ID. NO.:25), (SEQ. ID. NO.:26), or (SEQ. ID. NO.:27);
(B) a nucleotide sequence complementary to (A);
(C) a Papss2-specific fragment of (A) or (B) at least 15 nucleotides long; or
(D) a Papss2-specific nucleotide sequence overlapping at 5 or more contiguous nucleotide positions any sequence of (A) or (B) at its 5′ or 3′ end.
30. A pair of oligonucleotide primers comprising a forward and a reverse primer, said pair capable of producing detectable nucleic acid amplification products having:
(A) (SEQ. ID. NO.:1) or (SEQ. ID. NO.:9);
(B) a nucleotide sequence complementary to (A); or
(C) a PAPSS2 gene-specific fragment of (A) or (B).
31. The pair of oligonucleotide primers of claim 30, wherein
the forward primer has a nucleotide sequence comprising 5′-TGGACCAAGGATGACGATGT-3′ (SEQ. ID. NO.: 3), a complementary nucleotide sequence, or a PAPSS2-specific fragment of either of these at least 15 nucleotides long; and
the reverse primer has a nucleotide sequence comprising 5′-CGGAAAGATGGCAACAATGG-3′ (SEQ. ID. NO.: 4), a complementary nucleotide sequence, or a PAPSS2-specific fragment of either of these at least 15 nucleotides long.
32. The pair of oligonucleotide primers of claim 30, wherein
the forward primer has a nucleotide sequence comprising 5′-CTGGTGCTGGAAAAACAACG-3′ (SEQ. ID. NO.: 5), a complementary sequence, or a PAPSS2-specific fragment of either at least 15 nucleotides long; and
the reverse primer has a nucleotide sequence comprising 5′-TGCGAATGGAGAAATA AAGCTG-3′ (SEQ. ID. NO.: 6), a complementary sequence, or a PAPSS2-specific fragment of either at least 15 nucleotides long.
33. The pair of oligonucleotide primers of claim 30, wherein
the forward primer comprises:
(A) (SEQ. ID. NO.:3), (SEQ. ID. NO.:5), (SEQ. ID. NO.:11), (SEQ. ID. NO.:12), or (SEQ. ID. NO.:13);
(B) a nucleotide sequence complementary to any of (A);
(C) a gene-specific fragment of (A) or (B) at least 15 nucleotides long; or
(D) a PAPSS2-specific nucleotide sequence overlapping at 5 or more contiguous nucleotide positions any sequence of (A) or (B) at its 5′ or 3′ end; and
a reverse primer comprising:
(A) (SEQ. ID. NO.:4), (SEQ. ID. NO.:6), (SEQ. ID. NO.:14), (SEQ. ID. NO.:15), (SEQ. ID. NO.:16), (SEQ. ID. NO.:17), or (SEQ. ID. NO.18);
(F) a nucleotide sequence complementary to any of (E);
(G) a PAPSS2-specific fragment of (E) or (F) at least 15 nucleotides long; or
(H) a PAPSS2-specific nucleotide sequence overlapping at 5 or more contiguous nucleotide positions any sequence of (E) or (F) at its 5′ or 3′ end.
34. A pair of oligonucleotide primers comprising a forward and a reverse primer, said pair capable of producing detectable nucleic acid amplification products having:
(A) (SEQ. ID. NO.:2) or (SEQ. ID. NO.:10);
(B) a nucleotide sequence complementary to (A); or
(C) a Papss2 gene-specific fragment of (A) or (B).
35. The pair of oligonucleotide primers of claim 34, wherein
the forward primer comprises:
(A) (SEQ. ID. NO.:20), (SEQ. ID. NO.:22), (SEQ. ID. NO.:23), or (SEQ. ID. NO.:27);
(B) a nucleotide sequence complementary to any of (A);
(C) a Papss2-specific fragment of (A) or (B) at least 15 nucleotides long; or
(D) a Papss2-specific nucleotide sequence overlapping at 5 or more contiguous nucleotide positions any sequence of (A) or (B) at its 5′ or 3′ end; and
the reverse primer comprises:
(E) (SEQ. ID. NO.:19), (SEQ. ID. NO.:21), (SEQ. ID. NO.:24), (SEQ. ID. NO.:25), or (SEQ. ID. NO.:26);
(F) a nucleotide sequence complementary to any of (E);
(G) a Papss2-specific fragment of (E) or (F) at least 15 nucleotides long; or
(H) a Papss2-specific nucleotide sequence overlapping at 5 or more contiguous nucleotide positions any sequence of (E) or (F) at its 5′ or 3′ end.
36. The pair of oligonucleotide primers of claim 34, wherein
the forward primer has a nucleotide sequence comprising (SEQ. ID. NO.:20), a complementary nucleotide sequence, a gene-specific fragment of either of these at least 15 nucleotides long; and
the reverse primer has a nucleotide sequence comprising (SEQ. ID. NO.:21), a complementary nucleotide sequence, or a gene-specific fragment of either of these at least 15 nucleotides long.
37. A genetically modified vertebrate cell comprising the nucleic acid construct of claim 6.
38. A genetically modified vertebrate cell comprising the nucleic acid construct of claim 12.
39. A non-human vertebrate comprising the cell of claim 37.
40. A non-human vertebrate comprising the cell of claim 38.
41. An isolated PAPS synthetase protein comprising a polypeptide having an amino acid sequence of (SEQ. ID. NO.:7), (SEQ. ID. NO.:8), or an antibody binding fragment of either of these at least 6 amino acids long.
42. A PAPSS2 fusion protein, comprising:
a first PAPSS2 polypeptide segment comprising an amino acid sequence of (SEQ. ID. NO.:7) or a gene-specific antibody binding fragment thereof at least 6 amino acids long; and
a second predetermined polypeptide segment.
43. The fusion protein of claim 42, wherein the PAPSS2 polypeptide segment is encoded by a nucleic acid segment having a nucleotide sequence of (SEQ. ID. NO.:9) or a gene-specific fragment thereof.
44. A Papss2 fusion protein comprising:
a first Papss2 polypeptide segment comprising an amino acid sequence of (SEQ. ID. NO.:8) or a gene-specific antibody binding fragment thereof at least 6 amino acids long; and
a second predetermined polypeptide segment.
45. The fusion protein of claim 44, wherein the Papss2 polypeptide segment is encoded by a nucleic acid segment having a nucleotide sequence of (SEQ. ID. NO.:10), or a gene-specific fragment thereof.
46. A method of diagnosing spondyloepimetaphyseal dysplasia in a human subject, comprising:
a) amplifying a nucleic acid segment from a sample of a bodily substance containing human nucleic acid, said sample being derived from a human subject having at least one symptom of spondyloepimetaphyseal dysplasia, said nucleic acid segment defining a sequence from human chromosomal region 10q23-24, between microsatellite markers D10S1143 and D10S2470, to produce amplification products; and
b) analyzing the amplification products for the presence of homozygosity for a variant allele of a PAPSS2 gene, the presence of homozygosity for the variant allele of the gene corroborating a diagnosis of spondyloepimetaphyseal dysplasia in the human subject.
47. The method of claim 46, wherein the sample is of blood, hair root, urine, amniotic fluid, spinal fluid, skin, vascular epithelium, oral epithelium, or chorionic villus.
48. The method of claim 46, wherein an oligonucleotide primer is used to amplify the nucleic acid segment.
49. The method of claim 48, wherein the oligonucleotide primer has a nucleotide sequence of 5′-TGGACCAAGGATGACGATGT-3′ (SEQ. ID. NO.:3), 5′-CGGAAAGATGGC AACAATGG-3′ (SEQ. ID. NO.:4), a sequence complementary to either, a PAPSS2-specific nucleotide sequence at least 15 nucleotides long and overlapping at 5 or more contiguous nucleotide positions of any of these at its 5′ or 3′ end, or a PAPSS2-specific fragment of any of these at least 15 nucleotides long.
50. The method of claim 48, wherein the oligonucleotide primer has a nucleotide sequence of 5′-CTGGTGCTGGAAAAACAACG-3′ (SEQ. ID. NO.:5), 5′-TGCGAATGGAGAA ATAAAGCTG-3′ (SEQ. ID. NO.:6), a sequence complementary to either, a PAPSS2-specific nucleotide sequence at least 15 nucleotides long and overlapping at 5 or more contiguous nucleotide positions of any of these at its 5′ or 3′ end, or a PAPSS2-specific fragment of any of these at least 15 nucleotides long.
51. The method of claim 46, wherein the variant allele is characteristic of SEMD Pakistani-type.
52. A method of diagnosing spondyloepimetaphyseal dysplasia Pakistani-type in a human subject, comprising:
a) amplifying a nucleic acid segment from a sample of a bodily substance containing human nucleic acid, said sample being derived from a human subject having at least one symptom of spondyloepimetaphyseal dysplasia Pakistani-type, said nucleic acid segment defining a sequence from human chromosomal region 10q23-24, between microsatellite markers D10S1143 and D10S2470, to produce amplification products; and
b) analyzing the amplification products for the presence of homozygosity for a variant allele of a gene encoding a PAPS synthetase, said variant allele defining a stop codon instead of a serine codon corresponding to amino acid residue 475 of SEQ. ID. NO.:7, the presence of homozygosity for the variant allele corroborating a diagnosis of spondyloepimetaphyseal dysplasia Pakistani-type in the human subject.
53. The method of claim 52, wherein the sample is of blood, hair root, urine, amniotic fluid, spinal fluid, skin, vascular epithelium, oral epithelium, or chorionic villus.
54. The method of claim 52, wherein an oligonucleotide primer is used to amplify the nucleic acid segment.
55. The method of claim 52, wherein the oligonucleotide primer has a nucleotide sequence of 5′-TGGACCAAGGATGACGATGT-3′ (SEQ. ID. NO.:3), 5′-CGGAAAGATGGC AACAATGG-3′ (SEQ. ID. NO.:4), a sequence complementary to either, a PAPSS2-specific nucleotide sequence at least 15 nucleotides long and overlapping at 5 or more contiguous nucleotide positions of any of these at its 5′ or 3′ end, or a PAPSS2-specific fragment of any of these at least 15 nucleotides long.
56. The method of claim 52, wherein the oligonucleotide primer has a nucleotide sequence of 5′-CTGGTGCTGGAAAAACAACG-3′ (SEQ. ID. NO.:5), 5′-TGCGAATGGAGAA ATAAAGCTG-3′ (SEQ. ID. NO.:6), a sequence complementary to either, a PAPSS2-specific nucleotide sequence at least 15 nucleotides long and overlapping at 5 or more contiguous nucleotide positions of any of these at its 5′ or 3′ end, or a PAPSS2-specific fragment of any of these at least 15 nucleotides long.
57. A method of diagnosing spondyloepimetaphyseal dysplasia Pakistani-type in a human subject, comprising:
a) amplifying a nucleic acid segment from a sample of a bodily substance containing human nucleic acid, said sample being derived from a human subject having at least one symptom of spondyloepimetaphyseal dysplasia Pakistani-type, said nucleic acid segment defining a sequence from human chromosomal region 10q23-24, between microsatellite markers D10S1143 and D10S2470, to produce amplification products, using at least one oligonucleotide primer having a sequence that comprises (SEQ. ID. NO.: 3), (SEQ. ID. NO.:4), (SEQ. ID. NO.:5), (SEQ. ID. NO.:6), a sequence complementary to any of these, a PAPSS2-specific nucleotide sequence at least 15 nucleotides long and overlapping at 5 or more contiguous nucleotide positions of any of these at its 5′ or 3′ end, or a PAPSS2-specific fragment of any of these at least 15 nucleotides long; and
b) analyzing the amplification products for the presence of homozygosity for a variant allele of a gene encoding a PAPS synthetase, said variant allele defining a stop codon instead of a serine codon corresponding to amino acid residue 475 of SEQ. ID. NO.:7, the presence of homozygosity for the variant allele corroborating a diagnosis of spondyloepimetaphyseal dysplasia Pakistani-type in the human subject.
58. The method of claim 57, wherein analyzing the amplification products comprises digesting the amplification products with a Hinc II restriction endonuclease.
59. The method of claim 57, wherein the sample is blood, hair root, urine, amniotic fluid, spinal fluid, skin, vascular epithelium, oral epithelium, or chorionic villus.
60. A method of identifying a human carrier of an heritable allele associated with spondyloepimetaphyseal dysplasia, comprising:
a) amplifying a nucleic acid segment from a sample of a bodily substance containing human nucleic acid, said sample being derived from a human subject without a symptom of spondyloepimetaphyseal dysplasia, said nucleic acid segment defining a sequence from human chromosomal region 10q23-24, between microsatellite markers D10S1143 and D10S2470, to produce amplification products; and
b) analyzing the amplification products for the presence of a variant allele of a gene encoding a PAPS synthetase, the presence of the variant allele of the gene identifying the human subject as a carrier of an heritable allele associated with spondyloepimetaphyseal dysplasia.
61. The method of claim 60, wherein the sample is of blood, hair root, urine, amniotic fluid, spinal fluid, skin, vascular epithelium, oral epithelium, or chorionic villus.
62. The method of claim 60, wherein an oligonucleotide primer is used to amplify the nucleic acid segment.
63. The method of claim 62, wherein the oligonucleotide primer has a nucleotide sequence of 5′-TGGACCAAGGATGACGATGT-3′ (SEQ. ID. NO.:3), 5′-CGGAAAGATGGC AACAATGG-3′ (SEQ. ID. NO.:4), a sequence complementary to either, a PAPSS2-specific nucleotide sequence at least 15 nucleotides long and overlapping at 5 or more contiguous nucleotide positions of any of these at its 5′ or 3′ end, or a PAPSS2-specific fragment of any of these at least 15 nucleotides long.
64. The method of claim 62, wherein the oligonucleotide primer has a nucleotide sequence of 5′-CTGGTGCTGGAAAAACAACG-3′ (SEQ. ID. NO.:5), 5′-TGCGAATGGAGAA ATAAAGCTG-3′ (SEQ. ID. NO.:6), a sequence complementary to either, a PAPSS2-specific nucleotide sequence at least 15 nucleotides long and overlapping at 5 or more contiguous nucleotide positions of any of these at its 5′ or 3′ end, or a PAPSS2-specific fragment of any of these at least 15 nucleotides long.
65. The method of claim 61, wherein the variant allele is characteristic of spondyloepimetaphyseal dysplasia Pakistani-type.
66. A method of identifying a human carrier of an heritable allele associated with spondyloepimetaphyseal dysplasia Pakistani-type, comprising:
a) amplifying a nucleic acid segment from a sample of a bodily substance containing human nucleic acid, said sample being derived from a human subject without a symptom of spondyloepimetaphyseal dysplasia Pakistani-type, said nucleic acid segment defining a sequence from human chromosomal region 10q23-24, between microsatellite markers D10S1143 and D10S2470, to produce amplification products; and
b) analyzing the amplification products for the presence of homozygosity for a variant allele of a gene encoding a PAPS synthetase, said variant allele defining a stop codon instead of a serine codon corresponding to amino acid residue 475 of SEQ. ID. NO.:7, the presence of the variant allele of the gene identifying the human subject as a carrier of an heritable allele associated with spondyloepimetaphyseal dysplasia Pakistani-type.
67. The method of claim 66, wherein the sample is blood, hair root, urine, amniotic fluid, spinal fluid, skin, vascular epithelium, oral epithelium, or chorionic villus.
68. The method of claim 66, wherein an oligonucleotide primer is used to amplify the nucleic acid segment.
69. The method of claim 68, wherein the oligonucleotide primer has a nucleotide sequence of 5′-TGGACCAAGGATGACGATGT-3′ (SEQ. ID. NO.:3), 5′-CGGAAAGATGGC AACAATGG-3′(SEQ. ID. NO.:4), a sequence complementary to either, a PAPSS2-specific nucleotide sequence at least 15 nucleotides long and overlapping at 5 or more contiguous nucleotide positions of any of these at its 5′ or 3′ end, or a PAPSS2-specific fragment of any of these at least 15 nucleotides long.
70. The method of claim 68, wherein the oligonucleotide primer has a nucleotide sequence of 5′-CTGGTGCTGGAAAAACAACG-3′ (SEQ. ID. NO.:5), 5′-TGCGAATGGAGAA ATAAAGCTG-3′ (SEQ. ID. NO.:6), a sequence complementary to either, a PAPSS2-specific nucleotide sequence at least 15 nucleotides long and overlapping at 5 or more contiguous nucleotide positions of any of these at its 5′ or 3′ end, or a PAPSS2-specific fragment of any of these at least 15 nucleotides long.
71. The method of claim 66, wherein analyzing the amplification products comprises digesting the amplification products with a Hinc II restriction endonuclease.
72. The method of claim 66, wherein the sample is of blood, hair root, urine, amniotic fluid, spinal fluid, skin, vascular epithelium, oral epithelium, or chorionic villus.
73. A gene therapy method for treating a human subject having an osteoarthritic disorder, comprising:
exposing a cell derived from a tissue of a human subject having at least one symptom of an osteoarthritic disorder that is caused or aggravated by deficient enzymatic sulfation activity to a gene delivery mixture comprising at least one gene delivery agent and a nucleic acid construct having a segment encoding a PAPS synthetase protein comprising an amino acid sequence of (SEQ. ID. NO.:7) or (SEQ. ID. NO.:8), said construct being DNA and further comprising a promoter sequence, operable in the cell, operatively linked in a transcriptional unit to the sequence encoding the PAPS synthetase protein;
causing said nucleic acid construct to be taken up by, and released into, the cell so that said polynucleotide is incorporated into the genome of the cell, whereby expression of functional PAPS synthetase is enhanced in the cell; and
implanting the cell into the tissue of the human subject, whereby PAPS synthetase activity in said tissue is enhanced and at least one symptom of the osteoarthritic disorder in the human subject is improved.
74. The gene therapy method of claim 73, wherein the osteoarthritic disorder is spondyloepimetaphyseal dysplasia, Stickler syndrome, spondyloepiphyseal dysplasia, achondrogenesis, achondroplasia, chondrodysplasia, diastrophic dysplasia, pseudoachondroplasia, or multiple epiphyseal dysplasia.
75. The gene therapy method of claim 73, wherein the cell is a chondrocyte, hepatocyte, epithelial, or hemopoietic precursor cell.
76. The gene therapy method of claim 73, wherein the cell is a chondrocyte and the tissue comprises a cartilage-forming tissue.
77. The gene therapy method of claim 73, wherein the cell is a hemopoietic precursor cell and the tissue is bone marrow.
78. The gene therapy method of claim 73, wherein the cell is a hepatocyte, and the tissue is liver.
79. The gene therapy method of claim 73, wherein the cell is an epithelial cell, and the tissue is vascular epithelium.
80. A gene therapy method for treating a human subject having an osteoarthritic disorder, comprising:
exposing a cell derived from a tissue of a human subject having at least one symptom of an osteoarthritic disorder that is caused or aggravated by deficient enzymatic sulfation activity to a nucleic acid construct comprising a nucleic acid segment of a PAPSS2 gene comprising a nucleotide sequence of (SEQ. ID. NO.:9), (SEQ. ID. NO.:10), or a gene-specific fragment of either of these, said construct being a chimeric RNA/DNA;
causing said nucleic acid construct to be taken up by, and released into, the cell so thatsaid nucleotide sequence is incorporated into the genome of the cell, whereby expression of functional PAPS synthetase protein is enhanced in the cell; and
implanting the cell into the tissue of the human subject, whereby PAPS synthetase activity in said tissue is enhanced and at least one symptom of the osteoarthritic disorder in the human subject is improved.
81. The gene therapy method of claim 80, wherein the osteoarthritic disorder is spondyloepimetaphyseal dysplasia, Stickler syndrome, spondyloepiphyseal dysplasia, achondrogenesis, achondroplasia, chondrodysplasia, diastrophic dysplasia, pseudoachondroplasia, or multiple epiphyseal dysplasia.
82. The gene therapy method of claim 80, wherein the cell is a chondrocyte, hepatocyte, epithelial, or hemopoietic precursor cell.
83. The gene therapy method of claim 80, wherein the cell is a chondrocyte and the tissue comprises a cartilage-forming tissue.
84. The gene therapy method of claim 80, wherein the cell is a hemopoietic precursor cell and the tissue is bone marrow.
85. The gene therapy method of claim 80, wherein the cell is a hepatocyte, and the tissue is liver.
86. The gene therapy method of claim 80, wherein the cell is an epithelial cell, and the tissue is vascular epithelium.
87. A genetic testing kit for diagnosing SEMD in a human subject or for identifying a human carrier of SEMD, said kit comprising an oligonucleotide primer(s) comprising:
(A) a nucleotide sequence of (SEQ. ID. NO.:3), (SEQ. ID. NO.: 4), (SEQ. ID. NO.:5), (SEQ. ID. NO.:6), (SEQ. ID. NO.: 11), (SEQ. ID. NO.: 12), (SEQ. ID. NO.:13), (SEQ. ID. NO.:14), (SEQ. ID. NO.:15), (SEQ. ID, NO.:16), (SEQ. ID. NO.:17), (SEQ. ID. NO.:18), or (SEQ. ID. NO.:28);
(B) a nucleotide sequence complementary to (A);
(C) a PAPSS2-specific fragment of (A) or (B) at least 15 nucleotides long; or
(D) a PAPSS2-specific nucleotide sequence at least 15 nucleotides long and overlapping at 5 or more contiguous nucleotide positions any sequence of (A) or (B) at its 5′ or 3′ end; and
instructions for using the primer(s) in diagnosing SEMD in a human subject or for identifying a human carrier of SEMD.
88. A genetic testing kit for diagnosing spondyloepimetaphyseal dysplasia in a human subject or for identifying a human carrier of spondyloepimetaphyseal dysplasia, comprising the pairs of oligonucleotide primers of claim 30; and
instructions for using the primer(s) in diagnosing SEMD in a human subject or for identifying a human carrier of SEMD.
89. A genetic testing kit for diagnosing spondyloepimetaphyseal dysplasia in a human subject, or for identifying a human carrier of spondyloepimetaphyseal dysplasia, comprising the pair of oligonucleotide primers of claim 33; and
instructions for using the primer(s) in diagnosing SEMD in a human subject or for identifying a human carrier of SEMD.
90. A kit for genetically modifying a vertebrate cell, comprising a polynucleotide that comprises a PAPSS2 sequence having (SEQ. ID. NOS.:1), a sequence complementary thereto, or a degenerate coding sequence thereof, or a gene-specific fragment of any of these; and
instructions for using the polynucleotide for genetically modifying a vertebrate cell.
91. The kit of claim 90, further comprising a gene delivery agent.
92. The kit of claim 90, wherein the polynucleotide further comprises a promoter sequence operatively linked in a transcriptional unit to a nucleic acid segment encoding a PAPSS2 protein having an amino acid sequence of (SEQ. ID. NO.:7).
93. The kit of claim 90, wherein the polynucleotide is a chimeric RNA/DNA
94. A kit for genetically modifying a vertebrate cell, comprising a polynucleotide that comprises a Papss2 sequence having (SEQ. ID. NOS.:2), a sequence complementary thereto, or a degenerate coding sequence thereof, or a gene-specific fragment of any of these; and
instructions for using the polynucleotide for genetically modifying a vertebrate cell.
95. The kit of claim 94, further comprising a gene delivery agent.
96. The kit of claim 94, wherein the polynucleotide further comprises a promoter sequence operatively linked in a transcriptional unit to a nucleic acid segment encoding a PAPSS2 protein having an amino acid sequence of (SEQ. ID. NO.:8).
97. An isolated antibody or antibody fragment, comprising an antibody or antibody fragment that selectively binds a PAPS synthetase protein that has an amino acid sequence of (SEQ. ID. NO.:7) or (SEQ.ID. NO.8), or that selectively binds an antibody binding fragment of either of these at least 6 amino acids long.
98. The antibody or antibody fragment of claim 97, wherein the antibody is a monoclonal antibody.
99. The antibody fragment of claim 97, being a Fab′, F(ab′)2, or F(v) fragment.
100. The nucleic acid construct of claim 6, further comprising a reporter gene.
101. The nucleic acid construct of claim 22, further comprising a reporter gene.
102. The PAPSS2 fusion protein of claim 42, wherein the second polypeptide segment is an human immunodeficiency virus TAT protein.
103. The PAPSS2 fusion protein of claim 43, wherein the second polypeptide segment is an human immunodeficiency virus TAT protein.
104. A protein therapy method for treating a human subject having an osteoarthritic disorder, comprising:
exposing a cell of a tissue of a human subject having an osteoarthritic disorder that is caused or aggravated by deficient enzymatic sulfation activity to a fusion protein comprising a first PAPSS2 polypeptide segment that comprises an amino acid sequence of (SEQ. ID. NO.:7), or an enzymatically active fragment thereof, and a second polypeptide segment capable of infiltrating the cell, whereby the fusion protein is taken up by the cell and the PAPSS2 polypeptide segment is enzymatically active therein.
105. The protein therapy method of claim 104, wherein the second polypeptide segment is an human immunodeficiency virus TAT protein.
106. The protein therapy method of claim 104, wherein the osteoarthritic disorder is spondyloepimetaphyseal dysplasia, Stickler syndrome, spondyloepiphyseal dysplasia, achondrogenesis, achondroplasia, chondrodysplasia, diastrophic dysplasia, pseudoachondroplasia, or multiple epiphyseal dysplasia.
107. A kit for the treatment of osteoarthritic disorders caused or aggravated by deficient enzymatic sulfation activity, comprising:
a fusion protein comprising a first PAPSS2 polypeptide segment that comprises an amino acid sequence of (SEQ. ID. NO.:7), or an enzymatically active fragment thereof, and a second polypeptide segment capable of infiltrating the cell; and
instructions for using the fusion protein for treating osteoarthritic disorder(s) caused or aggravated by deficient enzymatic sulfation activity.
108. The kit of claim 107, wherein the second polypeptide segment is an human immunodeficiency virus TAT protein.
US09/898,200 1999-09-17 2001-07-02 Genetic marker for spondyloepimetaphyseal dysplasia Abandoned US20030195162A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/898,200 US20030195162A1 (en) 1999-09-17 2001-07-02 Genetic marker for spondyloepimetaphyseal dysplasia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39921299A 1999-09-17 1999-09-17
US09/898,200 US20030195162A1 (en) 1999-09-17 2001-07-02 Genetic marker for spondyloepimetaphyseal dysplasia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US39921299A Division 1999-09-17 1999-09-17

Publications (1)

Publication Number Publication Date
US20030195162A1 true US20030195162A1 (en) 2003-10-16

Family

ID=28792115

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/898,200 Abandoned US20030195162A1 (en) 1999-09-17 2001-07-02 Genetic marker for spondyloepimetaphyseal dysplasia
US09/898,165 Expired - Fee Related US6818428B1 (en) 1999-09-17 2001-07-02 3-phosphoadenosine-5-phosphosulfate (PAPS) synthetase proteins and methods for treating osteoarthritic disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
US09/898,165 Expired - Fee Related US6818428B1 (en) 1999-09-17 2001-07-02 3-phosphoadenosine-5-phosphosulfate (PAPS) synthetase proteins and methods for treating osteoarthritic disorders

Country Status (1)

Country Link
US (2) US20030195162A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090035768A1 (en) * 2007-09-11 2009-02-05 Axial Biotech, Inc. Method of Determining Predisposition to Scoliosis and Uses Thereof
WO2014204025A1 (en) * 2013-06-18 2014-12-24 한국원자력의학원 Marker for diagnosing cellular senescence and uses thereof
CN112522390A (en) * 2020-12-21 2021-03-19 山东大学 Application of Smoc2 gene and SNP marker thereof in multiple epiphyseal dysplasia
RU2795482C1 (en) * 2022-10-25 2023-05-04 Публичное акционерное общество "Центр Генетики и Репродуктивной Медицины "ГЕНЕТИКО" Preimplantation genetic testing method for achondroplasia

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106626A (en) * 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5525500A (en) * 1994-04-22 1996-06-11 American Cyanamid Company Chromatographic process for the copurification of chondroitinase I and II proteins from Proteus vulgaris
US5627050A (en) * 1992-08-28 1997-05-06 Hoechst Japan Limited Bone-related sulfatase-like protein and process for its production
US5750651A (en) * 1988-04-08 1998-05-12 Stryker Corporation Cartilage and bone-inducing proteins
US5869273A (en) * 1996-09-13 1999-02-09 Glyko, Inc. Chondroitin sulfate as a marker of bone resorption

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6338966B1 (en) * 1998-07-14 2002-01-15 E. I. Du Pont De Nemours & Company Genes encoding sulfate assimilation proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750651A (en) * 1988-04-08 1998-05-12 Stryker Corporation Cartilage and bone-inducing proteins
US5106626A (en) * 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5627050A (en) * 1992-08-28 1997-05-06 Hoechst Japan Limited Bone-related sulfatase-like protein and process for its production
US5525500A (en) * 1994-04-22 1996-06-11 American Cyanamid Company Chromatographic process for the copurification of chondroitinase I and II proteins from Proteus vulgaris
US5869273A (en) * 1996-09-13 1999-02-09 Glyko, Inc. Chondroitin sulfate as a marker of bone resorption

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090035768A1 (en) * 2007-09-11 2009-02-05 Axial Biotech, Inc. Method of Determining Predisposition to Scoliosis and Uses Thereof
WO2014204025A1 (en) * 2013-06-18 2014-12-24 한국원자력의학원 Marker for diagnosing cellular senescence and uses thereof
CN112522390A (en) * 2020-12-21 2021-03-19 山东大学 Application of Smoc2 gene and SNP marker thereof in multiple epiphyseal dysplasia
RU2795482C1 (en) * 2022-10-25 2023-05-04 Публичное акционерное общество "Центр Генетики и Репродуктивной Медицины "ГЕНЕТИКО" Preimplantation genetic testing method for achondroplasia
RU2803650C1 (en) * 2022-10-25 2023-09-19 Публичное акционерное общество "Центр Генетики и Репродуктивной Медицины "ГЕНЕТИКО" Method of preimplantation genetic testing for spondyloepiphyseal dysplasia

Also Published As

Publication number Publication date
US6818428B1 (en) 2004-11-16

Similar Documents

Publication Publication Date Title
Thierfelder et al. α-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere
Merante et al. Maternally inherited hypertrophic cardiomyopathy due to a novel T-to-C transition at nucleotide 9997 in the mitochondrial tRNA (glycine) gene.
US9115400B2 (en) LMNA gene and its involvement in Hutchinson-Gilford Progeria Syndrome (HGPS) and arteriosclerosis
Fanen et al. Identification of mutations in the putative ATP-binding domain of the adrenoleukodystrophy gene.
van den Maagdenberg et al. Apolipoprotein E* 3-Leiden allele results from a partial gene duplication in exon 4
US20040132021A1 (en) Osteolevin gene polymorphisms
CA2414403A1 (en) Methods for diagnosis and treatment of psychiatric disorders
US20020197602A1 (en) Nucleic acid sequences and proteins associated with aging
CN110997906A (en) B4GALT1 variants and uses thereof
CA2554380C (en) Mecp2e1 gene
US20070277251A1 (en) Diagnosis and Prediction of Parkinson's Disease
US6818428B1 (en) 3-phosphoadenosine-5-phosphosulfate (PAPS) synthetase proteins and methods for treating osteoarthritic disorders
Angrist et al. Genomic structure of the gene for the SH2 and pleckstrin homology domain-containing protein GRB10 and evaluation of its role in Hirschsprung disease
US8361723B2 (en) Keratin 8 mutations are risk factors for developing liver disease of multiple etiologies
US5827730A (en) Mutant DNA encoding insulin receptor substrate 1
US7122328B2 (en) Gene involved in mineral deposition and uses thereof
EP2501825B1 (en) Methods for diagnosing skin diseases
JP2001508291A (en) Methods for diagnosis and treatment of pathological conditions caused by insufficient ion transport
RU2805557C2 (en) B4galt1 options and their applications
US20040234982A1 (en) Human ugrp (uteroglobin-related protein) 1 promoter and its use
JP2005525079A (en) ALS2 gene and amyotrophic lateral sclerosis type 2
CN113957076A (en) New mutation site gene of RUNX2 causing cranial clavicle dysplasia, polypeptide and application
US20040002079A1 (en) Sodium-phosphate cotransporter in lithium therapy for the treatment of mental illness
US20030207272A1 (en) Composition and methods for detection of von willebrand's disease
WO1997001634A2 (en) Polypeptide for repairing genetic information, nucleotidic sequence which codes for it and process for the preparation thereof (guanine thymine binding protein - gtbp)

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, MA

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:CEDARS-SINAI MEDICAL CENTER;REEL/FRAME:041569/0587

Effective date: 20170314

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:CEDARS-SINAI MEDICAL CENTER;REEL/FRAME:042021/0980

Effective date: 20170313